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ii 
Opsomming 
 
Navorsing op menslike subjekte gee aanleiding tot ‘n konflik tussen mediese 
vooruitgang as ‘n voordeel vir die samelewing en die beskerming van 
deelnemers as iets waarby die individu direkte belang het. 
 
Voor 1960 het die diskresionêre gesag vir die beskerming van deelnemers by die 
individuele navorsers berus.  ‘n Golf van navorsingsvergrype, van Tuskegee in 
1932 tot die Beecher onthulling in 1966,  het egter veranderinge in die rigting van 
‘n stelsel van beginsel-gebaseerde regulasie gestimuleer.   
Navorsingsetiekkomitees (NEKs) en Institusionele Beoordelings- en toesigrade 
(IBRs) is gevolglik  belas met die verantwoordelikheid om toe te sien dat mense 
wat deelneem, sover moontlik beskerm word.  Sedert 1966 is hierdie stelsel van 
navorsingshersiening en -toesig internasionaal tot stand gebring – ook, 
aanvanklik, by een instansie in Suid-Afrika. 
 
In 1997 het plasebo-beheerde HIV-vertikale oordrag-proewe in ‘n aantal 
ontwikkelende lande, insluitend Suid-Afrika, tot ongekende kontroversie op die 
terrein van navorsingsetiek aanleiding gee, internasionaal en nasionaal.  In 2000 
het die bedrog met borskankerproewe, uitgevoer deur dr Bezwoda by 
Baragwanath Hospitaal, internasionale aandag op navorsing in Suid-Afrika 
gevestig.  Hierdie gebeure het egter die effektiwiteit van die stelsel van etiese 
toesig in Suid-Afrika en elders in die wêreld bevraagteken. Die mees 
kommerwekkende onlangse insident was die dood van navorsingsvrywilligers by 
sentra van uitmuntendheid in die Verenigde State.  Daar is beweer dat as daar 
tekortkominge in die navorsingsetiektoesigsisteem in ontwikkelende lande is, 
daar ‘n groter moontlikheid bestaan dat dit ook (en moontlik meer) in 
ontwikkelende lande voorkom. Ongeveer dieselfde tyd is die Interim Nasionale 
Gesondheidsnavorsings-etiekkomitee (INGNEK) [Interim National Health 
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Research Ethics Committee (INHREC)] in Suid-Afrika gestig om die 
etiekoorsigstelsel in Suid-Afrika te ondersoek en te reguleer. 
 
Met dit in gedagte is die huidige studie onderneem om die verskillende 
strukturele-, prosedurele- en substantiewe etiese uitdagings wat regverdigbare 
en etiese oorsig van en toesig oor navorsing in Suid-Afrika in die gesig staar, vas 
te stel.  Daar is van ‘n kombinasie van konseptuele, filosofiese refleksie en 
empiriese navorsing in hierdie proefskrif gebruik gemaak. Die empiriese werk 
maak gebruik van sowel kwantitatiewe as kwalitatiewe navorsingsmetodes.  Die 
kwantitatiewe opname bestudeer die samestelling van NEKs wat toesig hou oor 
kliniese proewe in Suid-Afrika,  met die klem op komiteesamestelling,  -struktuur 
en die toesigproses.  Die kwalitatiewe navorsing is gedoen met behulp van van 
semi-gestruktureerde onderhoude van tien NEK-voorsitters in Suid-Afrika  om die 
komplekse substantiewe aspekte, soos onder andere ingeligte toestemming, 
standaard van versorging en deelnemervergoeding, te ondersoek. 
 
Terwyl die etiek-toesigstelsel in Suid-Afriks op ‘n redelike vlak funksioneer, is 
daar ‘n groot verskil tussen verskillende NEKs.  NEKs is geografies verspreid en 
funksioneer dikwels in isolasie sonder ‘n geleentheid om te kommunikeer en 
idees te deel.    Ten opsigte van die institusionele NEKs bestaan daar ‘n 
duidelike kontras tussen histories benadeelde instansies en histories 
bevoordeelde instansies.  NEK-lidmaatskap word, tien jaar na demokrasie, 
steeds gedomineer deur blanke mans.  Gemeenskapsverteenwoordiging is 
onvoldoende.  Die meerderheid NEKs word gedomineer deur wetenskaplikes en 
klinici.   Die toesig- en hersieningsprosesse in die verskillende komitees verskil 
grootliks, met vertragings wat wissel van 10 dae to 10 weke.  Prosedurele- en 
burokratiese vereistes het ‘n impak op die vermoëns van NEK-lede om by 
debatte oor belangrike substantiewe etiese aangeleenthede betrokke te raak, 
soos byvoorbeeld die standaard van versorging, ingeligte toestemming en 
deelnemervergoeding.  Opleiding en opvoedkundige behoeftes verskil wyd oor 
die land. 
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Ernstige aandag moet geskenk word aan die wyse waarop NEKs in Suid-Afrika 
saamgestel is.  Herstrukturering van NEKs met ‘n visie op verbeterde 
verteenwoordiging in terme van ras, geslag en geloof is ‘n prioriteitsvereiste.  
Gemeenskapsverteenwoordiging en lidmaatskap van nie-wetenskaplikes moet 
verder ondersoek word.  NEKs in Suid-Afrika moet die vraag of hulle sowel 
wetenskaplike- as etiektoesig moet uitvoer, of sl slégs etiektoesig, opnuut 
ondersoek.  Die nasiensproses vereis ‘n paradigmaskuif, vanaf ‘n klem op 
rapportering van gebeurtenisse, na monitering van ingeligte toestemmingsvorms 
sowel as na ‘n kultureel toepaslike ingeligte toestemmingsproses.  ’n 
Paradigmaskuif is noodsaaklik ten einde die fokus te verskuif vanaf ingeligte 
toestemming na ‘n meer omvattende toesig- en nasiensraamwerk.  Beleid 
rakende standaard van versorging en deelnemervergoeding moet verduidelik en 
geartikuleer word. 
 
Alhoewel die rol van NEKs in die beskerming van menslike deelnemers aan 
navorsing bevraagteken word, is dit duidelik dat NEKs in die meerderheid van 
gevalle wel ‘n belangrike rol vervul. Hul funksie kan natuurlik uitgebrei word.  Dit 
sal gefasiliteer word deur opleidingsprogramme en ‘n elektroniese nuusbrief.  
Verantwoordelikheid vir die beskerming van mense wat deelneem aan navorsing 
berus egter nie uitsluitlik by NEKs  nie.  ‘n Kollektiewe verantwoordelikheid, 
gedeel deur navorsers, instellings, navorsingsetiekkomitees, borge en 
deelnemers is ‘n integrale vereiste vir hierdie beskerming sowel as vir die 
verwerwing van nuwe, geldige en relevante wetenskaplike kennis. 
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Summary 
 
Human participant research raises a conflict between medical progress as a 
societal good and the protection of participants as an individual good. 
 
Prior to 1960 the discretionary authority for the protection of participants resided 
in the hands of individual investigators.  However, a wave of research atrocities 
from Tuskegee in 1932 to the Beecher expose in 1966 stimulated a change to a 
principle based system of regulation.  Research Ethics Committees (RECs) and 
Institutional Review Boards (IRBs) were henceforth charged with the 
responsibility of human participant protection.  Since 1966, this system of 
research review was established internationally and at one institution in South 
Africa. 
 
In 1997, placebo-controlled HIV vertical transmission trials in a number of 
developing countries including South Africa raised unprecedented controversy in 
research ethics internationally and nationally.  In 2000, the fraudulent breast 
cancer trials conducted by Dr Bezwoda at Baragwanath Hospital drew 
international attention to research ethics in South Africa.  However, the events 
that called into question the efficiency of the system of ethical review most 
poignantly were the recent deaths of volunteers in research at centres of 
excellence in the United States.  It was charged that if there were deficiencies in 
the research ethics review system in developed countries, these were more likely 
to be present in developing countries.  Around the same time the Interim National 
Health Research Ethics Committee (INHREC) was established in South Africa to 
explore and regulate the ethical review system in South Africa.  
 
Cognisant of these issues, the current study was undertaken to establish the 
various structural, procedural and substantive ethical challenges facing justifiable 
and ethical review of research in South Africa.  A combination of conceptual 
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philosophical reflection and empirical research was employed in this dissertation.  
The empirical work employed both quantitative and qualitative research 
methodology.  The quantitative survey explored the composition of RECs 
reviewing clinical trials research in South Africa with an emphasis on committee 
composition and structure as well as the review process.  The qualitative 
research was conducted using semi-structured interviews of ten REC 
Chairpersons in South Africa to explore complex substantive issues like informed 
consent, standards of care and participant remuneration, inter alia. 
 
While the review system in South Africa is functioning at a reasonable level, there 
is wide variation from one REC to the next.  RECs are geographically distant and 
function in isolation without opportunity to communicate and share ideas.  
Amongst institutional RECs, there is a stark contrast between historically 
disadvantaged institutions and historically advantaged institutions.  REC 
membership, ten years into democracy remains white male dominated. 
Community representation is inadequate.  Most RECs are dominated by 
scientists and clinicians.  The review process is widely variable with delays in 
review ranging from ten days to ten weeks.  Procedural and bureaucratic 
demands impact on the ability of REC members to engage in debate on 
important substantive ethics issues like standards of care, informed consent and 
participant remuneration.  Research ethics training and educational needs vary 
widely across the country. 
 
Serious attention must be paid to the way in which RECs are constituted in South 
Africa.  Restructuring of RECs with a view to improving representation in terms of 
race, gender and religion must be prioritized.  There is  a need for community 
representation and non-scientific membership to be explored.  RECs in South 
Africa need to revisit the question of whether they should be conducting both 
scientific and ethics review or ethics review alone.  The review process requires a 
paradigm shift in emphasis from adverse event reporting to monitoring, from 
informed consent forms to a culturally relevant informed consent process.  A 
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paradigm shift is indicated to shift the focus from informed consent to a more 
comprehensive review framework.  Policies regarding standards of care and 
participant remuneration must be clarified and articulated. 
 
Although the role of RECs in human participant protection has been questioned, 
it is clear that in the vast majority of cases, they are fulfilling an important role.  
Their function could certainly be enhanced.  This is being facilitated by training 
programs and an electronic newsletter.  However, responsibility for human 
participant protection does not reside in the domain of the REC alone.  A 
collective responsibility shared by researchers, institutions, research ethics 
committees, sponsors and participants is integral to human participant protection 
and the generation of new, valid and relevant scientific knowledge.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
Acknowledgements 
 
This dissertation represents the culmination of a long journey that began in 1997 
when my interest in research ethics was first stoked by the international debate 
on HIV research being conducted in South Africa.  This interest escalated when I 
received a scholarship from Harvard University in 1999 to attend my first course 
in International Health Research Ethics.  My association with Dr Richard Cash 
has continued and my interest in research ethics has grown.  His excellent 
program at the School of Public Health continues to flourish and I have had the 
opportunity to attend it again both in 2003 as a result of support from Professor 
Nulda Beyers and at Richard’s invitation in 2004. 
 
The idea for this dissertation was conceived in 2001 when as a Fogarty Fellow at 
Columbia University, New York City, I was exposed to the work of Professor Ron 
Bayer.  I am grateful for his insights and guidance in the initial stages of my work. 
 
None of this would have been possible without the excellent training I received at 
the Centre for Applied Ethics, University of Stellenbosch where I attended the 
MPhil program in 1998.  I will always be indebted to Professor Anton van Niekerk 
and the Department of Philosophy for introducing me to the field of Applied 
Ethics.  I am also grateful to Anton for his scholarly supervision of this 
dissertation. 
 
A work of this magnitude is not possible without a robust support system.  For 
this I am grateful to my administrative assistant Anne-Marie Moolman for her 
vigilant resourcing of all the literature required for this work and her monitoring of 
my progress.  My friend and colleague, Landon Myer, has assisted me with his 
statistical expertise in analysing my quantitative data and with his constant 
support.  Ineke Meulenberg-Buskens and Lindy Wilbraham provided valuable 
support and advice in my qualitative research. 
ix 
My parents have always encouraged my academic endeavours by providing 
support and encouragement in a host of different ways.  This dissertation would 
not have reached completion without the support of Premesh Narismulu, who has 
both ‘managed’ my career and assisted me with researching this topic but most 
importantly, has helped me to raise our two sons and maintain my professional 
career.  
 
Finally, but most of all, I am forever thankful for my two wonderful boys Kehar 
and Nikhal for their love, understanding and patience while I toiled away at my 
work often encroaching on the special time they are entitled to with their mother.  
 
 
 
 
 
 
x 
ACRONYMS 
 
 
 
 
CIOMS  Council for International Organizations of Medical Sciences 
 
DHHS   U.S. Department of Health and Human Services 
 
DOH   Declaration of Helsinki 
 
DSMB   Data and Safety Monitoring Board 
 
FDA   Food and Drug Administration 
 
GCP   Good Clinical Practice 
 
ICH   International Conference on Harmonisation 
 
INHREC  Interim National Health Research Ethics Committee 
 
IND   Investigational New Drug Application 
 
IRB   Institutional Review Board 
 
MCC   Medicines Control Council 
 
MRC   Medical Research Council 
 
NBAC   National Bioethics Advisory Council 
 
NIH   National Institute of Health 
 
OHRP   Office for Human Research Protection 
 
PI   Principle Investigator 
 
REC   Research Ethics Committee 
 
SOP   Standard Operating Procedure 
 
SAE   Serious Adverse Event 
 
SAGCP  South African Good Clinical Practice 
 
xi 
Contents 
 
General Introduction and problem statement  
  
  
1 Introduction 1 
2 Historical Background 2 
3 The South African Situation 8 
4 The Complex of Substantive Ethics Review Challenges in  
 South Africa 
10 
5 Methodological Issues 13 
6 Empirical Research Component  13 
7 Structure of Dissertation 15 
8 New Contributions to the Ethics Review System in 
 South Africa 
18 
  
  
Chapter 1: Human Experimentation – the early days… 20 
  
  
Chapter 2: Research Ethics – A Historical Perspective 35 
  
  
2.1 Introduction 35 
2.2 The Tuskegee Syphilis Study 36 
2.3 Experimentation during the Second World War  38 
 2.3.1 The Nazi Experiments 38 
 2.3.2 The Japanese Experiments 39 
2.4 The Thalidomide Disaster 40 
xii 
2.5 The Beecher Expose 41 
 2.5.1 The Willowbrook Story 41 
2.6 Commentary 44 
  
Chapter 3: International Codes and Declarations for  
  Research Ethics 
45 
  
  
3.1 Introduction 45 
3.2 The Doctors' Trial at Nuremburg 45 
3.2 The Nuremberg Code – 1947 46 
3.4 The Declaration of Helsinki – 1964 48 
3.5 The Belmont Report – 1979 51 
3.6 CIOMS – 1993  53 
3.7 The Evolution of Good Clinical Practice – 1997 55 
 3.7.1 United States 55 
 3.7.2 Japan and Europe 56 
 3.7.3 ICH GCP 56 
3.8 Commentary 56 
  
Chapter 4: Controversies revisited : The Ethics of Research 
  in Developing Countries 
59 
  
4.1 Introduction 59 
4.2 ACTG 076 and the Vertical Transmission Trials 60 
 4.2.1 The Placebo Debate 60 
 4.2.2. The Scientific Debate 61 
 4.2.3 The Ethical Debate 65 
4.3 Vertical Transmission Trials in South Africa – The Results 70 
4.4 Tuskegee Revisited 73 
4.5 Declaration of Helsinki 2000 and CIOMS 2002 76 
xiii 
4.6 Commentary 77 
  
  
Chapter 5: Continuing Controversies in Developed  
  Countries despite regulatory changes 
79 
  
  
5.1 Introduction 79 
5.2 The Nicole Wan Case 79 
5.3 The Jesse Gelsinger Case 81 
5.4 The Ellen Roche Case 83 
5.5 Commentary 84 
  
  
Chapter 6: Research Ethics Committees in South Africa ; A 
  Status Report 
87 
  
  
6.1 Introduction 87 
6.2 Methodology 89 
6.3 Data Analysis 91 
6.4 Sample 91 
6.5 Ethics Committee Survey Results 92 
 6.5.1 Composition 92 
 6.5.2 Remuneration of Committee Members 109 
 6.5.3 Training and Development of Members 110 
 6.5.4 Ethics Review System 113 
 6.5.5 REC Workload and Review Procedures 120 
6.6 Commentary 125 
 
 
 
xiv 
Chapter 7: Substantive Ethical Review Issues in South  
  Africa 
127 
  
  
7.1 Introduction 127 
7.2 Initial Review 
7.2.1 Informed Consent 
133 
133 
7.2.2 Placebos and Standard of Care 152 
7.2.3 Declaration of Helsinki (DOH) 162 
7.2.4 Participant Remuneration 166 
7.2.5 Post-Trial treatment 172 
7.2.6 Review of HIV Vaccine Trials 178 
7.3 Continuing Review : the Ethical Issues 186 
 7.3.1 Adverse Event Reporting 186 
 7.3.2 Audit / Monitoring of Research 191 
7.4 Emergent Ideas 197 
7.5 Commentary 198 
  
Chapter 8: Towards National Standardisation 200 
  
  
8.1 Introduction 200 
8.2 Challenges in the Ethics Review System in South Africa 201 
 8.2.1 General Variability in Ethics Review 201 
                       8.2.1.1 Variability in the Ethics Review System  201 
                       8.2.1.2 Lack of Communication amongst RECs 203 
 8.2.2 Specific Problems in the Review System 203 
  8.2.2.1 Structural 203 
  8.2.2.2 Review Process 205 
  8.2.2.3 Substantive Review Issues 207 
  
xv 
8.3 Resolution Options to Improve Research Review in South  
      Africa 
209 
 8.3.1 Eliminating Variability and Achieving Standardisation 209 
 8.3.2 Changes to the Review System 210 
  8.3.2.1 Structural Changes Recommended 210 
  8.3.2.2 Resolution Options for the Review 
    Process 
216 
  8.3.2.3 Resolution Options to Improve  
    Deliberation on Substantive Issues in 
    the Review of Human Participant  
    Research in South Africa 
218 
8.4 Summary of Major Recommendations 222 
 8.4.1 National Association of local RECs 222 
 8.4.2 National Newsletter 222 
 8.4.3 National Health Research Ethics Council (NHREC) 223 
 8.4.4 National Research Ethics Guidelines 223 
 8.4.5 Research Ethics Training and Development 223 
 8.4.6 Participant Advocacy 224 
           8.4.7 Research Ethics Review System 224 
8.5 Commentary 224 
  
  
Chapter 9: Participant Protection – 
  Who’s Responsibility ? 
227 
  
  
9.1 Introduction 227 
9.2 The Bezwoda Case 227 
9.3 The Poisson Case 229 
  
Chapter 10:  Conclusion 234 
xvi 
  
Bibliography 239 
  
Addendum  
 
  1 
General introduction and problem 
statement 
 
1. Introduction 
 
In spite of the enormous advances that medical science has made for the 
benefit of humankind, particularly over the last century1, scientific research on 
human participants sometimes creates a conflict between the generation of 
new scientific knowledge and the protection of study participants.  Research 
Ethics Committees (RECs) are charged with the responsibility of protecting 
potential and enrolled study participants.  Recent deaths of study participants 
at centres of excellence in the United States have called into question the 
ability of RECs in the developed world to offer adequate protection to human 
participants in research.  By extrapolation, the competence of RECs in 
developing countries has been called into question. 
 
The problem I wish to address in this dissertation concerns the challenges 
facing RECs in the protection of human research participants, with special 
emphasis on the situation in a developing country such as South Africa.  As a 
developing nation, we experience specific problems relating to informed 
consent from educationally disadvantaged study participants or participants of 
diverse cultural and linguistic origins.  The debate on the standard of care  
constantly questions the use of placebos in clinical trials.  Remuneration of 
economically challenged trial participants impacts on the voluntary nature of 
participation.  The ethical conduct of HIV vaccine trials poses a special 
challenge to RECs in South Africa.  There are a number of ethical issues that 
pertain to continuing review such as adverse event reporting and monitoring 
of approved research.  These problems remain largely unresolved. 
 
                                            
1 As is the case with all science, medical science can also, and indeed often has been, an 
instrument of social progress. I shall deal with some of these instances of undeniable 
progress at the beginning of chapter 2. Most of the dissertation will, however, be occupied 
with the instances where things can, and indeed have gone wrong in the practice of scientific 
medical research. 
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Certain problems that are experienced in South Africa are also experienced in 
other parts of the world, such as the dual function enshrined in ethics 
committees to review the science and the ethics of research protocols 
(Redshaw, 1996: 76-82).  The question remains whether there is adequate 
expertise on local RECs in the event of dual review.   
 
The main focus of this dissertation therefore has to do with the complex of 
problems that face effective and morally justifiable ethical review of medical 
research in South Africa. 
 
2. Historical Background 
 
Science has both a descriptive component and an experimental component.  
The descriptive component is the result of passive research based largely on 
observation and description of the course of events in disease.  This has been 
invaluable in the generation of knowledge.  However, observation alone, in 
the absence of controlled experimentation is inadequate.  Hippocrates (460 - 
370 BC) has been credited for initiating the descriptive science of medicine 
(Ivy, 1948: 1).  He was aware that physicians in his time practiced medicine 
on a case-by-case basis and hence the knowledge and practice of medicine 
could not be generalised.  When Hippocrates described experience in 
medicine as “uncertain”, many physicians were aware that a treatment that 
would be successful in one patient might not work on another patient.  In 
desperation, physicians often tried remedies that were previously untested, 
sometimes with unexpected success.  The Hippocratic maxim “benefit and do 
no harm” helped physicians to maintain a “constant intent to cure”. 
 
For most of medical history, the experimental (which in Latin means 
“putting to the test of experience”) was folded into the therapeutic; 
patients were experimental subjects only as their doctors worked to 
heal them. 
       (Jonsen, 1998: 125) 
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The evolution of deliberate experimentation represented an escape from the 
limitations of observational research. Galen (131-201 AD) was credited with 
the initiation of the experimental science of medicine including the use of 
animals (Garrison, 1929).  After his death, throughout the Dark Ages and for 
most of the Middle Ages the experimental method was not used in medicine 
(Bull, 1959: 221).  As a result of dissection of the human cadaver (which had 
previously been forbidden) and via animal experimentation, Vesalius (1514-
1564 AD) revealed inaccuracies in Galen’s conception of the circulation of 
blood (Beecher, 1959: 462).  In 1628, Harvey’s discovery of the circulation 
resulted from controlled observation on animals and man (Ivy, 1948: 2). 
 
It was only in the 18th century that experimentation impacted significantly on 
medical knowledge with Edward Jenner’s work on the smallpox vaccine.  
Even then, his son was his first research subject.  Louis Pasteur, during his 
experimentation on rabies, agonized over inoculating the first human subject 
and did so only when it was required in a life-saving situation demonstrating 
the use of extreme discretion in the conduct of experimentation (Rothman, 
2003: 22).  In the 19th century, Claude Bernard made an important 
contribution both to physiological research and the ethics of research when he 
wrote in 1865: 
 
The principle of medical and surgical morality consists in never 
performing on man an experiment which might be harmful to him to any 
extent, even though the result might be highly advantageous to 
science. 
        (Rothman, 2003: 23)  
 
His principles remained within the Hippocratic tradition of keeping experiments 
therapeutic in intent (Jonsen, 1998: 127).  His work has been documented as 
the “most significant formulation of research ethics in the nineteenth century” 
(Rothman, 2003: 23). 
 
Prior to the Second World War, research was “almost always therapeutic in 
intent” (Rothman, 2003: 30).  Experimentation in the context of the doctor-
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patient relationship was conducted in a manner that was consistent with 
patient and community expectations and the ethics of human investigation did 
not require much attention.  Research that transcended the boundaries of the 
doctor-patient relationship was an intimate small-scale exercise where a few 
physicians conducted experiments on themselves, their families and 
neighbours.  Physicians conducted these experiments at their own discretion 
at a time when the integrity of individual doctors was held in high regard by 
patients, communities and colleagues. 
 
The Second World War heralded a distinct change in the conduct of human 
experimentation.  The research endeavour was transformed from a small-
scale cottage industry to a national program in the United States.  At that 
stage, research had lost its purely therapeutic nature and experiments were 
designed to benefit others – especially soldiers on the battlefield.  The 
interests of science and society took precedence over the individual interests 
of research subjects.  The utilitarian justification for war was, by many, 
extrapolated to research, and participant protection was subjugated to the 
urgency of progress in medical research.  During the Second World War 
researchers achieved enormous victories over smallpox, typhoid, tetanus, 
yellow fever and other infectious diseases.  This coincided with the discovery 
of the sulpha drugs in 1935 and penicillin in 1945.  Wartime notions of “drafts” 
and “forced military duty” impacted on the mindsets of researchers who were 
very active at that time.  Many drew parallels between soldiers who had been 
conscripted and subjects who had been enrolled in research projects. In 1942 
Hitler went so far as to say: 
 
As a matter of principle, if it is in the interest of the state, human 
experiments are to be permitted.” It was unacceptable for “someone in 
a concentration camp to be totally untouched by war, while German 
soldiers had to suffer the unbearable. 
     (Quoted in Rothman, 2003: 61) 
 
Henceforth, medical experimentation on vulnerable groups continued without 
sanction and many violations of participant rights ensued. 
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Prior to the Second World War, research was primarily therapeutic in nature 
and consequently, treatment and research were intertwined.  However, when 
therapeutic research became organised and groups of individuals were 
deliberately submitted to experimentation and when non-therapeutic 
experimentation became an important part of the research endeavour, the 
roles of investigator and physician ought to have become distinct.  Instead, 
the lines between therapy and research remained blurred. 
 
A central concept in the debate surrounding research ethics is the important 
distinction that must be drawn between the doctor-patient relationship and the 
investigator-participant relationship. Traditionally, the doctor-patient 
relationship is based on concern for individual patients and the patient is seen 
as an end in him- or herself. In therapeutic research, the study participant may 
stand to benefit to a certain degree while he or she does not benefit at all in 
non-therapeutic research or in placebo controlled therapeutic trials where the 
participant might be randomized to the control arm of the study.  Under such 
conditions, the benefit to science and society is bound to be significant 
enough to render the research participant a means to an end. 
 
As a result of this precarious relationship between participant and investigator, 
the research participant requires special protection of his/her rights.  In South 
Africa, as in most developing countries, care and research are often 
integrated, placing research subjects in a very vulnerable position.  Our legacy 
of apartheid further increases the asymmetrical nature of the investigator 
participant relationship resulting in greater risk of exploitation of 
disempowered research participants. 
 
During and subsequent to the Second World War, many problems have arisen 
either because the distinction between doctor-patient and researcher-
participant has not been recognized or because special protection has not 
been afforded to participants resulting in the violation of their rights.  The 
utilitarian justification for the Second World War as an endeavour of national 
interest and societal good was extrapolated to research.  In many ways, the 
war against nation states was transformed into a war against disease. 
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The research atrocities of the Nazi concentration camps were brought into 
focus at the Nuremberg Trial of 1946 and the Nuremberg Code was the first 
attempt to protect the rights of research participants. In spite of this, research 
violations continued – Tuskegee, Thalidomide, Willowbrook… 
 
Violations of the rights of research participants exposed the “stark conflict of 
interest between clinical investigators and human subjects, between 
researchers’ ambitions and patients’ well-being” (Rothman, 2003: 10).  This 
resulted in a shift from individual researcher discretion and integrity to 
collective decision-making.  A system of peer review and international 
regulations and guidelines substituted self-regulation by individual 
researchers.  Trust in the discretion of individual researchers was replaced by 
trust in Research Ethics Committees (RECs) and Institutional Review Boards 
(IRBs). 
 
The Declaration of Helsinki in 1964, made the first reference to the review of 
research by an ethics committee.  In 1966, the Surgeon-General in the United 
States called for each application to conduct research funded by the Public 
Health service to be reviewed by an Ethics Committee.  Similarly, in 1966 
Canada and the United Kingdom also recommended committee review of 
research proposals.  The first REC in South Africa was established in 1966 at 
the University of the Witwatersrand.  New Zealand introduced a requirement 
for committee review in 1972 and Australia followed in 1973.  Some of the 
Scandinavian countries followed suit in the 70s and 80s (McNeill, 1998: 372-
73). 
 
Ethical review of health research conducted on human participants by RECs 
has become an institutional requirement in most countries today.  Even 
though the practice has its origin in Western countries, it has been adopted 
globally.  Apart from the Declaration of Helsinki, a number of other guidelines 
were developed to address the ethics of research in general and in 
developing countries in particular.  The guideline of the Council for 
International Organisations of Medical Science (CIOMS) drawn up by the 
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World Health Organisation (WHO) in 1993 pays specific attention to health 
research ethics in a developing country. 
 
While these international guidelines had been accepted unquestioningly for 
many years, HIV research in 1997 called into question placebo-controlled 
studies and standards of care in developing country based research.  Doctors 
Lurie, Wolfe and Angell initiated a heated debate in the New England Journal 
of Medicine in 1997 when they questioned the lack of clinical equipoise in HIV 
vertical transmission trials being conducted in developing countries around the 
world.  This debate reached a climax when Dr Angell drew an analogy 
between these trials and the infamous Tuskegee syphilis study.  Charges of 
ethical imperialism were hurled at her by developed- and developing-world 
investigators.  The impact of this crisis in international research ethics was 
poignant in many respects.  One consequence of this controversy was the 
widespread review of both the Declaration of Helsinki and the CIOMS 
guideline from 2000 to 2004.  Many of these revisions remain controversial 
and unresolved.  The reliance on guidelines and regulations in ethical review 
was intensified and reinforced in developed and developing countries alike.  
This type of ethical review has attracted criticism as it is argued that an 
obsession with procedural correctness is detracting from a substantive 
approach to ethical reasoning by REC members.  Further criticism of the 
debate is the far-reaching consequences the debates and guideline revisions 
have had on other types of research.  This begs the question of whether the 
HIV vertical transmission trial debate, now employed as a case study for the 
discussion of research ethics in general, is an appropriate case study for 
widespread generalizations. 
 
In spite of the heightened international awareness of research participant 
protection and revised regulations and guidelines precipitated by the HIV 
pandemic and HIV research, the deaths of research participants in developed 
countries in 1996, 2000 and 2001, has resulted in a second wave of interest in 
the risk-benefit ratio of research as well as adequacy of review by research 
ethics committees.  These recent controversies in research ethics in the USA 
(Steinbrook, 2002: 716-20) and in South Africa (Weiss, 2000: 2771-77) raised 
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by research disasters at first world centres of excellence therefore make it 
necessary to revisit the concept of ethical review by RECs in developed 
countries but especially in developing countries.  This is a very large concern 
given the fact that dual review of research is mandated in multinational 
research yet 44% of developing country researchers surveyed reported that 
their studies are not reviewed by a local REC (Hyder, 2004: 68). 
 
3. The South African Situation 
 
South Africa is a popular research site for conducting clinical trials.  The 
clinical trial industry increased by 40% between 1997 and 1998 (Christley, 
1998: 56-59). The pharmaceutical industry budget for clinical trial research for 
2000 was R826 million (Joffe, 2002).  Some of the reasons quoted for 
conducting research in Africa rather than in developed countries include lower 
costs, lower risk of litigation and less stringent ethical review (Wilmshurst, 
1997: 840).  
 
The system of ethical review in South Africa dates back to 1966 when the first 
REC was established at the University of the Witwatersrand.  Since then, a 
number of other RECs affiliated to major tertiary institutions were formed.  
Today there are approximately 22 local RECs in South Africa, two of which 
are private institutions.  In keeping with the apartheid policies historically 
entrenched in South Africa, many of these RECs have been dominated by 
white male South African scientists or clinicians.  The South African Good 
Clinical Practice (SAGCP) guideline specifies composition of RECs in terms of 
race and gender.  The empirical research component of this dissertation 
examines the composition of RECs at the time of the survey (2003-2004) to 
assess whether, ten years into democracy, RECs are now representative of 
population demographics in South Africa.  Another important feature of the 
composition of an REC relates to community or lay representation on the 
committee.  This has recently been increased from one lay member to two lay 
members per committee, and should preferably include people from the 
community being researched.  This is an area that will be explored in the 
survey conducted on RECs in SA. 
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While the practice of ethical review by health research ethics committees is 
firmly entrenched in South Africa, the quality and consistency of ethical review 
in South Africa is largely unknown. To date there have been no published 
studies on the work of RECs in South  Africa. The need for such data was 
highlighted in 2000 when Werner Bezwoda from the University of the 
Witwatersrand raised national and international attention to research ethics in 
South Africa.  Bezwoda had presented a paper at the annual meeting of the 
American Society of Clinical Oncologists in 1999 on the treatment of high-
grade breast cancer with high dose chemotherapy.  A team from the United 
States visited his research site in South Africa to verify his results only to find 
marked discrepancies between the data presented and existing data (Weiss, 
2000: 999-1003).  This was the most widely publicized case of research fraud 
in South Africa and the role of the REC was questioned.  However, the 
investigation revealed that the protocol had not been submitted to the REC at 
the University of the Witwatersrand – the oldest and most established REC in 
South Africa. 
 
The quality and extent of ethical review in South Africa is also a source of 
concern for the newly constituted National Interim Health Research Ethics 
Committee (NIHREC) in South Africa – the body created by the Department of 
Health to regulate and co-ordinate all ethical review activities in South Africa. 
 
South Africa is a captive site for multinational collaborative research.  The 
CIOMS guideline specifies dual review of research protocols for multinational 
research (CIOMS, 1993).  Concerns have been raised that RECs in 
developing countries may not promote high standards of research participant 
protection as a result of a lack of financial and adequately trained human 
resources (Hyder, 2004: 68).  In the absence of acceptable practices of ethical 
review, foreign collaborators are hesitant to become involved in research in 
South Africa, with the consequence that their considerable contributions in 
terms of expertise and resources may be withheld.  The challenge in this 
regard is to better understand the level of research review capacity in South 
Africa and to define the “gap” that needs to be bridged to satisfy optimal 
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accreditation criteria to be developed by the National Interim Health Research 
Ethics Committee.  
 
4. The Complex of Substantive Ethics Review Challenges in South 
 Africa 
 
RECs in South Africa experience specific substantive ethical problems relating 
to the review of clinical trials: informed consent, the use of placebos, 
remuneration of trial participants, post trial benefit to study participants, the 
use of international guidelines and the review of HIV vaccine trials.  There are 
also problems pertaining to continuing review of approved research such as 
adverse event reporting and monitoring of research.  These problems 
continue to generate concern yet escape resolution. I shall briefly discuss the 
main issues that are of concern in this dissertation. 
 
Informed consent is a major challenge in South Africa where the majority of 
research participants are educationally disadvantaged.  Autonomous decision-
making requires both freedom from controlling influences and freedom from 
limitations such as inadequate understanding (Beauchamp, 2001: 58).  In the 
research setting, lack of understanding of scientific concepts and complicated 
clinical trials impair autonomous decision-making.  In collaborative research, 
federal regulations and donor agency rules require detailed and elaborate 
consent documents.  Are these appropriate in terms of what research 
participants would see as important protections of their rights?  Are consent 
documents serving to indemnify sponsors and investigators rather than 
protect study participants?  In addition, our multicultural, multi-linguistic 
society requires a unique approach to the informed consent process.  In 
traditional African societies, the Nguni philosophy of Ubuntu defines 
personhood very differently from the Western notion of autonomy (Mkhize, 
2004: 46).  This has important implications for family and community consent 
as distinct from individual consent. Many cultural beliefs also impact on 
obtaining written informed consent as opposed to verbal consent. 
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Remuneration of trial participants is particularly challenging amongst poor 
communities in South Africa where a fine line exists between what is regarded 
as adequate recompense for trial participation as compared with what is 
regarded as coercive.  The Medicines Control Council (MCC), a regulatory 
agency in SA, has since 2003 unilaterally decided to stipulate a payment of 
R150 ($24) per visit to research participants as opposed to R50 ($8) a visit 
previously accepted by all RECs.  South African RECs currently face the 
challenge of reaching consensus on how much research participants should 
be remunerated for participation in research and who has a mandate to 
determine adequate non-coercive recompense. 
 
Issues related to the standards of care in a developing country are largely 
unresolved.  While the debate around this concept originated in the context of 
international collaborative research where different standards of medical care 
exist between host and sponsor nations, it is now debated in country specific 
research where different standards of care exist in different regions.  In such a 
setting, as in South Africa, different standards of care might also exist 
between the public health sector and private health care institutions.  It is 
uncertain whether we should adopt a universal standard of care as opposed 
to a local standard of care or what is described as a de facto standard as 
compared with a de jure standard, each of which could be local or global. 
(London, 2000: 379-97).  Terminology relating to a standard of care for the 
control group ranges from “best current” to “ best proven” to “best available” to 
“highest attainable and sustainable” and these definitions need to be clarified.  
Several proposals have been created in an attempt to resolve the ambiguity 
and these will be critically appraised. 
 
Given the inequities in health care between developed and developing 
nations, what should happen when the trial is over?  Do wealthy sponsoring 
nations have an obligation to trial participants or even developing world 
communities when the research is over?  Should this be negotiated by 
investigators with sponsors on behalf of study participants when the project is 
submitted for ethical review?  What should accrue to participants and local 
communities when the research study has ended – experimental drugs only or 
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a contribution to infrastructure in the form of clinics and local health care 
providers?  This remains a contentious issue and is currently being debated 
by the World Medical Association and local RECs. 
 
A number of international guidelines impact on the review of research in South 
Africa.  Much of the regulation of research has originated in developed 
countries.  Current international regulations and guidelines have been 
described as paternalistic and imperialistic.  International guidelines based on 
universal principles are allegedly not always applicable in many developing 
countries where cultural, political and socio-economic contextual differences 
do not merge with Western concepts of personhood and autonomy.  To what 
extent are these international guidelines being used by South African RECs?  
There are also a host of local research ethics guidelines in South Africa – the 
Medical Research Council (MRC) Guidelines which comprise 5 different 
books and the South African Good Clinical Practice Guideline.  It is unclear 
which guidelines are being used by RECs and what the problems are in 
implementing such guidelines. 
 
Undoubtedly, the greatest challenge for RECs in South Africa will rest with the 
review of HIV vaccine trials.  While significant problems have already been 
encountered with phase one trial submissions, greater problems are 
anticipated with phase three trials.  The contentious issue of enrolling children 
and adolescents in HIV vaccine trials is an example of the many issues that 
RECs will grapple with over the next decade.  Other issues relate to informed 
consent, assessment of the risk-benefit ratio of participation, treatment of HIV 
positive participants who are screened out during recruitment or during the 
conduct of the trial.  This is another example of how science informs ethical 
deliberation as the completed phase three HIV vaccine trials to date clarify 
some of the vexing ethical issues inherent in the trials. 
 
South African RECs conduct both scientific and ethical review of research.  Is 
justice being done in this dual review system or is it time to consider other 
options?  Does adequate and appropriate scientific expertise exist on local 
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RECs?  If not, how can that be remedied, given the kinds of constraints that 
exist in South Africa? 
 
Having taken all of the above issues into consideration in the initial review of 
research protocols, RECs have an ongoing responsibility in the form of 
continuing review.  This involves monitoring the research to ensure that the 
study is being conducted in accordance with the protocol.  It also requires a 
continuous safety assessment of any serious or unexpected side-effects of 
the experimental treatment.  Such side-effects are also referred to as serious 
adverse events.  Monitoring and safety reporting remain two highly 
problematic areas of continuing review both internationally and locally. 
 
5.  Methodological Issues 
 
This dissertation is based on both empirical and conceptual research.  While it 
is a concern that empirical ethics research could detract medical ethics from 
its “true intellectual base in philosophy”, it is important to acknowledge that 
“philosophical argument often depends on empirical issues” (Hope, 1999: 
219).  This is borne out by the examples of the HIV vertical transmission trials 
and HIV vaccine trials presented in this dissertation.  The contribution that the 
empirical method can make to medical ethics will be presented in a manner 
that is complementary to the conceptual philosophical method.  Hence, 
methodologically, I am proceeding on the basis of both my empirical findings 
and independent philosophical-ethical reflection in response to most of the 
findings. 
 
6.  Empirical Research Component 
 
The empirical research component of this dissertation, includes both a 
questionnaire-based survey of RECs as well as the outcome of semi-
structured interviews with REC chairpersons in South Africa conducted during 
2003/2004.  Hence both quantitative and qualitative research methodologies 
have been incorporated. 
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The empirical research conducted for the purposes of this dissertation focuses 
on the ethical dilemmas faced in the review of clinical trial research.  Hence, 
the RECs included in the sampling process were those RECs that reviewed a 
significant proportion of clinical trial protocols.  Smaller RECs that review 
predominantly academic research were excluded. 
 
In the quantitative section, emphasis is placed on the structural and functional 
components of RECs in South Africa reflecting both their constitution and the 
review process.  The REC has been described as “a creature of a liberal, 
Western and pluralistic society”.  It is also constituted in terms of the “highly 
bureaucratized institutional structures of modernity”.  Such systems 
emphasize “procedural solutions to social controversy”.  As a result RECs 
may be “process orientated to the extreme” (Moreno, 1998: 476).  It has been 
charged that reliance on procedural aspects of review enshrined in guidelines 
and regulations that have their origin in the developed world may be 
insufficient to guarantee ethical standards of research in the developing world 
(London, 2002: 1080).  The quantitative survey assesses this and looks at the 
impact of REC constitution on function.  It also assesses the impact of 
bureaucratic procedures on substantive ethics issues in human participant 
research examined in the qualitative research component of the study.  These 
substantive issues were explored during semi-structured interviews with 
chairpersons or vice chairs of the major RECs in South Africa.  A semi-
structured interview guide was employed to conduct the interviews to elicit 
information on substantive ethical issues in clinical trial research in South 
Africa.  A number of important themes emerged from these interviews and are 
discussed in detail in Chapter Seven. 
 
The empirical research component presented in this dissertation aims to 
identify the extent and nature of structural, functional and substantive ethical 
problems inherent in the ethical review system in South Africa with a view to 
formulating solutions to some of the major challenges being faced.  It is 
intended that the solutions proposed will assist to improve the quality of 
ethical review in South Africa.  It is also intended that reflection on the 
substantive ethical issues that are problematic will empower South African 
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researchers to negotiate multinational collaborative research contracts from a 
position of strength with the ultimate objective of securing the protection of 
South African participants who volunteer for research projects. 
 
7. Structure of the Dissertation 
 
Chapter One examines the ethical issues that underpin the use of human 
subjects in medical experimentation.  The peculiarity of experimentation is 
discussed in respect of the conflict generated by the unavoidable use of 
humans as guinea pigs in the name of science and society.  In order to 
resolve this conflict, different theories are invoked as justification.  These 
range from justification based on a sacrificial theme to a social contract 
theory.  Of central importance is the concept of genuine informed consent.  
Here a hierarchy exists in terms of the most suitable subjects who are best 
equipped to provide valid consent.  Undoubtedly, scientists and researchers 
themselves lie at the top of this hierarchy.  Hence this chapter reflects on the 
tradition of self-experimentation by researchers as a point of departure.  
However, self-experimentation in itself cannot sustain the research 
endeavour, hence the justification for the use of healthy volunteers and 
patients must also be provided. 
 
As the research endeavour evolved further and further away from self-
experimentation to the use of groups of volunteers outside the scientific 
community, the potential for exploitation has increased exponentially.  Chapter 
Two highlights the historical accounts of exploitation of the rights of human 
research participants from 1932 to 1966.  The Tuskegee Syphilis Study 
conducted in Alabama between 1932 and 1972 is discussed and some of the 
research experiments conducted in the Nazi Concentration Camps at Dachau 
are recounted.  The Thalidomide disaster that resulted in phocomelia in 
newborn infants is discussed.  The Beecher expose is also explored using the 
Willowbrook Experiment as a case study. 
 
As a result of the exploitation detailed in Chapter Two, the international 
regulations and guidelines that resulted are outlined and critically appraised in 
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Chapter Three.  This includes the Nuremberg Code of 1946 as a result of the 
Nuremberg Trial, the 1964 version of the Declaration of Helsinki from the 
World Medical Association, The Belmont Report in 1979 after the Thalidomide 
disaster and the Tuskegee exposure.  The World Health Organisation’s 
guideline for developing world research – CIOMS 1993 will be discussed.  
Finally, the International Conference on Harmonisation Guideline (ICH-GCP) 
of 1997 will be briefly introduced. 
 
Chapter Four gives an account of the evolution of the HIV research debates 
that emerged in 1997.  The scientific and ethical arguments surrounding these 
debates are presented.  The response from South Africa is documented and 
the results of the South African arm of this very controversial study are 
presented.  This represents a very interesting illustration of how science 
informs ethical deliberation.  However, before such results were available to 
inform the debate, an attempt was made to revise major international 
documents – The Declaration of Helsinki 2000 and Council for the 
Organization of Medical Sciences (CIOMS) 2002.  The context and content of 
these revisions are also discussed in Chapter Four. 
 
Chapter Five describes and critically evaluates research disasters in 
developed countries since 1996.  It begins with a description of the events 
surrounding the death of Nicole Wan, a University of Rochester student.  The 
issues involving the death of Jesse Gelsinger in a gene therapy study at the 
University of Pennsylvania in 2000 are examined.  This chapter also dissects 
the intricacies of the Ellen Roche case that occurred at Johns Hopkins in 
2001.  Investigation into these problems has exposed the inadequacy of 
ethical review in some of the most developed institutions globally.  The case 
studies have also exposed a serious lapse in investigator responsibility.  This 
sets the stage for the concern that hence exists in respect of RECs in 
developing countries using South Africa as a prototype, bearing in mind the 
perception that South Africa is one of the more developed developing 
countries globally. 
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Chapter Six introduces the main part of the dissertation. In this, as well as in 
the next chapter, the empirical study on the nature and work of RECs in South 
Africa is reported and discussed. Chapter Six deals with the quantitative part 
of the study, and Chapter Seven with the qualitative study. Chapter Six 
presents the results of a questionnaire-based survey conducted on major 
RECs in SA during 2003/2004.  A status report on the composition and 
functioning of some of the major RECs in South Africa is contained in this 
chapter.  Composition is reflected in terms of gender, race, professional and 
non-affiliated expertise.  The ethics review system is described.  Procedural 
issues related to workload and the review process are surveyed.  Training and 
development of REC members is explored.  Commentary on the relevant 
issues is included. 
 
Chapter Seven contains a critical discussion of the complex of substantive 
issues in research ethics that RECs are currently grappling with, and that 
were alluded to earlier in this introduction – see paragraph 4, pp. 10-13. 
These issues are informed consent, standards of care, use of placebos in 
research, post-trial care of participants, participant remuneration, and the 
ethics of HIV vaccine trials.  These themes have emerged from an analysis of 
semi-structured interviews with REC Chairpersons and reflect the ethical 
deliberation taking place on RECs in South Africa.  The comments of the 
various chairpersons have been collated on each theme and are presented, 
followed by a commentary to contextualise each theme on a national and 
global level. 
 
An important outcome that must be achieved in South Africa relates to 
reaching an adequate consensus on a host of research ethics concepts to 
achieve national standardisation and a high level of consistency in ethical 
review.  In addition, initiatives are necessary to improve research participant 
protection in this era of high risk and novel research.  The major problems 
identified in the empirical research conducted will be summarised and 
recommendations will be made in Chapter Eight to address some of the major 
issues being faced in research ethics in South Africa.  Recommendations will 
of necessity relate to improvements in REC structure and function such as 
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REC composition and the structure of the REC system in South Africa.  They 
will also extend to improvement of substantive research ethics issues in South 
Africa.  These recommendations will explore ways in which the informed 
consent process can be enhanced.  The implementation of some of these 
recommendations will also be described. 
 
However, even if the review system in South Africa is functioning at an optimal 
level, this in itself is insufficient to avert research disasters of the magnitude 
that have recently occurred.  The findings of this study, examination of recent 
research disasters at centres of excellence, in particular, the Bezwoda case in 
South Africa, and a review of international literature indicate that participant 
protection cannot be ensured even by a highly efficient REC.  This situation 
arises when individual researchers are inadequately trained, evade the 
system of ethical review or conduct scientific fraud after receiving ethics 
committee approval.  Hence, scientific integrity is examined in Chapter Nine 
using Professor Bezwoda as a South African case study. 
 
In Chapter Ten, the final chapter, my conclusions will be briefly presented and 
discussed. 
 
8. Contribution to the ethics review system in South Africa 
 
Based on empirical data and conceptual analysis, proposals are made in this 
dissertation to restructure both RECs and the ethics review system in South 
Africa – see, in particular, chapter eight.  It is also proposed that local RECs 
reviewing clinical trials form a national association.  An electronic 
communication network to link all RECs in South Africa is described.  While 
many initiatives are underway in South Africa to improve capacity of REC 
members, clinical investigators must receive rigorous training simultaneously.  
A principle based ethics review system combined with an ethic of 
responsibility on the part of investigators is presented as an important 
requirement to improve participant protection in research.  The development 
of an enhanced Good Clinical Practice training program for investigators and 
REC members is briefly discussed as an important solution.  Finally, patient 
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advocacy within research is neglected both on RECs in the form of community 
representation and in research settings.  Participants in research are 
important but neglected role-players in the research endeavour.  Education 
programs to empower research participants and actively engage them in the 
informed consent process are suggested as an innovative idea for South 
Africa. 
 
At an international level, the relationship between research and health care is 
explored. Redefining this relationship will impact significantly on a number of 
substantive ethics review issues in South Africa.  
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Chapter 1 
 
Human Experimentation – The Early Days... 
 
The ethics of experimentation with human participants revolves around a 
critical moral point where science and ethics intersect.  There is no doubt that 
the goals of medical progress conflict with the inviolability of the human 
person.  Research ethics committees aim to offer protection to human 
participants in the course of research.  However, what moral goods are they 
aiming to protect?  Most RECs are aiming to protect human health and safety 
while simultaneously trying to promote medical progress, making the 
assumption that informed consent will allow for both goals to be achieved 
satisfactorily.  Jonas in 1969 raised the question of whether informed consent, 
in itself, is enough and Emanuel echoes this sentiment today in the 21st 
century when he argues that informed consent in and of itself is insufficient to 
justify human experimentation (Emanuel, 2000: 2701). 
 
Experimentation, although originally sanctioned by natural science, did not 
raise moral problems as long as inanimate objects were involved.  However, 
as soon as animate sentient beings were used as experimental subjects, 
questions of conscience arose.  Medical experimentation using human beings 
who possess both sentience and rationality is morally problematic (Macklin, 
1975: 435-37).  Human experimentation especially in medical research raises 
questions of human dignity: 
 
What is wrong with making a person an experimental subject is not so 
much that we make him thereby a means, which happens in social 
contexts of all kinds, as that we make him a thing, a passive thing 
merely to be acted on and passive not even for real action, but for 
token action whose token object he is.  His being is reduced to that of a 
mere token or sample. 
       (Jonas, 1969: 107) 
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The entire process of human experimentation invokes the Kantian concept of 
the use of people not only as a means to an end but as ends in themselves.  
The research setting has the potential to regard human participants as useful 
instruments to achieving the goals of the investigator and hence it is important 
to take cognisance  of the Kantian formulation: 
 
 One must act to treat every person as an end and never as a means 
 only 
      (Quoted in Beauchamp, 2001: 350) 
 
Kant essentially would approve of the research endeavour as long as a 
participant was treated as an end in him or herself as well as a means to an 
end.  Whether this can be achieved in non-therapeutic research or in placebo 
controlled therapeutic research is unclear. 
 
From Hippocratic times, medical practice was not clearly distinguished from 
experimentation (Jonsen, 1998: 125-165).  Unlike the doctor-patient 
relationship, where the human patient is an end in him/herself, the 
investigator-participant relationship renders the study participant a means to 
an end.  The objectification of the human subject in the context of medical 
research creates a conflict between individual interests and societal interests 
and renders it necessary to justify the possible infringement on human dignity. 
 
Such justification may be based on a sacrificial theme or a social contract 
theme where health is viewed as a public good.  Jonas, in his ground breaking 
article on the ethics of human experimentation in 1969, refers to the 
commonly used conceptual framework of individual good versus societal 
good.  He argues that the basic good of an individual is a known and 
accepted entity.  However, the concept of societal good is less clear.  If 
research is an established societal good, society may have a moral right to 
the resultant common good in which case consent of individuals would not be 
necessary. 
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Human subjects could then be conscripted for research in the same way 
soldiers are conscripted for military duty.  
 
The sacrificial theme as justification for participation in research has been 
invoked on the basis of its historical compulsory role in early communal life.  
War invokes a strong use of this justification where soldiers are conscripted by 
law without consent.  During times of war, a sacrificial justification was 
employed for research as it was employed for conscription of soldiers.  World 
War Two created an intensification of the research endeavour.  In 1941, 
President Roosevelt’s Committee on Medical Research (CMR) urged 
institutions and investigators to produce “rapid improvement in military 
medicine”.  Approximately 600 protocols costing $25 million were “sponsored 
and supervised by the CMR”.  Much of the research, especially infectious 
disease research was conducted in prisons, mental hospitals and military 
camps.  The prisoners involved in malaria research at Michigan’s Joliet prison 
were praised for their “contribution to the war effort”. According to David 
Rothman, 
 
the nation was at war and a sense of urgency pervaded the 
laboratories…. the rules of the battlefield seemed to apply to the 
laboratory. 
     (Rothman, 2003: 85) 
 
While Jonas does not wish to draw a parallel between early human sacrifice 
and experimentation, he concedes that 
 
something sacrificial is involved in the selective abrogation of personal 
inviolability and the justified exposure to gratuitous risk of health and 
life, justified by a presumed greater good.    
       (Jonas, 1969: 111) 
 
Jonas, however, dismisses the possibility of conscription of research subjects. 
He argues that conscription of soldiers must be distinguished from the 
research endeavour because conscription for war is in the setting of a real 
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national emergency while the research endeavour is an artificial situation – 
“token action” - not born out of dire need and where benefit to society is 
uncertain. He describes experimentation as “fictitious”. In war “we conscript 
them according to law” (Jonas, 1969: 109-10).  As such, society may have 
only a moral claim and not a moral right to the common good. In this event 
consent would be absolutely necessary. 
 
While I agree that conscription of research participants is not justifiable by a 
research endeavour that produces uncertain benefit to society, I would argue 
that the basis for the Jonas argument is flawed in the following respects.  
Firstly, he raises a contentious point regarding the motivation for war.  Just as 
the research endeavour may not be born out of dire need, so too may the 
situation of war not necessarily be born out of national emergency but rather a 
host of other political agendas.  This view is expressed by Jimmy Carter ex-
president of the United States regarding the war against Iraq.  He describes 
the following principles of a “just war”: 
 
1. The war can be waged only as a last resort, with all non-violent options 
 exhausted. 
2. The war’s weapons must discriminate between combatants and non-
 combatants. 
3. Its violence must be proportional to the injury suffered. 
4. The attackers must have legitimate authority sanctioned by the society 
 they profess to represent 
5. The peace it establishes must be a clear improvement over what 
 exists. 
 
He argues that the war against Iraq in the absence of international support 
violates these principles and hence does not justify the war (Carter, 2003).  I 
would support this view. 
 
It is understandable that in 1969 when Jonas wrote this article, the justification 
for wars waged at the time may have been valid, but this does not hold true 
today. 
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The second point that undermines the basis for the Jonas argument that one 
cannot draw parallels between the motivation for war and the motivation for 
research is the national emergency he ascribes to a war and the “fictitious” 
situation he ascribes to research.  There are many examples today of 
research being motivated by national and international emergencies – the HIV 
pandemic and the Severe Adult Respiratory Syndrome (SARS) outbreak 
represent two important examples– yet even under these circumstances, one 
cannot conduct research without consent. 
 
The Jonas argument rests on differentiating war and research to prove that 
conscription cannot be justified in research.  However, a fair comment to 
make in the 21st century is that neither war nor research can justify 
conscription.  He also assumes that most research is conducted in an artificial 
setting under non-emergency situations.  It is however evident that 
circumstances exist for urgent research based in the reality of global health 
care needs.  
 
Hence his argument can be reformulated as follows: 
 
If research is a social good and society has a moral right to research, consent 
would be unnecessary.  Participants for research could then be conscripted as 
soldiers are in wartime.  However, war is not always based on national 
emergency, when it is claimed to be so, this may be questionable.  Similarly, 
research is not always based on national urgency but even when it is, the 
situation is not so urgent as to require conscription.  Hence neither war nor 
research justifies conscription.  Therefore consent for research is always 
necessary. 
 
On the other hand, a social contract theory would infringe on the rights of 
individuals for their own benefit and the benefit of society.  The purely 
sacrificial nature of the participation is thus eliminated.  Benefit is mutual and 
general and one cannot be expected to die for a cause.  Jonas sees the 
research endeavour as lying somewhere between a purely sacrificial ritual 
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where society benefits at the peril of individuals and a social contract 
fulfillment where there is mutual benefit of individuals and society. 
 
While medical research can be viewed as emergency research when 
extraordinary measures must be taken to save humanity, most of medical 
research is conducted in non-emergency situations to improve the health of 
society.  It is an expectation of society that there is active and constant 
improvement in all domains of life.  This is an expansive goal that definitely 
lacks urgency but it is certainly worth sacrifices in the name of progress.  
Progress is by choice an acknowledged interest of society.  Science is a 
necessary instrument of progress and research is a necessary instrument of 
science.  In medical science, experimentation on human subjects is a 
necessary instrument of research.  Therefore, Jonas concludes that human 
experimentation has come to be a societal interest.  However, he argues that 
such progress is melioristic.  Future society receives the improvements we 
create as an act of grace, not as a right.  Jonas illustrates this with an 
example:  It is a right of future society to inherit a planet that is not plundered 
but it is not their right to inherit a cure for arthritis.  This sentiment is echoed 
by Henry Beecher, in his world renowned article on “Ethics and Clinical 
Research” when he quotes Pope Pius XII: 
 
 …science is not the highest value to which all other orders of 
 values….should be subordinated. 
        (Beecher, 1966: 1354) 
 
As a result of the gratuitous nature of research, the way in which self-sacrifice 
for research is elicited is important.  Freedom and voluntariness are the first 
conditions to be observed.  The surrender of one’s body to medical 
experimentation does not fall within a social contract. It can be argued that it 
does – as a form of repayment for experimentation in the past and medical 
progress that occurred in the past.  However, in that case, Jonas argues, 
humans would be indebted to past martyrs, not society.  As such society 
would have no right to call in the debt.  Furthermore, gratitude is not an 
enforceable social obligation and does not imply emulations of the deed.  
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Provided the submission to medical experimentation in the past was a 
voluntary deed, it can be done again – based on free will. 
 
Moral law, on the other hand, asks more of an individual than social contract.  
According to the Golden Rule, an individual is required to give as she or he 
wishes to be given to under like circumstances, but not in order that he or she 
be given to and not in expectation of a return. 
 
In the positive formulation of the Golden Rule – do unto others as you would 
wish them to do unto you – the prescriptive force is gradually lost.  We may 
expect someone to come to the assistance of his/her neighbour but we may 
not expect that person to give his/her life for the neighbour.  If the person did 
give his or her life that would be morally praiseworthy but if he omitted to do 
this, it would not be morally blameworthy.  Giving his life is a matter between 
him and God. 
 
Jonas argues that moral value exceeds moral law; self-sacrifice is an ultimate 
commitment and must be respected.  As such, who should be approached to 
make this level of commitment to participate in research?  Who should be 
used as a guinea-pig in human experimentation?  A patient already involved 
in the care of a doctor was the natural point of departure in early days of 
experimentation.  However, the dependent nature of such a relationship would 
make voluntary consent problematic.  In 1886, Dr Withington advocated a Bill 
of Rights to protect patients from the injustices that could arise in the pursuit 
of science (Withington, 1886: 15-19).  In the early days of experimentation, a 
“roughly defined ethic” accompanied the use of patients for experimentation 
(Jonsen, 1998: 130).  New treatments could be used on patients only if such 
treatments were to benefit patients.  However, new treatments that had no 
relationship to the patient’s illness could not be used on patients.  Instead, the 
new interventions, especially if they were dangerous, had to be tested on 
volunteers with free and voluntary consent.  In addition, the “researcher was 
to make himself the first volunteer” (Jonsen, 1998: 130). 
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The philosophical question of the worth of human life must be examined.  
Whose life should be sacrificed in the interests of science?  Is the life of the 
investigator more crucial to future scientific endeavours and hence too 
valuable to be sacrificed?  Early experimentation indicated that human life that 
was experimented on in unethical ways frequently involved prisoners and 
mentally ill patients.  This was an indication that these members of society 
were accorded a lower status and were regarded as dispensable – a social 
utility standard of utility and expendability. 
 
This is documented in the oldest world literatures that make reference to 
experimental work with man and animals.  In ancient Persia the king would 
hand over condemned criminals for use in experimental purposes for science.  
Later, this practice was followed by the Ptolomies in Egypt (Beecher, 1969: 
109). 
 
This practice continued in modern times.  Colonel R. P. Strong was a 
professor of tropical medicine at Harvard University.  He is credited as the first 
investigator (in modern times) to use prisoners as experimental subjects.  In 
1904 he used prisoners who had been condemned to death in experiments on 
plague.  Later, he used prisoners in the Phillipines to study Beriberi.  These 
prisoners were given gifts of tobacco for their participation.  In 1914, doctors 
Goldberger and Wheeler conducted experiments on Pellagra on white male 
convicts in the State of Mississippi who had apparently volunteered for the 
experiments (Ivy, 1948: 4).  In many instances, participation in research was 
rewarded with a sentence reduction.  This clearly indicates that participation in 
research under these circumstances was less than voluntary. 
 
If informed consent is used as the basis for justifying the conduct of research 
then it follows that those who are experimented upon should be those who are 
most capable of providing consent.  According to Jonas, the best educated 
with the greatest degree of choice – such as investigators themselves - should 
be at the top of the list.  The person with the “strongest motivation”, the person 
with the “fullest understanding”, the “freest decision” is most capable of 
consenting.  The scientist sits at the top of this hierarchy of people and is most 
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likely to provide free and fully informed consent that the research endeavour 
requires. 
 
Dr Rosalyn Yalow, a scientist from the Bronx in New York, won the Nobel 
Prize in 1977 for development of a laboratory test known as the radio immune 
assay (RIA).  This technique is used to measure very small amounts of 
substances in the body. Her discovery required an enormous amount of 
experimentation. 
 
Like Jonas, her thoughts on informed consent are reflected in her statement: 
 
In our laboratory, we always used ourselves because we are the only 
ones who can give truly informed consent.    
       (Altman, 1985: 314) 
 
The most valuable and scarcest members, the least expendable members of 
society would have to be the first for risk and sacrifice provided that the 
research objective is worthy enough (Jonas, 1969: 120).  The most vulnerable 
members of society - the mentally challenged, children, prisoners and 
vulnerable communities - would then fall to the bottom of the list of possible 
research subjects and would require the highest degree of protection. 
Claude Bernard emphasized the importance of self-experimentation: 
Morals do not forbid making experiments on one’s neighbour or on 
one’s self….Christian morals forbid only one thing, doing ill to one’s 
neighbour.         
     (Quoted in Altman, 1985: 16) 
 
Santorio Santorio is the earliest recorded self-experimenter.  He lived in Italy 
from 1561 to 1636.  He is recognised as the first physician to use a 
thermometer to measure body temperature.  He also described a concept 
known as “insensible perspiration” used widely by physicians in the 
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prescription of intravenous fluids.  Over a thirty year period he conducted a 
number of experiments on himself to document the response of his own body 
to various physiological and pathological conditions. 
 
More than 200 years later, Max von Pettenkofer swallowed a pure culture of 
the cholera bacillus when he was 74 years old.  Due to previous exposure to 
Cholera, he had developed immunity and did not become seriously ill despite 
the large dose of bacteria he had ingested. 
 
When he recovered, he had the following to say: 
 
I would have died in the service of science like a soldier on the field of 
honour.  Health and life are, as I have so often said, very great earthly 
goods but not the highest for man.  Man, if he will rise above the 
animals, must sacrifice both life and health for the higher ideals. 
               (Altman, 1985: 25) 
 
In 1767, John Hunter inoculated himself with pus from a lesion containing 
gonorrheal pus and later developed both gonorrhea and syphilis.  He 
concluded, erroneously, that gonorrhea and syphilis were manifestations of 
the same disease (Beecher, 1969: 110). 
 
In 1789, Edward Jenner found himself in the midst of a swinepox outbreak in 
Gloucestershire and decided to immunise his ten month old son and two of his 
neighbour’s servants.  He inoculated his son with pus from a lesion on the 
baby’s nurse who had herself contracted the swinepox infection.  Eight days 
later the baby became ill and developed a skin rash.  Several months later, 
Edward deliberately infected his son and the nurse with smallpox five times to 
test the efficacy of the immunisation.  Neither the baby nor the nurse 
developed any symptoms of smallpox.  Two years later, Jenner challenged his 
son with smallpox again.  This time he had a severe reaction as a result of 
contamination of the inoculation material but he recovered.  A year later, 
Jenner inoculated him with smallpox again and he survived.  However, in the 
years following those inoculations, he was often unwell and displayed signs of 
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mild mental retardation.  At the age of 21 he died of tuberculosis.  Jenner was 
devastated but considered the swinepox experiment to be successful (Kerns, 
2004). 
 
Reed’s Yellow fever experiments in the 1880s illustrated both the concepts of 
self-experimentation and the emergence of the healthy volunteer.  Yellow 
Fever was a disease associated with high morbidity and mortality.  During the 
Spanish American War thousands of soldiers had died as a result of the 
disease.  The Panama Canal Project in the 1880s was halted as a result of 
the disease.  The hypothesis was that the disease was mosquito borne.  Dr 
Reed and three colleagues doctors Carroll, Lazear and Agramonte went to 
Cuba to verify the mosquito hypothesis.  Their plan was to allow mosquitoes 
that had fed on patients with Yellow Fever to bite humans.  They were the first 
subjects.  Carroll and Lazear initiated the experiment and both became ill.  
Carroll recovered but Lazear died.  Dr Reed decided to omit further self-
experimentation and to recruit volunteers.  Twenty five volunteers became ill 
but none of them died.  The experiment identified the source and mode of 
infection in Yellow Fever and made an enormous contribution to medical 
science. 
 
In the 1940s Dr Andrew Ivy stated that there should be no prior reason to 
suspect that death or disabling injury might result from an experiment.  He 
referred to the Yellow Fever experiments where experimenters served as 
research subjects “along with non-scientific personnel” (Jonsen, 1998: 135). 
 
Self-experimentation is generally viewed with scepticism.  However, there are 
a number of arguments that could be used to justify self-experimentation 
(Davis, 2003: 179-182). 
 
The “Good Faith” argument was raised by Henry Beecher in his suggestion 
that the willingness of an investigator to be a subject in his/her own trial is a 
good test of how reasonable he/she thinks it is to enroll others (Beecher, 
1969: 110).  However, the investigator’s vested interest in the research may 
result in him/her underestimating the risks and overestimating the value of the 
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research.  The investigator’s health profile may also differ significantly from 
that of the subjects. 
 
The “Golden Rule” argument classically refers to doing unto others as one 
would have done unto oneself.  In research 
 
 one ought not to inflict risks on others in the cause of science that one 
 is not willing to inflict on oneself. 
                (Davis, 2003: 177) 
 
Similarly Kant’s Categorical Imperative states that  
 
 I ought never to act except in such a way that I can also will that my 
 maxim should become a universal law. 
        (quoted in Paton, 1964) 
 
According to Davis, this argument “does not support a duty to experiment on 
oneself but rather a duty not to experiment on others if one would not be 
willing to experiment upon oneself.”  Dr Kenneth Mellanby, a British 
researcher, invokes this argument to support his decision to participate in any 
experiment at least once before asking a volunteer to follow suit (Altman, 
1985: 309). 
 
The “Risk Argument” refers to experiments where the risk seems too high to 
enroll lay subjects or has not been pre-determined.  Self-experimentation 
might then prove the experiment to be less risky than originally feared with the 
resultant enrolment of lay subjects. 
 
Unlike the above three arguments which attempt to justify self-
experimentation, the “Investigator’s Autonomy” argument emphasizes the 
investigator’s right to self-experimentation.  Based on the principle of 
autonomy an investigator has a moral right to self-experiment. 
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Hans Jonas has stated that  
 
 no scientist can be prevented from making himself a martyr for his 
 science. 
                (Jonas, 1969: 110) 
 
Respect for autonomy forbids the interference with sufficiently informed and 
competent people whose actions affect only themselves.  Hence autonomy 
may be limited by the principle of harm to other people (Mill, 1986).  The 
investigators autonomy argument holds true as long as no risk is posed to 
third parties. 
 
The most common reasons doctors give for self-experimentation is that it 
allows them to “share the risk with a patient or volunteer and that it provides 
confidence to prospective subjects” (Altman, 1985: 303).  In addition, there 
are other reasons cited such as reliability, dependability, convenience, 
curiosity, tradition and an ethical code reflecting the Golden Rule as applied to 
medical research (Altman, 1985: 304).  Researchers believe they will be more 
reliable in adhering to protocol blueprints and more dependable in 
observations and data recording than non-scientific lay volunteers. 
 
On the other hand, self-experimentation alone may not be practical for the 
following reasons: 
 
1. The requirement for large numbers in experimentation would render 
 self-experimentation by itself inadequate and scientifically invalid. 
2. Double blinding is not possible. 
3. The use of a control group is required in most clinical trials. 
4. Investigators may be biased towards a new intervention 
5. Investigators may minimise their risk calculations in their enthusiasm to 
 proceed with the research. 
6. Investigators may not meet one or more of the inclusion criteria to 
 participate in the research like age or gender or disease being 
 researched. 
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In many ways self-experimentation was used as a substitute for the ethics 
committee’s sanction of research in an era when ethics committees had not 
been established.  With the establishment of RECs and sanction for research 
on large groups of volunteers, the practice of self-experimentation faded into 
obscurity. 
 
However, with the advent of HIV vaccine research in the 20th century, the 
notion of self-experimentation has been revisited.  In 1986 Dr Daniel Zagury of 
the Pierre-et-Marie Curie University in Paris was the first person to test a 
candidate HIV vaccine on himself.  The vaccine contained a protein from the 
outer coat of the HI virus called gp160 which was inserted into a live vaccine 
(cowpox) virus.  After injecting himself with the vaccine, he tested his blood 
weekly for 9 weeks and detected antibodies to gp160.  The purpose of this 
self-experiment was to test the vaccine’s ability to produce an immune 
reaction in humans and to determine its safety.  It was not intended to test 
efficacy of the vaccine (Altman, 1985: 26-27). 
 
Since March 1998, a large number of doctors, health care professionals and 
healthcare advocates had volunteered for vaccine trials – currently in progress 
(IAPAC 2003).  As recently as 2000 a group of clinicians volunteered to 
participate in trials of a live attenuated vaccine (Pinching, 2000: 44-46). 
 
However, a survey conducted in the Western Cape, South Africa in 2001 
amongst a group of doctors to assess their willingness to participate in a 
hypothetical phase 1 trial yielded interesting results.  While 20% of the sample 
of 289 doctors initially agreed to self-participation, this figure dropped to 10% 
after trial related risks were contemplated (Moodley, 2002: 904-06). 
 
While only 10% of the doctors were themselves willing to participate, 32% of 
doctors were happy to recruit lay people to participate – indicating a clear 
abrogation of the “Golden Rule” – do unto others as you would have done 
unto yourself. 
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Furthermore, commentators on self-experimentation emphasize the fact that 
willingness to perform the experiment in itself is insufficient.  The critical issue 
lies in whether the researcher actually participates in the experiment.  One 
can only assume that with low levels of willingness to participate in 
hypothetical HIV vaccine trials, actual participation in real time trials will be 
even lower. According to Sir George Pickering, Regius Professor of Medicine 
at Oxford in England, there is one golden rule to guide the researcher 
regarding the justifiability of the experiment: 
 
Is he prepared to submit himself to the procedure?  If he is, and if the 
experiment is actually carried out on him, then it is probably justifiable. 
If he is not, then the experiment should not be done.   
             (Altman, 1985: 313) 
 
The HIV vaccine trials also raise the issue of the conceptual challenge to 
medical ethics that is posed by a situation of urgency as exists with the HIV 
pandemic.  Does this situation of urgency justify self-experimentation?  Does 
the “Risk argument” of Davis apply where a live attenuated strain of the virus 
is to be tested? 
 
Despite the ethical justification for self-experimentation, even Jonas 
acknowledged that using the scientific community and the most highly 
educated non-scientific members of society exclusively would represent an 
ideal situation that would not be statistically or scientifically sustainable.  
Hence at some point it becomes absolutely critical to make a pragmatic shift 
from self-experimentation to experimentation on patients and healthy 
volunteers.  This, however, would have to be done with the greatest caution, 
respect and freedom of enrolment and participation. 
 
In the next chapter it will become evident how research atrocities were 
committed when the sanctity of participation in human research was not 
acknowledged and when participation was conducted without fully informed 
and voluntary consent. 
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Chapter 2 
 
Research Ethics – A Historical Perspective 
 
 
2.1. Introduction 
 
Even though Jonas refers to medical progress as melioristic and gratuitous, it 
is important to acknowledge the enormous advances generated by the 
research endeavour in medical diagnosis and treatment.  The global 
eradication of smallpox as a result of experimentation described in chapter 
one bears testimony to this.  A range of other advances in all spheres of 
medical science impacted on patient care and quality of life as a result of 
experimentation.  While the initial emphasis was placed on the eradication of 
infectious diseases, an objective greatly enhanced by the discovery of 
Penicillin and other antibiotics, this was later expanded to chronic diseases as 
well.  There is no doubt that enormous benefits accrued to society as a direct 
result of the research endeavour.  It is therefore not surprising that as the 
tradition of self-experimentation gave way to deliberate experimentation on 
groups of human subjects, the utilitarian justification for research was invoked.  
Unfortunately, in many instances this was equated with the utilitarian 
justification for war.  The spirit of wartime urgency was extrapolated to 
research. During and after the Second World War pressure was brought to 
bear on researchers to provide cures for infectious diseases to protect troops 
and civilians alike.  Between 1932 and 1966 there was an enormous 
expansion in research activity globally, but most notably in the United States. 
Individual good was subjugated to the common good without hesitation.  In 
many instances, the rights of the individual were subjugated to the benefits of 
science and society.   Human subjects were enrolled into research projects 
often without their consent and under a therapeutic misconception based on 
an unflinching trust of the medical profession. 
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The story begins in 1932… 
 
2.2 The Tuskegee Syphilis Study 
 
On 26 July 1972 the New York Times carried a shocking story: 
 
For 40 years, the United States Public Health Service has conducted a 
study in which human beings with Syphilis, who were induced to serve 
as guinea pigs, have gone without treatment for their disease……the 
study was conducted to determine from autopsies what the disease 
does to the human body. 
 
The Tuskegee Syphilis Study began in 1932 and ended in 1972.  Although 
initially planned for one year, it continued for 40 years.  The population of 
Macon County, Alabama had one of the highest rates of Syphilis in the 
country. 
 
600 Poor African-American men from Macon County were recruited into a 
project that set out to establish the natural history of Syphilis.  400 of these 
men had Syphilis and 200 were used as controls.  Both patients and controls 
were told that they had “bad blood” and should have regular medical 
examinations including lumbar punctures. 
 
These men had been promised free transportation to and from hospital, free 
hot lunch, free medical care for any disease other than Syphilis and free burial 
after autopsies had been performed.  However, they were not aware that they 
were subjects in a research study! 
 
When the study began, there was no definitive treatment for Syphilis.  Heavy 
metals (arsenical and mercurials) were being used but were of doubtful 
efficacy.  However, when Penicillin was discovered in 1945 and was found to 
be effective against Syphilis, this treatment was deliberately withheld from the 
men on this study as the researchers wanted to see what the natural history of 
untreated Syphilis would be.  Even though it was known that Penicillin would 
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be useful in the early stages of the disease and most subjects were already in 
the late stages of the disease, the treatment was not offered to any of the 
volunteers (Altman, 1985: 18). 
 
The Tuskegee Syphilis Study was not a secret.  It was well known in the 
Public Health Service and had been published in medical journals.  An 
employee of the Public Health Service, Peter Buxtun accidentally heard about 
it in 1966 and attempted to expose it.  Even though he wrote a letter to the 
Centres for Disease Control (CDC) and got the study reviewed, a decision 
was taken to continue with the study.  It was only in 1972, when he leaked the 
story to the media that steps were taken to investigate and terminate the 
study. 
 
On 24 August 1972 the Tuskegee Syphilis Study Ad Hoc Panel comprising 
nine citizens was appointed to establish, inter alia, whether the study was 
ethical, whether and how it should be terminated.  The report published in 
1973 found the study to be unethical at its inception and during the 
continuation.  It ordered the study to be terminated and the surviving victims to 
be compensated. 
 
When the story was eventually exposed in 1972, 74 of the untreated subjects 
were still living (Jonsen, 1998: 146-48).  However, by this time, 100 men had 
died of Syphilis, 40 of their wives had become infected and 19 babies were 
born with Congenital Syphilis. 
 
The expose highlighted both racial discrimination and abuse of the poor and 
powerless as well as unethical research and clinical practices. 
 
As a direct result of the Tuskegee study, the National Research Act was 
passed in 1974 in the United States and the Belmont Report was published in 
1979.  In 1997 President Clinton issued a formal apology to the study 
participants and their families on behalf of the United States government. 
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2.3. Experimentation during the Second World War 
 
2.3.1 The Nazi Experiments 
 
The Nazi experiments actually preceded the Second World War. 
 
In 1933, in keeping with an emphasis on Eugenics, the “Law for the 
Prevention of Genetically Diseased Descendants” was in existence and 
sterilization was enforced.  Within four years, 300 000 patients had been 
sterilized.  As can be expected, sterilization research thrived. 
 
In 1939, at the beginning of the war, the T4 Euthanasia Program was initiated 
in which adults and children who were deemed futile or terminal were killed 
and their organs were harvested. 
 
Dr Klaus Karl Schilling, an eminent malaria expert, infected more than one 
thousand prisoners at Dachau with malaria.  More than 400 died, many from 
complications of treatment with experimental malaria drugs, often given in 
excessively large doses (Altman, 1985: 16). 
 
Other Dachau Concentration Camp experiments conducted with a military 
objective included: 
 
1. The prolonged submersion of people in subfreezing water to test the 
 limits of bodily endurance. Humans were held in tanks of ice water for 
 up to three hours to test methods of resuscitation for pilots who had 
 been chilled or frozen after falling into the sea (McNeill, 1998). 
2. Locking prisoners in airtight chambers and then rapidly changing the 
 pressures to duplicate atmospheric conditions that an aviator might 
 encounter in falling  long distances without a parachute or oxygen. 
3. Infecting individuals with infectious disease like cholera, diphtheria and 
 smallpox and then testing experimental and mostly useless vaccines 
 on them. 
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4. Injecting phenol or gasoline into the veins of prisoners, who died  
 within sixty seconds. 
5. Testing to establish how long humans could survive without water and 
 after eating huge amounts of salt (Altman, 1985: 17). 
6. Exposing subjects to irradiation followed by castration of subjects to 
 study the effects of X-Rays on the genitals. (Rothman, 2003: 61). 
 
The Mengele Twin Studies also became notorious at this time.  Josef Mengele 
was interested in the genetic study of twins.  He collected twin children from 
the camps, measured their physical features, performed cross-transfusions, 
transplanted genitals and other organs and created artificial Siamese twins.  
He also used his twin collection for comparative studies, infecting one child 
and then killing both for autopsy (Jonsen, 1998 : 135). 
 
At the end of the Second World War, the Nuremberg Trial was held and 22 
doctors were found guilty of research atrocities.  In 1947 the Nuremberg Code 
was developed.  This code is based on ten principles – the most striking of 
which are the importance of research being based on good science and the 
concept of voluntary consent.  The code is discussed in more detail in Chapter 
Three. 
 
2.3.2 The Japanese Experiments 
 
Coinciding with the Nazi experiments, Japanese doctors and bioscientists 
were conducting equally horrific experiments on Russian, Chinese, American, 
British and Australian prisoners.  Japanese General Shiro Ishii was in charge 
of the Japanese Army Unit 731 that he had set up in 1935 in remote, high 
security headquarters in a village in Japanese occupied Manchuria.  The 
experiments included freezing, ballistics and live vivisection.  General Ishii’s 
aim was to make a biological weapon that could win the war for Japan.  These 
experiments were, however, kept secret for many years after the war as a 
result of an agreement between the United States government and the 
Japanese government.  Japanese experimenters were granted immunity from 
prosecution in exchange for information about biological warfare (Williams, 
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1989). This reflects the pivotal role of politics in the development of codes of 
ethics for the conduct of research on human subjects (McNeill, 1998: 371). 
 
2.4. The Thalidomide Disaster (1962) 
 
In the 1950s Thalidomide was approved as a sedative in Europe.  The drug 
was widely used on pregnant women for sedation, morning sickness and to 
prevent abortion or premature delivery.  However, it had not been approved in 
the US by the Food and Drug Administration (FDA).  Dr Frances O. Kelsey of 
the FDA had succeeded in keeping the drug, “Kevedon” manufactured by 
Merrel Pharmaceuticals, off the American market.  She was sceptical about 
the scientific data.  She declared that “Merrel had compiled an interesting 
collection of meaningless pseudoscientific jargon apparently intended to 
impress chemically unsophisticated readers.”  Dr Kelsey later noticed an 
article in the British Medical Journal indicating that some users of the drug had 
developed peripheral neuropathy.  
 
By this time (1960) the pharmaceutical company (Merrel) had started a pre-
marketing campaign “in the guise of a clinical investigation program” and 
enlisted about 1200 “influential physicians” to prescribe the drug (Jonsen, 
1998: 140).  The drug was given to 20 000 American women, 3750 of whom 
were of child-bearing age and 624 of whom were pregnant (Rothman, 2003: 
64).  Many patients were not aware that they had been taking an experimental 
drug, nor had they given their consent.  During this time, Dr Helen Taussig of 
Johns Hopkins School of Medicine decided to investigate the European and 
British “epidemic of infant monsterism” where infants were being born with 
missing limbs and found that the condition was associated with the use of 
Kevedon.  The drug had severe terratogenic side-effects termed phocomelia. 
 
Merrel Pharmaceuticals informed doctors of the dangers of the drug and 
withdrew their New Drug Application from the FDA on 8 March 1962. 
 
This story broke on 15 July 1962 in the Washington Post (Jonsen, 1998: 140-
41). 
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As a result of this experience with Thalidomide, the government’s control over 
the approval of new drugs strengthened.  Pharmaceutical companies 
submitting applications for registration of drugs had to provide “substantial 
evidence of efficacy” in addition to safety.  For the first time full and free 
consent from all participants in drug trials was required in the United States.  
However, this meant that investigators had to inform participants that the new 
drug was being used “for investigational purposes” and consent would be 
obtained from participants or their representatives except where investigators 
“deem it not feasible or, in their professional judgement, contrary to the best 
interest of such human beings”.  This was a far cry from later versions of 
informed consent (Jonsen, 1998: 141). 
 
2.5. The Beecher Expose (1966) 
 
Dr Henry Beecher, an anaesthetist at Harvard University, played a crucial role 
in exposing numerous instances of how researchers abused their discretion in 
the decades that followed the Second World War.  As a researcher himself he 
had been sensitised to the slippery slope one enters in the context of 
research.  He was however, committed to good science and was concerned 
that unethical research would undermine the validity of good scientific 
research (Rothman, 72-73).  In 1966, he published 22 examples of unethical 
research out of a collection of 50 studies that he had read in leading journals 
at the time (Beecher, 1966: 1354-60).  In these experiments, participants had 
been exposed to excessive risks, the need for consent had been ignored, in 
some cases poor, mentally handicapped individuals had been used as 
subjects and therapies of known efficacy had been withheld (Jonsen, 1998: 
144). 
 
The Willowbrook case study is an example of one of the studies he exposed: 
 
2.5.1 The Willowbrook Story 
 
Willowbrook State School was one of New York’s largest institutions for 
mentally retarded children on Staten Island.  In 1949, Hepatitis was first 
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detected amongst the children.  In 1954 Dr Krugman and Dr Giles started to 
study the natural history of Infectious Hepatitis, an endemic disease amongst 
institutionalised children.  The doctors wanted to infect new admissions to the 
institution with hepatitis and observe the progress of the mild flu-like illness 
that would result. Their reasoning was that all children admitted to the 
institution would eventually contract the disease, they would be admitted to an 
isolation unit where they would be protected from other infectious diseases, 
they were likely to have a sub-clinical infection followed by immunity and only 
children whose parents gave informed consent would be included.  While their 
initial aim was to determine the period of infectivity of infectious hepatitis, their 
eventual aim was to develop a hepatitis vaccine and this was accomplished. 
 
Commentary on Willowbrook and the Beecher Expose 
 
As a result of the good outcome, this study generated a healthy debate.  
However, it was criticised for a number of reasons.  The major question 
revolved around the benefit that would accrue to these children.  If the natural 
environment would have resulted in them contracting the infection and 
developing immunity anyway, the experiment was non-therapeutic –and would 
benefit other children, not the participants.  
 
Furthermore, according to Henry Beecher 
 
 An experiment is ethical or not at its inception; it does not become 
 ethical post hoc, - ends do not justify the means. 
        (Beecher, 1966: 1360) 
 
While critics of this study like Paul Ramsey rejected the concept of proxy 
consent in non-therapeutic research, his arguments would have severely 
prohibited paediatric research.  The South African Medical Research Council 
guidelines on paediatric research are moderate in nature and permit 
reasonable research on children provided there is not more than minimal risk, 
provided that such research cannot be conducted on adults and provided that 
children will benefit from the research. On the other hand, American 
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guidelines require an explanation for why children are not included in 
research. This will be discussed further in Chapter Seven. 
 
The Willowbrook study was also criticized for its potential to cause harm. At 
the outset, it was anticipated that the children would develop a mild influenza 
like illness however, in some cases progression to fatal liver destruction could 
occur and the development of cirrhosis later in life was possible (Beecher –as 
quoted in Beauchamp 2001).  This would mean that the experiment would 
have exposed the children to more than minimal risk. 
 
The next criticism related to the fact that there were alternative ways to control 
Hepatitis in the institution and the use of gamma-globulin inoculations had 
reduced the incidence of infectious hepatitis by 80 to 85%.  It was charged 
that the paediatrician’s duty was to improve the situation not to take 
advantage of it. 
 
Finally, the nature of consent obtained was questioned.  The concept of 
“group consent” was criticised as Krugman had taken consent from groups of 
parents instead of individual parents.  The notion of voluntariness of the 
consent was also questioned when the doors of the institution were closed in 
1964.  However, children could be admitted to the research unit if parents 
were prepared for their children to be included in the project (Beauchamp, 
2001: 428-30). 
 
The Beecher expose called into question the motivation for a wide range of 
questionable behaviour by researchers.  A number of explanations for such 
behaviour could be advanced, the most prominent of which was the pressure 
placed on researchers in the post-war years by institutions and government 
agencies alike.  Most of the researchers in Beecher’s protocols were “heirs to 
this wartime tradition”. They were the “products of medical training in the 
immediate post-war period, trained to think in utilitarian terms and ready to 
achieve the greatest good for the greatest number” (Rothman, 2003: 79). 
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The Beecher expose drew attention to large numbers of patients having been 
placed at risk in the context of the research endeavour in the United States in 
the post-war period.  However, in 1967 Pappworth published his book entitled 
“Human Guinea Pigs” in London in which he described many more cases of 
unethical research (Pappworth, 1967).  He had collected more than 500 
papers in England based on unethical experimentation (Beecher, 1966: 
1355). 
 
Commentary on Chapter 2: 
 
The cases discussed in this chapter serve to illustrate the nature of some of 
the ethical violations that occurred both during and after the Second World 
War.  These cases range from intentional blatant disregard for human 
participant protection such as Tuskegee and the Nazi experiments to 
commercial greed as in the Thalidomide case to overzealous but well 
intentioned researchers as in Willowbrook.  Nevertheless, ethical violations in 
research in the post-war period were widespread.  Beecher’s expose was 
poignant in identifying these violations and in stimulating efforts to regulate 
research and promote participant protection.  These efforts are described in 
Chapter Three. 
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Chapter 3 
 
International Codes and Declarations for 
Research Ethics 
 
 
3.1. Introduction 
 
In the aftermath of the research atrocities outlined in Chapter Two and as a 
direct result of the various events, a number of international guidelines were 
sequentially developed in an attempt to regulate the conduct of research.  The 
important documents in which these guidelines were enshrined were the 
Nuremberg Code, the Declaration of Helsinki, the Belmont Report, the Council 
for International Organisations of Medical Sciences Guideline drafted by the 
World Health Organisation and the International Conference on 
Harmonisation (ICH-GCP) Guideline.  As the early attempts at regulation were 
developed in direct response to very specific events in research, the early 
documents contained deficiencies that required serial improvements over time 
to meet the changing demands of a rapidly expanding research industry.  As 
such, these documents may be viewed as a progressive series of guidelines 
with each one attempting to supercede its precursors (R. J. Levine, 1996: 
235).  They may also be viewed as “evolving yardsticks” and as such be 
“continually subject to critical appraisal and revision” (Richards, 2002: 796). 
 
This chapter outlines the evolution of some of the major guidelines from 1947 
to 1993. 
 
3.2. The Doctors’ Trial At Nuremberg 
 
Of the major trials conducted at Nuremburg to try a host of war criminals the 
most significant from the perspective of research ethics was the Doctors’ Trial 
conducted on 19 August 1947.  The charges against the defendants in this 
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trial were brought in the name of the United States of America hence this 
event is documented as the case of the United States v. Brandt –so named 
after Karl Brandt, Hitler’s personal physician - who represented the 
defendants.  The case was conducted under the auspices of the United States 
military. 
 
After a seven month long trial twenty doctors and three medical administrators 
were charged with “murders, tortures and other atrocities committed in the 
name of medical science” as outlined in Chapter Two.  They were tried by a 
court of American judges who relied on the testimony of two American 
physicians and researchers – Andrew Ivy and Leo Alexander.  Of the twenty-
three defendants, sixteen were found guilty and seven, including Brandt were 
hanged for various crimes against humanity (McNeill, 1998: 370).  Nine of the 
defendants were sentenced to long prison terms. 
 
3.3. The Nuremberg Code 
 
The Nuremberg Code represents the first attempt to provide guidelines for the 
conduct of research.  It described the Nazi experiments as being contrary to 
 
the principles of the law of nations as they result from the usages 
established among civilised peoples, from the laws of humanity, and 
from the dictates of public conscience. 
      (The Nuremberg Code, 1947) 
 
According to Levine, this statement reflects the claim to universality made by 
the Nuremberg Code. 
 
In essence, the following ten principles are enshrined in the Code: 
 
1. Voluntary Informed Consent was emphasized and documented for the 
 first time as a prerequisite for research. It also restricted the provision 
 of consent to those who had legal capacity to do so:  
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This means that the person involved should have legal capacity 
to give consent.  
      (The Nuremberg Code) 
 
2. The experiment had been for the good of society, unlike the many 
 experiments conducted in the concentration camps based on the 
 whims or political motivations of medical doctors. 
3. The experiment was to be based upon prior animal studies.  Many Nazi 
 experiments were conducted for the first time on human subjects. 
4. Physical and mental suffering and injury to participants had to be 
 avoided, a concept clearly overlooked when research subjects 
 were exposed to torture in the course of horrendous experiments. 
5. There had to be no expectation that death or disabling injury would 
 occur from the experiment as opposed to the blatant expectation of
 death that existed in many of the Nazi experiments. 
6. Risk had to be weighed against benefits, a calculation never computed 
 by Nazi physicians during the war. 
7. Subjects were to be protected against injury, disability or death unlike 
 what actually happened during the Nazi experiments 
8. Only scientifically qualified individuals could conduct human 
 experimentation, perhaps an inadequate specification as all the Nazi 
 researchers were scientifically qualified yet conducted inhumane 
 research. 
9. The subject was able to terminate his/her involvement in the research 
 project if he or she chose to do so, an opportunity clearly not accorded 
 to subjects in Nazi Camp research. 
10. The investigator could terminate the experiment if injury, disability or 
 death was likely to occur, clearly a thought that did not occur to Nazi 
 researchers. 
 
It is evident that the code was written in direct response to the Nazi 
concentration camp research and hence it has a narrow focus but was an 
excellent first step in the regulation of the research endeavour. 
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Furthermore, the Nuremberg Code has been criticized for being a document 
drawn up by jurists and not doctors.  As such it did not cover all research 
activities that medical doctors needed to conduct on human subjects.  No 
provision was made for research on those who lacked capacity to consent like 
children and the mentally ill (R. J. Levine, 1996: 236).  This would have 
excluded psychiatric research. 
 
It did not mention review of research by an ethics committee.  Instead, the 
responsibility for the conduct of research rested with the investigator. 
 
Even though the Nuremberg Code had been in existence since 1947, it did 
not receive the recognition it deserved from the Anglo-American world as it 
was regarded as something peculiar to Nazi Germany.  International groups 
were reluctant to accept the code as it included an absolute requirement for 
consent prior to any experimentation on human subjects. 
 
In 1954, the World Medical Association (WMA) adopted a Code for Research 
and Experimentation that allowed for proxy consent in experiments on 
patients who did not have the capacity to consent for themselves (McNeill, 
1998: 371).  
 
3.4. The Declaration of Helsinki – 1964 
 
The Declaration of Helsinki is criticised as being a watered down or diluted 
version of the Nuremberg Code as it extended the conduct of research to the 
very young, the unconscious and those lacking legal capacity such as the 
mentally ill.  The Nuremberg Code specified that research could be conducted 
only on those capable of giving voluntary informed consent. 
 
This document also drew a distinction between therapeutic and non-
therapeutic research that has been debated since its inception: 
 
 In the field of biomedical research a fundamental distinction must be 
 recognised between medical research in which the aim is essentially 
  49 
 diagnostic or therapeutic for a patient, and medical research the 
 essential object of which is purely scientific and without implying direct 
 diagnostic or  therapeutic value to the person subjected to the 
 research. 
                   (WMA, 1996) 
 
Therapeutic research is viewed as justifiable due to the benefit that accrues to 
patients, while non-therapeutic research has the well-being of society in mind 
(Schuklenk, 2000: 162-63). 
 
The distinction has raised criticism by several commentators most notably, 
Robert Levine who illustrates the unreasonableness of the distinction by 
juxtaposing two articles in the 1964 version referring to this distinction: 
 
Article II.6.  The doctor can combine medical research with professional care, 
the objective being the acquisition of new medical knowledge, only to the 
extent that medical research is justified by its potential diagnostic or 
therapeutic value for the patient. 
 
Article III.2.  The subjects should be volunteers – either healthy persons or 
patients for whom the experimental design is not related to the patient’s 
illness. 
 
Levine uses the hypothetical example of a study designed to explore the role 
of neurotransmitters in depression.  He argues that such research cannot be 
justified on the basis of its therapeutic benefit for the patient, as required by 
article II.6, hence it must be considered to be non-therapeutic.  Therefore, 
according to article III.2, the subjects of the research must be either normal 
volunteers or patients who have diseases other than depression. 
 
In the 1970s this distinction was rejected in the United States, and federal 
regulations were used in its place.  According to federal regulations, research 
had to be judged according to a level of risk and expected benefit.  An 
intervention that provides direct benefit to the patient can involve virtually any 
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degree of risk to individual subjects.  An intervention that does not benefit 
individuals must be justified by its intended benefit to society.  In the case of 
children and non-therapeutic research, if the procedure carries more than a 
minor increase over minimal risk this must be reviewed at a national level 
(Levine, 1999: 531-32).  This distinction will be considered again in Chapter 
Seven in the context of HIV vaccine trials in South Africa.  
 
The Declaration in 1964 included 22 principles.  A number of these issues had 
already been covered in the Nuremberg Code. In addition, the guideline 
specified that the experimental protocol should be reviewed by an 
independent committee (IRB or Research Ethics Committee): 
 
 The design and performance of each experimental procedure involving 
 human subjects should be clearly formulated in an experimental 
 protocol which should be transmitted to a specially appointed 
 independent committee for consideration, comment and guidance. 
                  (Declaration of Helsinki 1964) 
 
As such, the Declaration of Helsinki was the first guideline to make formal 
reference to the need for an REC. 
 
An issue that will be discussed at length in the next chapter is the reference to 
treatment of a control group: 
 
 In any medical study, every patient – including those of a control group, 
 if any- should be assured of the best proven diagnostic and therapeutic 
 method. 
                  (Declaration of Helsinki 1964) 
 
This specification of “best proven” treatment for a control group evolved into 
the centrepiece of the debate on the HIV vertical transmission trials that will 
be addressed in Chapter Four. 
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The Declaration of Helsinki’s claims of universality are grounded in its 
reference to the World Medical Association’s Declaration of Geneva and the 
International Code of Medical Ethics.  The declaration refers to its 
recommendations as “a guide to every physician in biomedical research 
involving human subjects” (R. J. Levine, 1996: 235-59). 
 
This declaration was amended in 1975 to account for the expanded scope of 
biomedical research.  This version was written from an observation point 
closer to active clinical science (Riis, 2000: 3045).  Further revisions took 
place in 1983, 1989, 1996 and most recently in 2000.  The most significant 
revision took place between 1997 and 1999 in response to the HIV vertical 
transmission trials and these changes are reflected in the controversial 2000 
version.  The final revision will be discussed in Chapter Four. 
 
In spite of the Declaration of Helsinki being in existence since 1964, the 
Tuskegee study continued until it was exposed in the media in 1972.  This 
disregard for the Declaration of Helsinki resulted in the promulgation of the 
National Research Act in the United States. 
 
3.5. The Belmont Report (1979) 
 
When the National Research Act was signed into law in 1974, the National 
Commission for the Protection of Human Subjects of Biomedical and 
Behavioural Research was created.  One of the charges to the commission 
was to identify the basic ethical principles that should underlie the conduct of 
biomedical and behavioural research involving human subjects and to develop 
guidelines that would ensure that research is conducted in accordance with 
these principles.  The Belmont report was drafted in 1979.  Unlike the 
previous codes and guidelines that specified rules, this document discussed 
broad principles that could be interpreted and applied in different research 
settings.  The Belmont Report was drafted in response to the expose on the 
Tuskegee study and hence reflected on the historical research violations that 
had preceded the expose.  It emphasized three major principles of theological 
and secular ethics (C. Levine, 1996: 106). This report used the distinction 
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between clinical practice and research as its point of departure and then 
explored three principles of importance in the conduct of research: 
 
1. Respect for Persons. 
 This principle outlines two moral requirements – the requirement to 
 acknowledge autonomy and the requirement to protect those with 
 diminished autonomy. 
 
2. Beneficence. 
 Beneficence requires that researchers working with human subjects 
 should in the first instance avoid harm but where this is not possible, 
 maximize benefits and minimize harm to subjects. 
 
3. Justice 
 Justice in research refers to the fair selection of those who must bear 
 the burdens of research. It is also important that this group of subjects 
 reaps the benefits of such research.  Justice is relevant to the selection 
 of subjects at two levels - at an individual level and at a social level.  
 
At an individual level it was advised that: 
 
 researchers exhibit fairness: thus, they should not offer potentially 
 beneficial research only to some patients who are in their favour or 
 select  only ‘undesirable’ persons for risky research 
 
At the social level: 
 
 distinctions [should] be drawn between classes of subjects that ought, 
 and ought not, to participate in any particular kind of research, based 
 on the ability of members of that class to bear burdens and on the 
 appropriateness of placing further burdens on already burdened 
 persons 
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The national commission recommended that classes of subjects be selected 
in an order of preference - adults before children – and that some classes of 
potential subjects like prisoners and the institutionalised mentally infirm be 
selected only under certain conditions and perhaps not at all. 
 
Application of the three principles leads to the consideration of informed 
consent, assessment of risks and benefits and subject selection. 
 
(The National Commission for the protection of human subjects of Biomedical 
and Behavioural Research, 1979). 
 
3.6 Council for International Organisations of Medical Sciences 
 (CIOMS) 1993 Guideline 
 
CIOMS is an international non-governmental organisation founded under the 
auspices of the World Health Organisation (WHO) and the United Nations  
Educational, Scientific and Cultural Organization (UNESCO) in 1949.  CIOMS 
started its work in the ethics of biomedical research in the late1970s.  It set 
out to prepare guidelines 
 
 to indicate how the ethical principles that should guide the conduct of 
 biomedical research involving human subjects, as set forth in the 
 Declaration of Helsinki, could be effectively applied, particularly in 
 developing countries, given their socio-economic circumstances, laws 
 and regulations, and executive and administrative arrangements. 
            (CIOMS, 1993) 
 
In 1982, the Council had developed “Proposed International Ethical 
Guidelines for Biomedical Research Involving Human Subjects.” 
 
However, the HIV/AIDS pandemic raised new ethical issues that had not been 
considered in the 1982 version.  Furthermore, rapid advances in medicine and 
biotechnology, multinational research and research on vulnerable populations 
  54 
necessitated a revision of the 1982 version.  In 1993, “International Ethical 
Guidelines for Biomedical Research Involving Human Subjects” was issued. 
 
The guideline was drafted by a heterogeneous group of people in terms of 
race, gender, nationality and profession.  This enhanced its global validity (R. 
J. Levine, 1996: 243). 
 
The CIOMS guideline, on the whole, was a much more comprehensive 
document than either the Nuremberg Code or the Declaration of Helsinki. 
 
It expanded the narrow focus of the Nuremberg Code and corrected some of 
the conceptual errors in the Declaration of Helsinki.  In addition, considerable 
attention was paid to ethical issues peculiar to developing world research. 
 
Guideline Eight specifies the following in the context of multinational research: 
 
• persons in underdeveloped communities will not ordinarily be involved 
in research that could be carried out reasonably well in developed 
communities; 
• the research is responsive to the health needs and the priorities of the 
community in which it is to be carried out; 
• every effort will be made to secure the ethical imperative that the 
consent of individual subjects be informed; and 
• the proposals for the research have been reviewed and approved by an 
ethical review committee that has among its members or consultants 
persons who are thoroughly familiar with the customs and traditions of 
the community. 
                   (CIOMS, 1993) 
 
It expanded the concept of informed consent from individual informed consent 
to situations where a community leader may need to be involved in the 
process.  Other methods to obtain informed consent could be incorporated 
based on the advice of the local REC. 
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Guideline 15 lists obligations of sponsoring and host countries in the context 
of multinational research.  With regard to dual review: 
 
 An external sponsoring agency should submit the research protocol to 
 ethical and scientific review according to the standards of the country of 
 the sponsoring agency, and the ethical standards applied should be no 
 less exacting than they would be in the case of research carried out in 
 that country. 
 
This guideline specifies dual review of research by both the host and the 
sponsor country REC.  This is why it so crucial that high standards of ethical 
review are upheld in a developing country like South Africa. 
 
Of note in the 1993 version of CIOMS is the absence of discussion about 
standards of care or control groups even though this was clearly articulated in 
the Declaration of Helsinki 1964. 
 
3.7. The Evolution of Good Clinical Practice 
 
3.7.1 United States 
 
In spite of the Nuremberg Code’s existence since 1947, American researchers 
regarded it as a document for Nazi doctors and scientists only.  The lesson of 
Nuremberg seemed to have “made little impression on the American world of 
medical research” (Jonsen, 1998: 137).  In 1964, as a result of the Declaration 
of Helsinki, review of research procedures was emphasized.  However, in the 
1970s fraud in research was still continuing in the United States in spite of 
Helsinki.  In the 1970s and early 1980s, the Food and Drug Administration 
(FDA) developed regulations on informed consent, Institutional Review Board 
(IRB) or Ethics Committee review and approval, and investigational new 
drugs. 
 
Collectively, these regulations, along with various guidelines, became known 
as Good Clinical Practices or GCPs.  
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3.7.2 Japan and Europe 
 
The first GCP guideline was issued in Japan in 1990 and in Europe in 1991.  
These guidelines were much less extensive and stringent than the FDA 
requirements.  In Europe and Japan, however, these were just guidelines 
rather than law.  And they were not widely accepted.  The various GCPs were 
widely variable and often inconsistent.  This inconsistency, together with the 
globalisation of many pharmaceutical companies, gave rise to the need for 
development of an international standard, and so the ICH process was born. 
 
3.7.3. ICH GCP 
 
Since 1991, the European Union, the United States and Japan had been 
collaborating in the International Conference on Harmonisation (ICH) of 
Technical Requirements for Registration of Pharmaceuticals for Human Use. 
 
In 1996, the ICH Harmonised Tripartite guideline for Good Clinical Practice 
was released.  The guideline came into effect in the European Union, the US 
and Japan in 1997.  The ICH GCP guidelines are based on the Declaration of. 
Helsinki (International Conference on Harmonisation, 1997).  This guideline is 
widely used in South Africa and abroad in clinical trial research.  It forms the 
basis of many Good Clinical Practice training programs locally and 
internationally.  
 
3.8 Commentary  
 
The development of international guidelines coincided with a principle based 
approach to ethical deliberation.  The Belmont Report of 1979 is the most 
blatant product of such deliberation.  The three principles enshrined in the 
Belmont Report also form the basis for guidelines that were developed 
thereafter.  Adoption of a principle based system of regulation of the conduct 
of research overshadowed in many ways the virtue based system of self-
regulation prior to the Second World War.  Individual researcher autonomy 
gave way to regulation by international guidelines and research ethics 
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committees constituted in accordance with the Declaration of Helsinki in 1964 
and the National Research Act in the United States in 1974.  The move to a 
principle based approach also represented a move from a utilitarian 
justification for research to a deontological approach.  Jonsen describes the 
critique leveled against “the utilitarian principle as a fundamental maxim of 
research ethics”.  The utilitarian maxim, “for the greater good of the greater 
number” was frequently invoked by researchers who believed that it 
sanctioned the use of subjects without consent.  This interpretation of 
“utilitarianism” was criticised by Dr Leo Alexander in his article “Medical 
science under dictatorship.” (Jonsen, 1998: 152-53).  The guiding documents 
all subscribed to the philosophy developed by Jonas when he described the 
research endeavour as a gratuitous venture requiring complete freedom of 
volunteers.  It is hence not surprising that virtually all the major documents 
invoke the principle of respect for autonomy. 
 
Although a host of guidelines had been developed between 1947 and 1993 
attention was not focused on the content of the guidelines until 1997 when the 
ethics of HIV vertical transmission trials were called into question.  However, 
as early as 1988, ethics commentators in developed countries started to 
anticipate the ethical considerations of conducting research in developing 
countries: 
 
 The basic ethical principles that guide human investigation, as defined 
 by the Helsinki Declaration and the Nuremberg Code, need to be 
 interpreted and applied within different cultural settings, many of which 
 were unfamiliar to the international bodies that originally formulated 
 these principles.  
               (Barry, 1988: 1083) 
 
Barry argued that the basic ethical principles might have different meanings in 
developing countries and undertook an examination of cross-cultural 
bioethics.  Her major concern rested with the American notion of personhood 
where individual rights, self-determination and privacy are emphasized.  
Application of the principle of autonomy as it was enshrined in international 
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guidelines of Western origin was predicted to be contentious in cross-cultural 
research.  She also alluded to the use of ethical standards that ought to be 
applied as stringently as they were in developed countries (Barry, 1988: 1083-
85).  A number of her concerns eventually unfolded as cross-cultural research 
projects were initiated in Africa.  Chapter four details the impetus provided by 
HIV research for a closer examination of existing guidelines. 
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Chapter 4 
 
Controversies revisited: The Ethics of 
Research in Developing Countries 
 
 
4.1 Introduction 
 
As the HIV/AIDS pandemic ravaged Africa and other developing countries in 
South America and South-East Asia in the 1980s, it became inevitable that 
the research focus would move to these sites.  In particular, sub-Saharan 
Africa was home to large patient populations at risk for HIV infection who 
could be “identified and studied”.  The National Institutes of Health (NIH) had 
started offering funding for collaborative research projects in Africa.  However, 
American and European investigators “often unfamiliar with the culture, 
customs, and economic pressures within these developing countries” were 
“designing large-scale studies”.  Recognizing the urgency of the HIV/AIDS 
pandemic, Barry urged that consideration be given to the “ethical implications 
and cultural obstacles involved in conducting research in developing nations” 
(Barry, 1988: 1083).  Marcia Angell, in an editorial in the New England Journal 
of Medicine in 1988, in response to Barry’s article argued for a core of basic 
human rights to be adhered to in research settings anywhere in the world, 
taking local considerations into account.  This would mean that the “ethical 
requirements of performing clinical research in Third World societies may be 
more, rather than less, exacting” (Angell, 1988: 1083). 
 
Chapter Four describes the sequence of events that followed these earlier 
deliberations when in 1997 the research projects that were anticipated in 1988 
were actually under way. 
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4.2 ACTG 076 and the Vertical Transmission Trials 
 
In 1994, the results of the first randomised placebo controlled study on 
pregnant women infected with HIV were published.  It was established that 
treatment of these women with the antiretroviral drug Zidovudine during 
pregnancy and delivery reduced the transmission of the virus from mother to 
child by 67%.  From this point onwards, Zidovudine became the best proven 
standard of treatment for all HIV infected pregnant women in the United 
States (Connor, 1994: 1173-80). 
 
The drug regimen used in this landmark study is, however, very expensive 
and totally unaffordable to Third World countries.  The next logical step was 
therefore to investigate the possibility of shorter and hence cheaper courses 
of treatment.  
 
The World Health Organisation urgently called for research in developing 
countries to explore simpler and less expensive drug regimens.  The United 
Nations AIDS program (UNAIDS) and other organisations united to set up 16 
clinical trials in 12 developing countries around the world.  Nine of these 
studies were conducted by the National Institutes of Health (NIH) and the 
Centres for Disease Control (CDC).  One of these trials (conducted in 
Thailand) was designed as an equivalency study – three short course 
regimens were compared and the control group was given the ACTG 076 
regimen.  However, 15 of these 16 trials were randomized and placebo 
controlled.  HIV infected pregnant women in the study group were given a 
short course of Zidovudine and the incidence of transmission of the virus to 
their babies was established.  However, the HIV infected pregnant women in 
the control group were given a placebo.  And, this is where the controversy 
began (Lurie, 1997: 853-56). 
 
4.2.1 The Placebo Debate 
 
In April 1997, Dr Peter Lurie and Dr Sidney Wolfe of the Health Research 
Group (an arm of the watchdog organisation, Public Citizen), sent a letter to 
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the secretary of the Department of Health and Human Services, Donna 
Shalala which stated the following: 
 
Unless you act now, as many as 1002 newborn infants in Africa, Asia 
and the Caribbean will die from unnecessary HIV infections they will 
contract from their HIV-infected mothers in nine unethical research 
experiments funded by your department through either [NIH or CDC]. 
 
In September 1997, Lurie and Wolfe repeated their charges in the New 
England Journal of Medicine.  They drew attention to the two studies being 
conducted in the United States where patients in all study groups had 
unrestricted access to antiretroviral drugs unlike the 15 short course trials in 
developing countries where women in the control group were given a placebo 
(Lurie, 1997: 853-56). 
 
The editorial in the same issue of the journal written by executive editor Dr 
Marcia Angell, supported the views of Lurie and Wolf.  In addition, she drew a 
parallel between withholding treatment in the placebo group and withholding 
treatment for Syphilis in the infamous Tuskegee study.  This set in motion an 
unprecedented debate on the vertical transmission trials and the ethics of 
collaborative multinational research (Angell, 1997: 847-49). 
 
4.2.2 The Scientific Debate 
 
The Research Question and Clinical Equipoise 
 
Lurie and Wolfe argued that by conducting a placebo-controlled trial the 
researchers were, by implication, asking the wrong question: 
 
 Is the shorter regimen better than nothing? 
 
The presumed answer to this question was that anything would be better than 
nothing.  It is an essential pre-requisite that when a randomised clinical trial 
compares two different treatments for a disease that there should be no good 
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reason for thinking that one is better than the other.  Hence, investigators 
need to be in this state of clinical “equipoise” when embarking on a 
randomised clinical trial.  If there is any evidence that one option might be 
better than the other, then 
 
 not only would the trial be scientifically redundant, but the investigators 
 would be guilty of knowingly giving inferior treatment to some 
 participants in the trial 
               (Angell, 1997: 847) 
 
Hence, randomised clinical trials create the potential for conflict between the 
investigator’s role as doctor and research scientist.  During recruitment, a 
doctor must ask a patient to submit him or herself to random assignment to 
one of two different treatments, one of which may be a placebo.  This request 
can only be ethically justified if the researcher is in a state of genuine 
uncertainty regarding which treatment is better.  This is so because 
randomisation is inconsistent with doing one’s best for the patient as a doctor 
(Miller, 2003: 3-9).  This rule applies to placebo-controlled trials in that it is 
only ethical to compare a potential new treatment with a placebo when there 
is no known effective treatment. 
 
In the opinion of Lurie and Wolfe, the question that should have been asked 
was: 
 
 Can we reduce the duration of prophylactic [zidovudine] treatment 
 without increasing the risk of perinatal transmission of HIV, that is, 
 without compromising the demonstrated efficacy of the standard ACTG 
 076 [zidovudine] regimen? 
                 (Lurie, 1997: 855) 
 
In response to this charge, Varmus and Satcher retorted that they were 
looking to answer a much more complex question than Lurie and Wolfe 
suggested.  Their concern was not simply to establish whether a short course 
of treatment was better than nothing but also whether the short course was 
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safe and if so whether the demonstrated efficacy compared to placebo was 
large enough to make it affordable to the governments in question.  This 
viewpoint was supported by a South African epidemiologist, Abdool Karim, 
who argued that the fundamental research question related to whether short 
courses of antiretrovirals could reduce vertical transmission sufficiently to 
warrant their wide-scale implementation in South Africa (Abdool Karim, 1998: 
564-66).  Varmus and Satcher argued further that 
 
 the most compelling reason to use a placebo-controlled study is that it 
 provides definitive answers to questions about the safety and value of 
 an intervention in the setting where the study is performed, and these 
 answers are the point of the research. 
                (Varmus, 1997: 1003-05) 
 
The investigators believed that two different populations were being studied 
and it was not possible to extrapolate findings from the United States to Africa.  
The ACTG 076 regimen in the United States required that women receive HIV 
testing and counseling early in pregnancy, comply with oral treatment for 
several weeks and intravenous antiretrovirals during labour and refrain from 
breast-feeding.  In addition, babies would have to receive six weeks of oral 
antiretrovirals.  South Africa, in common with other developing countries, has 
a high frequency of home deliveries especially in rural communities (Abdool 
Karim, 1998: 564-66).  In developing country settings, women present late for 
antenatal care, have limited access to HIV testing and counseling and depend 
on breastfeeding to protect their babies from malnutrition and diarrhoeal 
diseases.  The safety of Zidovudine in populations who have a high incidence 
of malnutrition and anaemia was unknown.  The cost of the ACTG 076 
regimen was approximately $800 per treatment, far in excess of the per capita 
health care expenditure of under $10 in most developing countries (Varmus, 
1997: 1003-06).  Charges were also made that the critics’ commentary of the 
trials “reflects a lack of understanding of the realities of health care in 
developing countries” (Halsey, 1997: 965-66). 
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The Utility of Existing Data 
 
There was disagreement on the use of observational or historical data to 
provide the same information that could be obtained from the placebo arm. 
 
Advocates of placebo-controlled trials and the WHO argued that “historical 
controls” were not reliable sources of data due to the change in vertical 
transmission rates from one country to another.  Abdool Karim agreed and 
substantiated his claims with data from South Africa that indicated differences 
in vertical transmission rates from 1991 to 1994.  He added that the vertical 
transmission rate is influenced by a number of factors including caesarean 
section rates, maternal viral load and breast-feeding rates.  As such, the use 
of historical controls would lead to spurious and hence unacceptable 
conclusions (Abdool Karim, 1998: 564-66). 
 
Critics of the trials believed that the differences between the ACTG 076 trial 
participants and those in Sub-Saharan Africa were being exaggerated and 
that HIV vertical transmission rates were known in Africa and were in the 
region of 20 to 30% making the use of historical controls possible. 
 
Equivalency Trial Issues 
 
When effective treatment exists, a placebo may not be used and subjects in 
the control group must be given the best known treatment (Angell, 1997: 847).  
Such a study is termed an equivalency study and the results are scientifically 
valid. 
 
If the ACTG 076 regimen were used as the control group in the controversial 
vertical transmission trials, it would be termed an equivalency trial.  Such a 
trial would be useful if it were proven that short course treatment regimens 
were as good as or better than the ACTG 076 regimen.  It is also necessary 
for the expected outcome of the control to be known.  Abdool Karim argued 
that the effect of 076 in South Africa is not known and could not be 
extrapolated from other settings given the differences in breast-feeding rates, 
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sexually transmitted disease rates, caesarean section rates, levels of viral 
load and other variables. 
 
Advocates of placebo controlled trials held that equivalency trials required a 
much larger sample size to show a difference between two active arms of the 
study and hence they would take longer to complete, and cost more.  
Furthermore, the larger numbers of participants would result in exposure of 
more people to the risk of research. 
 
4.2.3 The Ethical Debate 
 
The Guidelines 
 
Critics of placebo-controlled trials argued that the trials violated principles 
enunciated in several major international ethics guidelines.  The Declaration of 
Helsinki was exhaustively invoked. 
 
In support of her objections to the placebo-controlled trials, Angell cited the 
following tenets of the DOH 1996: 
 
In research on man, the interest of science and society should never 
take precedence over considerations related to the wellbeing of the 
subject. 
 
And 
 
In any medical study, every patient – including those of a control group, 
if any – should be assured of the best proven diagnostic and 
therapeutic method.        
                  (WMA, 1996) 
 
Guidelines 8 and 15 of the WHO document - CIOMS (1993) – were frequently 
invoked. 
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Here, researchers were required to ensure, inter alia,  
 
 that persons in underdeveloped communities will not ordinarily be 
 involved in research that could be carried out reasonably well in 
 developed communities and that research was responsive to the 
 health needs and priorities of the community in which it is to be carried 
 out. 
 
Guideline 15 stated that the proposed study should be submitted for ethical 
and scientific review, and the ethical standards applied “should be no less 
exacting that they would be” for research in the sponsoring country itself. 
(CIOMS, 1993) 
 
Advocates of the placebo trials cited the principles of the Belmont Report.  
Emphasis was placed on the shift from the principle of beneficence to justice – 
equitable access to clinical trials (The National Commission for the protection 
of human subjects of Biomedical and Behavioural Research, 1979). 
 
Guideline Eight of the CIOMs document relating to responsiveness to local 
needs in research conducted in developing nations was also cited. 
 
Hence the guidelines were used as ammunition to defend the positions of 
both proponents and critics of the placebo controlled trials indicating the 
internal contradiction that exists in many international documents. 
 
Standard of Care 
 
After the efficacy of the 076 regimen had been established in the United 
States in 1994  that became the “gold standard” in the prevention of mother-
to-child transmission of HIV.  Hence, both critics and proponents of placebo-
controlled trials were in agreement that placebo-controlled trials could not be 
conducted in the United States. 
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Critics of the trials argued for a universal standard of care irrespective of 
where in the world the research was being conducted.  
 
Proponents argued that participants in the control group would have received 
exactly the same standard of care if they had not participated in the trials – the 
local standard of care which at that time was no treatment in the developing 
world. 
 
According to Marcia Angell, the justifications for these trials are 
 
reminiscent of those for the Tuskegee study: Women in the Third World 
would not receive anti-retroviral treatment anyway, so the investigators 
are simply observing what would happen to the subjects’ infants if there 
were no study. And a placebo-controlled study is the fastest, most 
efficient way  to obtain unambiguous information that will be of greatest 
value in the Third World. 
               (Angell, 1997: 847) 
 
Ethical Imperialism 
 
Ethical Universality refers to the belief that the ethical principles that guide the 
conduct of research are the same wherever in the world research is 
conducted. 
 
Ethical Relativism refers to the belief that ethical principles that guide the 
conduct of research vary from one cultural setting to another.  This concept is 
based on scepticism and tolerance.  Scepticism refers to the belief that 
actions may be defined as right or wrong by specific people in specific cultural 
contexts at specific times. Hence behaviour is culturally relative.  Ethical 
relativity contends that the “impossibility of objectively determining moral 
action obliges tolerance toward other cultures” (Christakis, 1996: 261-78). 
 
Hence in transcultural research, the ethical requirements of both cultures 
involved will need to be met.  This approach is problematic in that a third 
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cultural system could regard the two systems involved as unethical and there 
is no provision made for conflict resolution. 
 
Ethical pluralism on the other hand “acknowledges the key position of culture 
in shaping both the content and the form of ethical rules and it includes a 
mechanism of dispute resolution through mutual evaluation and negotiation” 
(Christakis, 1996: 261). 
 
Critics of the placebo-controlled trials were accused of ethical imperialism – 
trying to impose their ethical standards on countries that had made their own 
judgements on the trials, based on their particular needs.  
 
This debate predated the actual conduct of HIV vertical transmission trials. 
Marcia Angell, in 1988, raised the fundamental question of whether  
 
 ethical standards are relative, to be weighed against competing claims 
 and modified accordingly, or whether like scientific standards, they are 
 absolute 
                  (Angell, 1988:1081) 
 
She argued then, as she did in 1997, that fundamental principles of humane 
research should not be compromised.  She maintained that  
 
 Subjects in any part of the world should be protected by an irreducible 
 set of ethical standards, including the requirements that they not be 
 subjected to unreasonable risks and that they be asked for informed 
 consent to participate. 
                  (Angell, 1988: 1083) 
  
Local investigators, however, thought otherwise. Commentary from the 
Uganda Cancer Institute was as follows:  
 
 These are Ugandan studies conducted by Ugandan investigators on 
 Ugandans. 
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The studies in Uganda had been approved by local ethics committees.  
 
Dr Nicolas Meda, an epidemiologist from Burkina Faso argued that health 
research in poor countries should be designed and conducted pragmatically, 
in keeping with local health needs and priorities.  In 2002, he addressed a 
conference of European medical ethicists and made the following statement: 
 
 Dogmatic interpretation of universal ethical principles in medical 
 research will paralyse research efforts to improve HIV/AIDS prevention 
 and treatment in sub-Saharan Africa. 
            (Richards, 2002:325) 
 
Marcia Angell argued that: 
 
ethical imperialism obscured a more insidious danger to developing 
countries: ethical relativism, which opened the door to exploitation of he 
vulnerable peoples of the Third World. 
 
Critics of the trials dismissed the charge of ethical imperialism and drew 
attention to the conflict of interest many investigators were in due to the 
substantial amount of research money at stake.  Marcia Angell argued that 
researchers who levied charges of ethical imperialism against her were not 
necessarily advocates of the poor in their countries. 
 
Professor Hoosen Coovadia, one of the investigators involved in the Petra 
trials in South Africa, responded to her charge as follows: 
 
 In these debates it was implied that we are merely passive recipients of 
 research plans devised in Europe or the USA.  This is not so, and in 
 many instances we actively seek assistance to pursue research ideas 
 of importance to our people.  Indeed, in South Africa the barren years 
 of apartheid isolation have instilled in us a keen appreciation of 
 international co-operation – the HIV projects are as much ours as they 
 are the property of our international partners.  We have demanding 
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 Ethics Committees in our Universities (the first was established at the 
 University of Witwatersrand in 1966) and regularly updated guidelines 
 on Ethics for  Medical Research published by the Medical Research 
 Council.  Our research is therefore conducted in an environment where 
 the protection of the individual and communities is safeguarded  
 The assertions by Angell, Lurie and Wolfe accordingly challenge our 
 sovereignty in making and implementing our own decisions. 
                 (Coovadia, 1999: 194-195) 
 
The debate on ethical relativism versus ethical universalism was highlighted 
by the attempt to apply international declarations in various developing world 
settings in the context of HIV vertical transmission trials.  
 
Justice 
 
Grodin and Annas based their objections to the trials on the principle of 
justice.  They argued that poor participants should not bear the burdens of 
research that they were not going to benefit from.  It was clear at the time the 
trials were conducted that the Ministry of Health in South Africa was not going 
to sanction the provision of short course antiretroviral treatment to pregnant 
women even if the trials did prove the treatment to be efficacious.  His 
argument was underscored in  Minister Zuma’s decision in 1998 not to provide 
the four week course of treatment to pregnant women (Knox, 1998).  In 
retrospect, that was probably a good decision.  After all, the four-week 
treatment regimen did not prove to be efficacious.  However, the basic tenet of 
the argument remains valid – a protocol should contain a plan to implement 
results. 
 
4.3 Vertical Transmission Trials in South Africa – The Results 
 
Many of the arguments posed by both critics and advocates of the placebo-
controlled vertical transmission trials were validated or rejected by the results 
of the trials in developing countries. 
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I will focus my discussion on the results of the Petra trials that were conducted 
in South Africa, Uganda and Tanzania between June 1996 and January 2000.  
 
1457 HIV positive pregnant women were randomised to one of four groups: A, 
B, C or placebo.  Groups A, B and C had different short course antiretroviral 
drug regimens.  
 
To facilitate ease of understanding of results, the HIV transmission rates in the 
various groups are presented in Table 1 at month six and month 18: 
 
Table 1: HIV Transmission at week 6 and month 18 
 
TRIALS HIV transmission 
Week 6 
HIV transmission 
Month 18 
PETRA A 5,7% 15%
PETRA B 8,9% 18%
PETRA C 14,2%  20%
PLACEBO 15,3%  22%
 
 
The results indicate that although regimens A and B were effective in reducing 
HIV transmission compared to placebo, this effect could not be sustained to 
18 months.  This can be attributed to the predominance of breast-feeding in 
these populations compared to the 076 regimen study population. 
 
The investigators in this study have justified the use of placebo on the basis of 
a difference in study populations.  They also indicate that if a placebo group 
had not been used or if the 076 regimen was used instead of placebo, two 
errors in interpretation would have occurred.  The Petra C regimen would 
have been considered to be effective and the degree of effectiveness of all 
three groups would have been overestimated (PetraStudyTeam, 2002: 1178-
86). 
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Similar results were established in the HIVNET 012 study in Uganda where 
breast-feeding impacted on HIV transmission rates at 20 months but to a 
lesser extent (Guay, 1999: 795-802). 
 
Discussion 
 
How do these results correlate with the criticism leveled against these trials in 
1997? 
 
The charge of lack of clinical equipoise cannot be substantiated. If there were 
no clinical equipoise, the short course treatment would have been more 
effective than placebo – this was only the case for six months after the study 
was initiated.  Follow-up to 18 months however, revealed no statistically 
significant difference between treatment and placebo groups. 
 
The reasons forwarded regarding the differences between the North American 
study population and the African study populations and uncertainty regarding 
how they would impact on the results were borne out in this study: breast 
feeding alone made an enormous difference to efficacy of short course 
regimens. 
 
The criticism regarding the use of placebo was also unjustified: there are two 
good scientific and statistical reasons why an equivalence trial would not have 
been feasible as discussed above.  It is most likely that an equivalence trial 
would have shown that 076 was better than short course treatment.  How 
would that have helped the HIV epidemic in South Africa? (Coovadia, 1999: 
194). 
 
The principle of justice was not at issue – the department of health did not 
implement the short course treatment in 1998 – this has proved to be a good 
decision.  The efficacy of the short course regimen compared to placebo was 
not large enough to make it affordable to the South African government.  
When Nevirapine was shown to be effective in the HIVNET 012 trials in 
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Uganda at a fraction of the cost of other short course regimens, treatment for 
pregnant women was made available in South Africa (Guay, 1999: 795-802). 
 
The charge leveled against critics of the placebo trials was that they were ill 
informed regarding health care and research priorities in developing countries 
and this appeared to be the case as was reflected in the outcome of these 
studies. 
 
Finally, it appears as if the charges of ethical imperialism leveled at Angell, 
Lurie and Wolfe by developing world researchers were justified and the results 
of the study serve to prove that. 
 
4.4 Tuskegee Revisited 
 
In the course of the debates surrounding the HIV vertical transmission trials, 
the justification presented for use of a placebo arm was the fact that the 
women on the placebo arm would have received no treatment (which was the 
standard of care in developing countries) in the absence of the clinical trial.  
Marcia Angell, in her critique of the use of a placebo arm in the trials, drew the 
following comparison to the Tuskegee Syphilis Study: 
 
The justifications are reminiscent of those for the Tuskegee study: 
Women in the Third World would not receive antiretroviral treatment 
anyway, so the investigators are simply observing what would happen 
to the subjects’ infants if there were no study. 
 
This comparison has been challenged by the investigators involved as well as 
by Fairchild and Bayer.  Fairchild outlines the three features in the Tuskegee 
study that characterize the consistent research abuses that occurred.  
 
 First, the study involved deceptions regarding the very existence and 
 nature of the inquiry into which individuals were lured. As such it 
 deprived those seeking care of the right to choose whether or not to 
 serve as research subjects. Second, it entailed an exploitation of social 
  74 
 vulnerability to recruit and retain research subjects. Third, Tuskegee 
 researchers made a wilful effort to deprive subjects of access to 
 appropriate and available medical care as a way of furthering the 
 study’s goals. 
        (Fairchild, 1999: 919) 
 
She objects to the analogy drawn in the context of the vertical transmission 
trials as “investigators clearly made efforts to inform the enrolled women that 
they would be part of a study to reduce maternal transmission” and that some 
would receive placebo. 
 
The nature of consent obtained from study participants had however been 
challenged by researchers working in Thailand and South Africa.  
 
In 1998, attention was drawn to the informed consent documents used in 
Thailand.  Discrepancies were noted in the Thai and English versions of the 
documents.  The Thai version described the placebo as a “comparison drug 
that does not contain zidovudine” while the English version described the 
placebo as an “inactive substance” which was “like a sugar pill”.  The Thai 
critics charged that the words “inactive substance”, “placebo” and “sugar pill” 
did not appear in the Thai documents even though Thai words or concepts did 
exist for these words (Achrekar, 1998: 1331-32). 
 
In South Africa, contention was also raised by the use of the word “chuff-chuff” 
drug which means “pretend drug” and “spaza” drug which alludes to “half the 
real thing” in colloquial terms.  While “chuff-chuff” drug is acceptable, “spaza” 
drug is misleading (Prabhakaran, 1997). 
 
Even though these controversies did exist regarding the content of informed 
consent documents used in the HIV trials, an informed consent process was 
followed in all the trials conducted in developing countries, some better than 
others. In no way did the HIV trials bear any resemblance to the Tuskegee 
study where there was an absence of the informed consent process 
altogether. 
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Fairchild goes on to contend that the social vulnerability of the women 
involved was not exploited.  On this claim I will argue that these were 
vulnerable women.   The United Nations UNAIDS definition of vulnerable 
communities includes communities with: 
 
• Limited economic development 
 
• Inadequate human rights protection and discrimination based on 
health status 
 
• Inadequate understanding of scientific research 
 
• Limited health care and treatment options 
 
• Limited ability to provide individual informed consent 
 
The black women enrolled in the trials in South Africa definitely shared a 
social and economic vulnerability with the African-American men in the 
Tuskegee study.  To the extent that this study would not have been approved 
in the United States on American women, an exploitation of their vulnerability 
cannot be denied. 
 
However, the placebo group served only as a comparison arm for the short 
course, potentially more affordable regimen being tested.  Tuskegee was an 
observational study where all participants were deprived of affordable 
treatment.  In the HIV trials women in the placebo group were deprived of 
treatment that was locally both unavailable and unaffordable. In this respect, 
an analogy with Tuskegee cannot be drawn. 
 
Furthermore, Benatar argues that the analogy: 
 
minimises the deception, maleficence, paternalism, lack of 
accountability, racism and gross exploitation demonstrated by the 
researchers in the Tuskegee study. The analogy serves to trivialize 
Tuskegee. 
 
                 (Benatar, 1998: 221-222) 
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4.5 Declaration of Helsinki 2000 and CIOMS Revision 2002 
 
Declaration of Helsinki 2000 
 
As a result of the international concern evoked by the placebo debate, an 
attempt was made to amend the 1996 version of the Declaration of Helsinki. 
 
A proposal was made to change the specification on treatment for control 
groups in the 1996 version from: 
 
 In any medical study, every patient – including those of a control group, 
 if any - should be assured of the best proven diagnostic and 
 therapeutic method. 
 
to 
 
 “In any biomedical research protocol, every patient-subject, including 
 those of a control group, if any, should be assured that he or she will 
 not be denied access to the best proven diagnostic, prophylactic or 
 therapeutic method that would otherwise be available to him or 
 her….When the outcomes are neither death nor disability, placebo or 
 other no-treatment controls may be justified on the basis of their 
 efficiency. 
 
This revision was open for comment and a second debate ensued (Hutton, 
2000: 185-206). 
 
Those who objected to the change feared that the changes would weaken the 
principles of the declaration: 
 
 these revisions may inappropriately cause a shift to an efficiency-based 
 standard for research involving human subjects and weaken the 
 principles of the investigator’s moral commitment to the research 
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 subject and the just allocation of the benefits and burdens of research, 
 which have heretofore been the hallmarks of ethical research.  The 
 revisions will also logically lead to an explosion of research in 
 developing countries that would be intended mainly to benefit 
 developed countries – another affront to current notions of ethical 
 research. 
                  (Brennan, 1999: 527) 
 
The change to “best available” could not be implemented in the face of the 
strong criticism leveled against the World Medical Association.  Ultimately, the 
change to “best current” treatment for the control group was implemented in 
the 2000 version. 
 
CIOMS 2002 
 
While the 1993 version did not include a guideline on standard of care, the 
2002 version added this consideration on in Guideline 11. 
 
 As a general rule, research subjects in the control group of a trial of a 
 diagnostic, therapeutic or preventive intervention should receive an 
 established effective intervention. In some circumstances, it may be 
 ethically acceptable to use an alternative comparator, such as placebo 
 or no treatment. 
 
There is no elaboration on “established effective” intervention – is this 
established globally or locally in the developing country?  This will be 
discussed further in Chapter Seven. 
 
 
 
4.6 Commentary 
 
While these major revisions were undertaken by the World Medical 
Association and the World Health Organisation in response to the placebo 
  78 
debate, commentators started to question the basis for making such sweeping 
changes.  It was charged that “tough cases make bad law”, so was it valid to 
generalize from the placebo trials?  After all the HIV vertical transmission case 
study had unique features – these were trials on pregnant women where 
placebo use meant passively allowing transmission to infants.  In many cases 
the risk calculations in using placebo were doubled by this situation alone.  
Using this case study as a precedent to make revisions in guidelines that 
affect all research would not be valid (Brennan, 1999: 530). 
 
The validity of this comment has been borne out in the numerous footnotes 
that have been added to the Declaration of Helsinki since 2000 to avoid 
generalisation and ultimately to encourage case-by-case decisions on the use 
of placebo – this will be considered in more detail in Chapter Seven. 
 
The revisions of both these international documents providing guidance in 
human participant protection evoked unprecedented attention in research 
ethics circles, amongst REC members and investigators alike.  This occurred 
in developed and developing countries alike.  Yet, in spite of the elaboration of 
the guidelines, human participant protection appeared to worsen in the United 
States. 
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Chapter 5 
 
Continuing controversies in Developed 
Countries despite regulatory changes 
 
 
5.1. Introduction 
 
Since 1997 the vigorous debate around the HIV vertical transmission trials 
focussed unprecedented attention on the ethics of research in developing and 
developed countries alike. By 2000, the Declaration of Helsinki had 
undergone another revision and the CIOMS 1993 guideline was in the 
process of being revised as well.  
 
Overshadowed by the HIV trial debate, the first major research catastrophe 
occurred in the United States in 1996.  At the time, although the Nicole Wan 
case received considerable attention in the United States, this was not 
publicized as a major research ethics disaster internationally.  Not until 2001 
when Ellen Roche died and the international literature started to highlight the 
deaths of healthy volunteers in non-therapeutic research. 
 
5.2 The Nicole Wan Case   (Day, 1998: 449-51) 
 
Nicole Wan was a healthy 19 year old student at the University of Rochester. 
She was involved in a trial early in 1996 investigating the function of lung 
cells. She underwent a bronchoscopy at the University of Rochester Medical 
Centre in New York.  The local anaesthetic that facilitated this procedure was 
topical lignocaine.  She required a considerably high dose of lignocaine to 
decrease the discomfort caused by the passage of the bronchoscope.  After 
the procedure, she complained of chest discomfort but was nevertheless 
discharged one hour after the procedure.  Later that day, she had an epileptic 
fit.  On admission to the emergency unit, she was found to be in cardiac arrest 
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and died two days later.  The proximate cause of death was a toxic lignocaine 
blood level. 
 
This study had been on going for a number of years.  The study protocol of 
1981 had indicated a maximum dose of 300mg of Lignocaine. 
 
The most recent study protocol did not specify an upper dose limit.  There was 
no record of the dose of lignocaine administered.  However, extrapolation of 
the dose was conducted from her blood lignocaine levels on admission and 
was estimated at 1200mg. 
 
Investigation Findings 
 
• This amendment had not been submitted to the REC as the 
researchers allegedly believed that deleting the upper limit did not have 
safety implications. 
• The University’s REC did not require formal approval of minor 
alterations that did not have safety implications. 
• The REC had not performed an “in-depth” or “complete” re-review of 
the protocol over the protocol’s 14 year lifespan. 
• The consent form did not mention the possibility of death. 
• A number of protocol violations were detected:  The lignocaine solution 
used was a higher concentration than that specified in the protocol and 
28 bronchial brushings were performed when the protocol specified 
“about ten”. 
 
Recommendations from New York State Department of Health (Day, 1998: 
449-51). 
 
1. RECs should pay attention to long running research programs with 
multiple protocols and amendments. 
2. There should be more attention focussed on minimising risk to 
participants.  
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3. All amendments must be submitted to the REC. 
4. Investigators should indicate how amendments will impact on risk. 
 
5.3 The Jesse Gelsinger Case (Sibbald, 2001: 1612-14) 
 
Jesse Gelsinger suffered from a partial deficiency of Ornithine 
Transcarbamylase (OTC) – a key enzyme in the urea cycle.  This is a liver 
disorder in which the body cannot eliminate urea through the ammonia cycle.  
It affects one in 40 000 newborn children, most of whom become comatose 
within 72 hours of birth.  They sustain severe brain damage and half die within 
a month of birth.  The other half die by the age of five years. Gelsinger 
survived due to the partial deficiency coupled with a low protein diet and 
medication.  On 13 September 1999 Gelsinger received an infusion of the 
OTC gene carried by an adenovirus vector – into his hepatic artery.  The 
adenovirus usually causes mild colds.  However, within hours of the injection 
of the virus vector Jesse experienced a severe immune system reaction to the 
vector and he died of multi-organ failure four days later. 
 
When Jesse died, the FDA suspended the trial for the following reasons: 
 
1. failure to train staff adequately 
2. failure to develop basic operating procedures 
3. inadequate informed consent. 
 
As part of the informed consent process, Jesse was not informed that other 
patients had experienced serious adverse events or that three monkeys had 
died of a clotting disorder and severe liver inflammation after being injected 
(Sibbald, 2001: 1612-14). 
 
Another major problem with this study was the failure to report adverse events 
to the Recombinant DNA Advisory Committee (RAC), the federal group that 
initially recommended approval of the study.  During the hearing, investigators 
admitted that they had not followed adverse event reporting procedures.  
There was a failure to notify the FDA of serious but transient adverse events 
  82 
in previous patients.  Investigators also did not inform the RAC of changes to 
the study protocol – the change involved injecting the gene directly to the liver 
rather than intravenously.  This was done in an attempt to prevent widespread 
vector distribution in the body.  However, post-mortem findings indicated that 
the hepatic infusion had led to “significant vector [distribution] outside the liver” 
including high amounts in the spleen and bone marrow (Jenks, 2000: 98). 
 
The reluctance of researchers to report adverse events and share other trial 
related information could be as a result of fear of loss of future patent rights in 
the event that a clinical trial produces a marketable product.  In gene therapy 
trials in the United States, an adverse event can be considered to be 
proprietary information (Sibbald, 2001: 1612-14). 
 
What was interesting about this case was the principal investigator – James 
Wilson.  He is a world renowned expert in his field but also president and 
major shareholder of a private company – Genova inc.  The company held 
patents for the procedure and provided funding for the research.  The 
University of Pennsylvania and some of its board members owned stock in 
Genova.  Of particular interest was the fact that Genova had granted research 
funds to Arthur Caplan, an international expert in the ethics of research in 
children – who had supported the project (Hoey, 2003: 10). 
 
The outcome: 
 
1. death of Jesse Gelsinger 
2. his family filed a lawsuit against the university which they settled 
3. Wilson resigned his post at the University 
4. University of Pennsylvania issued strict guidelines that prohibit faculty
 or members of their family from having any material financial interest in 
 a private company whose product they are evaluating. Harvard 
 University followed suit as did a number of other institutions. 
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5.4 The Ellen Roche Case (Steinbrook, 2002: 716-20) 
 
Ellen Roche was a 24-year old technician who worked at the Asthma and 
Allergy centre at Johns Hopkins University.  She was recruited into a non-
therapeutic research study as a healthy volunteer. 
 
The study related to Asthma and the neural mechanisms in the lung that keep 
the airways open in normal people.  The drug being used was a ganglionic 
blocker called Hexamethonium – a drug that would block the nerves and 
cause bronchoconstriction.  The study was designed to provoke a mild 
asthma attack in order to elucidate the reflex that protects healthy people from 
developing attacks of asthma (Savulescu, 2002b: 3-4).  In the 1950s and 60s, 
Hexamethonium was used to treat Hypertension but was withdrawn for human 
use by the Food and Drug Administration (FDA) in the 1970s. 
 
The study started in April 2001.  On 4 May 2001 Ellen was given the 
investigational drug, Hexamethonium, by inhalation.  On 5 May, she 
developed a dry cough – became progressively worse and was hospitalized 
on 9 May with fever, hypoxemia and chest x-ray abnormalities.  She got 
progressively more breathless and was transferred to the intensive care unit 
on 12 May.  On 2 June 2001, Ellen Roche died as a result of progressive 
hypotension and multi-organ failure.  On 19 July 2001 all research was halted 
at Johns Hopkins and an investigation was instituted. 
 
RESULTS OF THE INVESTIGATION 
 
(a) The study had a solid scientific basis and was well designed. 
(b) The drug was scientifically sound 
(c) The IRB/ REC was criticised: 
It did not ask for more safety information on a drug that was not 
approved by the FDA and that was no longer in clinical use. 
Furthermore, the drug was being given via a non-standard route 
(inhalation) 
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(d) The investigator was criticized for not reporting the symptoms in the 
first subject promptly, not delaying the exposure of the next subject to 
Hexamethonium until the symptoms in the first subject had resolved, 
and not searching “more comprehensively” for previous reports where 
Hexamethonium had pulmonary toxicity.  
(e) The Informed Consent document was insufficient. It did not list all the 
 side effects of the drug, the risks of the drug were not clearly stated 
 and the lack of the FDA’s approval was not mentioned. The word 
 “medication” was used, not experimental drug. 
 
Johns Hopkins University took full responsibility for the death of Ellen Roche 
and on 11 October 2001 announced a financial settlement with the Roche 
family. 
 
5.5 Commentary 
 
In non-therapeutic research involving healthy volunteers, the emphasis tends 
to shift from informed consent to prevention of harm.  This is based on the 
assumption that participants in these trials are usually better educated than 
patient volunteers in phase three trials – often students or institutional 
employees volunteer.  This in itself may serve as a point of contention 
regarding the voluntariness of participation.  As an employee at Johns 
Hopkins, the potential for coercion or consent under duress exists.  Ellen 
Roche’s name was obtained from a database of volunteers who had 
participated in previous studies.  If, however, there was no coercion involved 
and her participation was based on altruism or was motivated by monetary 
reward, it is generally assumed that these volunteers are in a better position to 
understand the nature of the research and to make an informed decision 
regarding participation.  The imperative then becomes protecting them from 
harm given the fact that very little benefit accrues to individual volunteers 
while science is seen as a major beneficiary. 
 
In these cases, however, both informed consent and minimisation of harm 
were flawed.  This meant the participants were not able to protect themselves 
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from making a risk-benefit analysis based on the information provided in the 
informed consent documentation and the investigator and REC had not taken 
adequate measures to minimize harm. 
 
One of the 13 principles of good clinical practice specifies that adequate 
information regarding the investigational product is gathered by the 
investigator.  
 
In the Ellen Roche case, there were two barriers to establishing all relevant 
investigational product information. In the first place, a study conducted using 
hexamethonium by inhalation in 1978 at the University of California, did not 
report the pulmonary toxicity as an adverse event as they regarded this to be  
unrelated to Hexamethonium.  In fact, the investigator on the Ellen Roche 
case used that study as evidence that the drug was safe (Savulescu, 2002b: 
3-4).  This is indicative of the far-reaching consequences of publication bias, 
when researchers fail to publish all relevant results of research (Savulescu, 
2002a: 1-2). 
 
The second barrier to establishing accurate investigational product information 
resided with the investigator himself and his failing to conduct an adequate 
literature review.  He relied on an internet search for investigational product 
information.  There were journal articles dating back to the 1950s warning of 
lung damage as a result of inhaling hexamethonium  According to the OHRP 
this information was “readily available via routine MEDLINE and Internet 
database searches, as well as recent textbooks on pathology of the lung” 
(Savulescu, 2002a: 1-2).  A number of reports between 1953 and 1962 as well 
as a review article from 1972 were later found during the investigation.  These 
articles had not been reviewed by the investigator.  In reports published after 
1980, five referred to pulmonary complications of Hexamethonium in the title 
(Savulescu, 2002a: 1-2). 
 
While the ethics committee was criticised for not conducting a literature review 
themselves, I would like to argue that this is not a routine mandate of the 
REC.  In routine practice, the investigator and the institutional department take 
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responsibility for reviewing the science of the study prior to submission to the 
REC.  While most RECs review both the science and the ethics, there are 
usually inadequate trained personnel on an REC to repeat a literature review 
on every project submitted.  This is a core responsibility of the investigator 
and perhaps this case has served to highlight the importance of this function. 
It is also perhaps a reason to reconsider the dual roles played by RECs in 
terms of reviewing both the science and the ethics of the protocol.  This will be 
discussed further in Chapter Six. 
 
The Ellen Roche and Nicole Wan case studies indicate that the traditional 
ways of protecting research participants – informed consent, voluntariness, 
risk-benefit analysis - have not been successful.  While the above participants 
were able to provide informed and voluntary consent based on the information 
contained in the relevant documents, “aspects of each protocol”, its 
“implementation and oversights were flawed” (Levine, 2004: 220). 
 
As a result of these flaws two healthy young volunteers lost their lives.  Given 
the melioristic role that Jonas has ascribed to the research endeavour, 
especially non-therapeutic research, such an outcome cannot be justified.  
However, these unfortunate events had a pivotal role to play in placing ethical 
review in the United States under intense scrutiny.  
 
Donna Shalala, secretary of the Department of Health and Human Services, 
argued that “even one lapse is too many”.  According to her “the American 
people expect that clinical researchers will never compromise or neglect the 
safety of human subjects”. The ultimate responsibility would rest with the 
institution (Shalala, 2000: 808). 
 
What is evident in all three case studies is that investigational findings 
revealed that investigators had failed to conduct the studies in keeping with 
the principles of good clinical practice.  On the whole the IRB reviews in the 
first two cases had minor flaws.  It is only in the Ellen Roche case that the 
REC did not insist on FDA approval and that was their major failing.  
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Chapter 6 
 
Research Ethics Committees in 
South Africa 
A Status Report 
 
 
6.1 Introduction 
 
Between 1996 and 2001, the deaths of Nicole Wan, Jesse Gelsinger and 
Ellen Roche evoked considerable public concern.  It was evident that there 
were widespread deficiencies in the review system.  This resulted in a review 
of the structure and functions of RECs and IRBS in developed countries 
(Institute of Medicine, 2003).  The adequacy of RECs in protecting research 
participants was called into question.  Similarly, the question was being 
debated in developing countries, including South Africa, except with a graver 
degree of concern given the fact that RECs in developing countries have been 
historically under-resourced and over burdened. 
 
The words of Dr Sidney Wolfe of the Public Citizen Heath Research Group 
echoed in both developed and developing world research ethics communities 
(Savulescu, 2002b): 
 
if protections are flawed at esteemed places such as Hopkins, they are 
likely flawed elsewhere.. 
 
It is with this concern in mind, that the empirical component of this dissertation 
was undertaken. 
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All research – both clinical trial and academic research - that is conducted in 
South Africa must be reviewed and approved by a local REC before the 
project commences.  All drug related research must, in addition, be reviewed 
and approved by the regulatory agency – the Medicines Control Council 
(MCC).  Research ethics approval is contingent on MCC approval where drug 
related research is concerned.  The research ethics review system in South 
Africa consists of approximately 22 local RECs and an Interim National Health 
Research Ethics Committee (INHREC).  Since 1994, when South Africa 
underwent a transformation from an “Apartheid” state to a democracy, an 
enormous amount of reform commenced in health regulation.  The Health Act 
has been revised and the National Health Bill is in the process of becoming 
the new National Health Act.  The INHREC has been established under the 
National Health Bill and reports directly to the Minister of Health.  This national 
body has the overall responsibility to promote, ensure and monitor compliance 
by approved ethics committees in South Africa.  At the time of this study, the 
INHREC was an interim body and had not as yet executed any of its 
mandates on local RECs. 
 
In 1998, the Director-General of the Department of Health convened a 
working group to compile a national guideline for the conduct of clinical trials 
in South Africa.  In 2000, Guidelines for Good Practice in the conduct of 
clinical trials in human participants in South Africa was published – referred to 
as SAGCP.  The purpose of the guideline was to provide South African 
researchers, RECs, research sponsors and the general public with clearly 
articulated standards of good clinical practice in research that are 
contextualised to the local setting. 
 
According to this national guideline,  
 
 the main responsibility of ethics committees is to ensure the protection 
 and respect of the rights, safety and wellbeing of participants involved 
 in a trial and to provide public assurance of that protection by 
 reviewing, approving and providing comment on clinical trial protocols, 
 the suitability of investigator(s), facilities, methods and procedures used 
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 to obtain informed consent. In the execution of these responsibilities 
 committees should be guided by relevant South African ethical 
 guidelines, professional standards and codes of practice. The 
 performance of ethics committees should be systematically audited in a 
 structured way. 
   (Guidelines for Good Clinical Practice in the conduct of 
   Trials in Human Participants in South Africa, 1999) 
 
6.2 Methodology 
 
The empirical component of the research employed a combination of 
quantitative and qualitative methods to address different components of the 
research question.  All the quantitative data is presented in Chapter Six.  
Where relevant, portions of the qualitative data are also presented here.  
However, the bulk of the qualitative data is presented in Chapter Seven. 
 
For both the quantitative and qualitative research, permission to administer 
the questionnaires and to conduct the interviews was sought telephonically 
from the Chairperson of each REC.  All 12 REC chairpersons agreed to 
participate and appointments were secured at the various institutions in South 
Africa.  Approval for the study was granted by the Research Committee, 
Faculty of Arts, University of Stellenbosch in 2002. 
 
The quantitative component assumed the format of a descriptive survey of 
RECs in South Africa that was based on a structured questionnaire.  This 
method ensured that each REC was exposed to the same questions so that 
their responses could be reliably compared (Bernard, 2002: 240). 
Development of the research tools (questionnaire and interview guide) was 
based on the following pre-existing information: 
 
Firstly, the basic functions that are intrinsic to any research ethics review 
system were considered: 
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1. comprehensive review of protocols (including scientific, financial 
 conflict of interest and ethical reviews) 
2. ethically sound participant-investigator interactions 
3. ongoing (and risk appropriate) safety monitoring, and 
4. quality improvement and compliance activities. 
            (Institute of Medicine, 2003: 49) 
 
Secondly, known deficiencies in the system including: 
 
1. REC membership 
2. education and training of REC members and investigators 
3. lack of institutional commitment 
4. inadequate initial and continuing review of protocols 
5. informed consent 
6. review of research on vulnerable populations 
 
The questionnaire sought to gather information on membership, workload, 
efficiency, review procedures, infrastructure and resources. (see addendum 
for detailed questionnaire).  It was administered to the administrative officer of 
each of 12 RECs in South Africa during 2003.  This was completed with the 
assistance of the interviewer.  This method of face-to-face completion of 
structured questionnaires enabled the form to be completed comprehensively 
(Bernard, 2002: 242-43).  It also ensured a better response rate compared to 
self-administered questionnaires that are usually used in a postal survey.  
When the administrative officer was unable to respond to any of the questions 
these answers were obtained from the chairperson of the REC during the in-
depth interview hence the use of exemplars from the interviews in the section 
on composition of RECs.  This represents a combination of quantitative and 
qualitative methodology and can be viewed as a form of triangulation in 
combination with the use of documentation.  Data was cross-checked from 
documentation containing standard operating procedures and membership 
lists.  
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This part of the research sought to answer the following question:  How are 
RECs composed in terms of membership and briefly, how do they function? 
 
6.3 Data Analysis 
 
Data from the questionnaires was captured using Microsoft Excel 
spreadsheets and was analysed by an epidemiologist using the Statistical 
Analysis Systems (SAS) package.  The descriptive information is tabulated – 
see tables 1, 2 and 3 in the addendum. 
 
6.4 Sample 
 
The RECs in South Africa were identified via the chair of the Interim National 
Health Research Ethics Committee (INHREC) who provided a list of 22 RECs. 
Of these three were private and 19 institutional.  Nine of the 19 were attached 
to tertiary educational institutions:  University of Cape Town (UCT), University 
of Stellenbosch (US), University of Pretoria (UP), Medical University of South 
Africa (MEDUNSA), University of Witwatersrand (Wits), University of Transkei 
(UNITRA), University of Kwa-Zulu Natal (UKZN), University of Orange Free 
State.  The ninth REC is attached to the Medical Research Council (MRC) of 
South Africa. 
 
The remaining 10 were smaller RECs attached to technicons – reviewing 
mainly academic research and not clinical trials.  Many of these institutions 
were in a state of fluidity with plans for mergers with each other or other 
tertiary institutions.  This is in keeping with policies for higher education in the 
Ministry of Education as part of a rationalisation process in tertiary educational 
institutions in South Africa.  Hence they were excluded from the sample.  
Where RECs were attached to universities, only those in the Health Sciences 
Faculties were included in the sample as this is where the clinical trials are 
reviewed.  RECs dealing with academic research in other faculties were 
excluded. 
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Hence nine institutional and three private RECs were included in the 
quantitative survey. 
 
The data that follows has emerged from the quantitative survey.  However, 
issues that emerged from the interviews that related to REC composition or 
function have been included in this chapter.  In particular, dual review of the 
science and ethics of protocols and the role of the National Interim Health 
Research Ethics Council in relation to local RECs, will be discussed here. 
 
6.5 Results of Ethics Committee Survey 
  
6.5.1 Composition 
 
12 Ethics committees participated in the quantitative survey: nine institutional 
committees associated with University Faculties of Health Sciences, which 
review academic research (both clinical and epidemiological studies) and 
industry-sponsored trials, as well as three private committees (Pharmaethics, 
South African Medical Association (SAMA) and Anglogold) which review 
primarily industry-sponsored studies or money-related research as in the case 
of Anglogold.  At the time of the quantitative survey, the Anglogold REC was 
operational.  However, by the time of the interview, the REC had been 
dissolved and the Chairperson had resigned. 
 
The data that follows reflects the structure and functioning of all 12 health 
sciences research ethics committees in the country. 
 
Of the 12 committees, ten have been in operation for at least ten years, with 
the oldest established more than 30 years ago.  The remaining two 
committees are less than a year old, both linked to historically disadvantaged 
academic institutions. 
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Figure 1: Duration of REC Existence in South Africa 
 
 
 
 
 
 
 
 
 
 
 
 
 
Committee Membership 
 
The size of the 12 committees ranges from seven to 29 members (average, 
16 members), excluding alternate members.  All of the committees, except 
one, were comprised of mostly men (mean proportion men, 63%, range 46%-
82%). 
 
Figure 2: Gender Representation on RECs in South Africa 
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All but three committees were comprised of mostly white members (mean 
proportion white, 62%, range 10%-86%).  
 
Figure 3: Racial Representation on RECs in South Africa 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Most of the committees were comprised primarily of scientists, primarily 
clinicians, (56% of all committee members).  At institutions, the RECs are 
larger, hence a variety of scientific disciplines are represented on the 
committee.  The private RECs are much smaller than institutional RECs and 
have very limited scientific review capacity – one REC has only one 
scientific/clinical member.  
 
Other backgrounds were more sparsely represented among committee 
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o Theologians (all from Christian denominations; 9 of 12 committees, 5% 
of all committee members) 
o Community representatives (10 of 12 committees, 8% of all committee 
members) 
o Other allied health professionals (on 5 of 12 committees, 5% of all 
committee members) 
o Pharmacists (on 5 of 12 committees, 5% of all committee members) 
 
In addition, only a handful of committees included statisticians or 
epidemiologists (three individuals on three separate committees, representing 
one% of all committee members). 
 
Of the ten committees reporting a community representative, the type of 
representatives included: priests, union members, educators (including a 
retired headmaster), local business people, students, a retired nurse, and an 
NGO member.  
 
Figure 4: Professional Membership of RECs in South Africa 
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Of the 12 RECs, two committees reported that all their members were 
independent or not affiliated with the institution, while another two reported 
that none of their members were independent of the institution.  The 
remaining eight committees reported that less than 50% of their members 
were independent or non-affiliated. 
 
Five of the 12 committees reported that their term of membership was 
unlimited (indefinite); among the remaining seven committees, the duration of 
membership was between two and five years. 
 
Only three of the 12 committees reported that they had procedures for the 
disqualification of members.  This referred to the compulsory resignation of 
members who were involved in unethical research themselves or who 
performed inadequate review of protocols related to a conflict of interest.  
 
Commentary on Composition 
 
Racial diversity 
 
According to Moreno, RECs may vary greatly in a number of different respects 
but  
 
it is a given that they must represent various perspectives, including 
that of the institution’s ‘community’, and that they should not be 
dominated by physicians. This is a reflection of  the fact that the ethics 
committee idea is legitimized as an expression of certain themes of 
democratic liberalism, including especially the notion that moral 
controversies are best resolved  through a process that takes into 
account multiple perspectives on the nature of the good life. 
        (Moreno, 1998: 477) 
 
Four years after democracy was established in South Africa, the Department 
of Health set up a committee to establish guidelines for good clinical practice.  
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In 2000 “Guidelines for Good Clinical Practice in the conduct of clinical trials in 
human participants in South Africa” was published, hereafter referred to as the 
SAGCP 2000 guidelines.  This guideline is currently undergoing revision. 
According to the Director-General of Health, this document is compulsory and 
where it differs from international guidelines, the local guideline is applicable.  
 
Specific recommendations are outlined in section 8.2 regarding the 
composition of a South African Research Ethics Committee (REC).  The REC 
must : 
 
• Be representative of the communities they serve and reflect the 
demographic profile of the population of South Africa; 
• Have a minimum membership of at least seven members; (nine 
members – revised guideline) 
• Have a chairperson; 
• Include members of both gender and not more than 70% of its 
members must be men or women; 
• At least one lay person with no affiliations with the institution, not 
currently involved in medical, scientific or legal work and who are 
preferably from the community; (two lay persons in the revised 
guideline) 
• At least one member with knowledge of and current experience in 
areas of research that are regularly considered by the ethics 
committee; 
• At least one member with knowledge of, and current experience in the 
professional care, counselling or treatment of people (e.g. medical 
practitioner, psychologist, social worker, nurse); and 
• At least one member who is legally trained. 
 
These guidelines are similar to the ICH (International Conference of 
Harmonisation) Harmonised Tripartite guideline for Good Clinical Practice – 
referred to hereafter as ICH GCP except for minimum membership of five in 
the international guideline. 
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Where the SAGCP guideline differs from an international guideline, the South 
African requirement is to be followed provided it does not dilute an 
international guideline. 
 
The survey of ethics committee membership in SA indicates that all 
committees exceed current minimum membership requirements in terms of 
numbers.  However, composition in terms of gender and race does not meet 
SAGCP requirements.  Most RECs in SA are white male dominant.  Reasons 
given for this included the following:  
 
 The representation [on the committee] at the moment reflects what is 
 happening at the university. 
 
Race is difficult [to represent on the committee] as people of all races 
are not available at the university. 
 
There is a question mark about representation because it has nothing 
to do with the activities of the committee, it is just to be more in line, 
now, with what is happening in the country… the ultimate is that the 
committee sticks to the guidelines, the national guidelines. 
 
 I can’t think we ever looked at race as an issue. 
 
We have tried… to really get our gender and race mixture right, and I 
think we have done that. 
 
It is a major concern that RECs in South Africa continue to fail to reflect 
gender and racial diversity in their membership.  It is even more concerning 
that some REC chairs do not appreciate the need for gender or racial diversity 
in a multicultural country like South Africa.  In most instances the lack of 
diversity on RECs is attributed to the university faculty community – most of 
whom are white males.  The paucity of Black faculty members at most 
medical faculties in South Africa is one of the many consequences of South 
Africa’s history of racial discrimination and the impact it had on the training of 
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Black medical students (Perez, 2004: 764).  Blacks, in particular those 
classified as African under the apartheid system, were restricted entry into 
medical schools by a permit system in operation from 1959 to 1986 (Baldwin-
Ragaven, 1999). 
 
In 1967, the ratio of white doctors trained per million of the white population in 
South Africa was almost 100 times higher than the equivalent ratio for Blacks. 
In 1985, 83% of all doctors and 94% of all specialists were white (Kale, 1995: 
1307).  Post 1994, admission of Black students to formerly predominantly 
white institutions increased but the median percentage of African students 
studying medicine in 1999 remained approximately half the equivalent 
proportion for whites across South Africa’s 8 medical schools (Lehman, 1999: 
187-99).  These eight medical schools are reflected in the survey undertaken 
for this dissertation. 
 
The implications for the university faculty compositions are grave indeed.  Ten 
years into democracy, insufficient redress has occurred to eliminate apartheid 
influences from major academic centres.  In view of the research populations 
being mainly vulnerable populations of colour, the composition of RECs as 
predominant white male bodies could be perceived as reinforcing the 
asymmetrical power relationship that already exists between predominantly 
white researchers and predominantly black participants.  As the body that 
represents protection of the rights of research participants the REC has to be 
perceived by the public and the participants to reflect justice and fairness. 
 
The Code of Federal Regulations (45CFR46) in the United States refers to 
this concept when it outlines IRB membership in 46.107 (Department of 
Health and Human Services, 2001): 
 
The IRB shall be sufficiently qualified through the experience and 
expertise of its members, and the diversity of the members, including 
consideration of race, gender, and cultural backgrounds and sensitivity 
to such issues as community attitudes, to promote respect for its advice 
and counsel in safeguarding the rights and welfare of human subjects. 
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Unfortunately in South Africa, a white male dominated body will be perceived 
to lack a sense of fairness or justice given our political history and will not be 
able to “promote respect for its advice and counsel”.  Hence, the SAGCP 
guideline, like the 45 CFR 46 guideline, specifies diversity of membership in 
terms of race and gender. 
 
There are also other implications where diversity is concerned in terms of the 
informed consent process.  It is essential that diversity exists on RECs so that 
culturally defined issues relating to research are acknowledged and 
incorporated.  This refers to issues of written consent, spousal consent, 
community consent, inter alia.  Diversity lends value to the ability of a REC to 
assess translations and this will be discussed later.  Diversity itself needs to 
be present not only in the form of community members, of whom there are few 
in any case on South African RECs, but also in terms of scientific, clinical and 
non-scientific membership.  Where community representatives are concerned, 
these are usually people of colour.  Studies of non-scientific members have 
shown that up to 88% of such members have reported negative experiences 
with scientific members – these have included having their opinions 
disrespected, not being understood or not being taken seriously (Sengupta, 
2003: 215).  One can only imagine that these issues will be intensified when 
community representatives are diluted in a sea of white male scientific 
members especially in the South African context.  There is no doubt that 
requirements for both gender and racial diversity on RECs transcend a mere 
political correctness and are specified to enhance the functioning of an REC 
at a more profound level. 
 
Finally, in the formal letter sent to the IRB at Johns Hopkins University after 
the investigation into the death of Ellen Roche, the OHRP commented as 
follows as they suspended all federally funded research at the institution 
(Office for Human Subject Protection (OHRP), 2001): 
 
OHRP is concerned that the current membership of the IRBs appears 
to lack the diversity, including consideration of race and cultural 
backgrounds and sensitivity to such issues as community attitudes, to 
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promote respect for its advice and counsel in safeguarding the rights 
and welfare of human subjects, as required under HHS regulations at 
45 CFR 46.107(a). 
 
While it is sometimes the case that members of all racial groups are not 
available at some tertiary institutions, inadequate efforts are being made to 
recruit and retain such faculty members.  Ten years into democracy in South 
Africa the ideology of apartheid is reflected in the REC membership at 
previously white universities. 
 
Gender Representation 
 
The disparity in gender representation is also problematic.  Except for one 
institution, all Chairpersons of RECs in South Africa are male.  Amongst REC 
members, the representation of women ranges from 18% to 54%.  This 
parallels the gender disparities that exist in academia with very few women 
occupying senior faculty positions. Three RECs have male representation in 
excess of the 70% specified by the SAGCP guideline. 
 
Professional Diversity 
 
While most committees reflect professional diversity in membership, there is 
however, a dominant presence on most committees of scientists/clinicians.  
Amongst the 12 South African RECs surveyed, doctors, scientists and 
pharmacists together made up 61% of the membership.  This exceeds 
international scientific/clinical membership trends.  A survey of 89 IRBs in the 
United States in 2001 found that physicians, scientists and pharmacists 
together made up 46% of IRB membership. 
 
While scientific/clinical membership is high on most RECs less than half of all 
RECs have a pharmacologist as a scientific/clinical member, yet all RECs in 
South Africa have a mandate to review both the science and the ethics of 
protocols.  This represents a serious hiatus as almost all RECs included in the 
survey are involved in the review of clinical trials of investigational drugs.  As 
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was demonstrated in the Ellen Roche case, drug toxicity was a key factor that 
resulted in her death.  On this basis, it can be argued that a pharmacologist 
should form part of the core membership of any REC reviewing drug trials.  
This is not specified in the SAGCP guideline.  On the one hand, in South 
Africa, it can be argued that the regulatory agency, the MCC, takes 
responsibility for assessing safety of the investigational product.  On the other 
hand, as the REC and MCC conduct simultaneous review of protocols and the 
MCC verdict is not available at the time of ethics review, final ethics approval 
is usually deferred pending MCC approval.  However, if the REC is mandated 
to conduct both scientific and ethics review, the scientific membership of the 
REC must include a pharmacologist.  In the case of Ellen Roche, the 
regulatory agency, the FDA, was not able to fulfil the role of “safety net” as the 
investigator did not submit an application to the FDA for approval of the use of 
an investigational new drug.  An important factor that eluded the REC at 
Johns Hopkins was the use of the drug via a new route and for a new 
indication.  Prior approval of hexamethonium by the FDA was for hypertension 
in an oral formulation and by 1972, that approval had been withdrawn as a 
result of lack of efficacy of the drug. 
 
Statistical review is becoming more and more challenging for RECs yet 
statisticians/epidemiologists comprise only one% of all RECs in the country. 
 
The trend towards conducting more equivalence trials as opposed to placebo 
controlled trials has resulted in significant trial design changes.  The advent of 
superiority and non-inferiority trials has highlighted the importance of sample 
size and adequate powering of studies.  This was illustrated in the SAINT 
study conducted in Durban, Kwa-Zulu Natal to assess efficacy of two different 
regimens of treatment in preventing mother-to-child transmission of HIV 
(Moodley D, 2003: 725-735).  The study was designed as a superiority study.  
However, it failed to show superiority and hence has been criticised for that 
design error (Colvin: 2002).  Garattini argues that a trial should be designed to 
show the superiority of a new treatment over the best treatment available for 
the same therapeutic indication.  Equivalence and non-inferiority trials reflect 
“a switch from the search for better drugs to the acceptance of drugs that are 
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similar to or not worse than those already on the market”.  He charges that it 
is conceptually difficult to establish the limits that define a drug as equivalent 
or not inferior.  Furthermore equivalence or non-inferiority designs reflect 
economic considerations – smaller sample sizes are required compared to 
superiority trials (Garattini, 2003: 1199-200). 
 
Furthermore, the conduct of underpowered trials is generally considered 
unethical except in very specific clearly defined cases (Halpern, 2002: 358-
62). This includes small trials for rare disease in which the investigators 
document their plans for merging their results with those of other trials in a 
meta-analysis and early phase drug trials provided they are adequately 
powered for defined purposes that do not include randomised treatment 
comparisons.  In both cases, informing participants that the study is going to 
be of limited benefit is seen as an ethical requirement.  Given the complexity 
of trial design in recent years it is of great concern how an REC may function 
without a statistician or epidemiologist. 
 
Ethicists are well represented on South African RECs.  This survey found that 
67% of RECs had at least one ethicist.  The 2001 United States survey found 
that only 23% of the 89 IRBs surveyed had an ethicist (De Vries, 2002: 206). 
 
Committee composition of private RECs is concerning.  One REC has only 
one scientific/clinical member.  This may be seriously inadequate for the wide 
range of medical disciplines in the private sector (usually specialists) who are 
submitting protocols. 
 
Representation of Independent or Non-affiliated Members on RECS 
 
Excluding the private RECs that are 100% independent, institutional RECs 
have independent or non-affiliated membership ranging from zero% to 19%.  
Most members of institutional RECs are affiliated to the institution.  This 
parallels trends internationally – a survey of 89 IRBs in the United States 
conducted in 2001 revealed that 85% of IRBs have a majority of affiliated 
members.  This was most marked on institutional IRBs where over 80% of 
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members are affiliated (De Vries, 2002: 206).  Where the majority of members 
are affiliated to the institution, the potential for biased and inadequate review 
exists (McNeill, 1998: 377). 
 
Members with no affiliation to the institution are important to lend objectivity to 
the review process and protect the REC from facing a conflict of interest in 
reviewing research that will benefit the institution.  The two institutional RECs 
with no independent members are particularly problematic in this regard. 
 
Lay and Community Representation 
 
Lay representation is present in 80% of RECs but these are not always people 
from the community.  
 
One REC commented as follows: 
 
 there is no lay [community] representation” on our committee. [The 
 committee] is made up of professionals.  
 
Another REC chair commented: 
 
 Yes, we have a minister of religion and a nursing sister. 
 
Those RECs that had community representation on their committees stated 
that these members were actively involved in reviewing all protocols with 
special emphasis on the patient information leaflet.  They considered whether 
these documents would be understood by participants and how the 
community would regard the research. The following comments were made: 
 
Their dedication is not as good as one would want but they do lend a 
certain perspective that you cannot find from anyone else 
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They provide: impressions of how studies may influence the 
public…That’s very important. In that way they are very good and they 
do lend a certain balance. 
  
Lay representation is sometime a problem as after two years these 
individuals have learnt the terminology and are not that lay anymore. 
However they play a valuable role in assessing the patient information 
leaflets. 
 
The main thing that we would like them to do is represent the 
community, the other thing is to really give us feedback on how they 
think the research that’s being conducted in a specific community will 
impact on that community…The other thing is the relevance of that 
research in a specific community…what we also expect from them is to 
see whether the translations that we do is really written in a language 
that’s being spoken in this specific community. 
 
With a representative ethics committee, many professional members of 
the committee are also members of the community. 
 
The SAGCP guideline makes the following recommendation regarding lay 
membership. 
 
At least one lay person with no affiliations with the institution, not 
currently involved in medical, scientific or legal work and who are 
preferably from the community 
   (Guidelines for Good Clinical Practice in the conduct of 
   Trials in Human Participants in South Africa, 1999) 
 
The South African Medical Research Council Ethical Guidelines for Research 
make the following recommendation regarding “lay” representation: 
 
Committees should accommodate respected lay opinion in a manner 
that provides effective representation of the non-clinical community as 
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well as clinical interests.  Lay opinion in the non- clinical community 
means opinions from a lawyer, social worker, religious leader, teacher 
or similar persons of standing able to contend with pressures from 
individuals within the broad health profession. 
 
The guidelines also recommend 
 
representation of disadvantaged communities, where research is to be 
carried out in these communities. 
                       (South African Medical Research Council, 2002) 
 
It is evident that while the SAGCP guideline regards lay representation as 
non-academic and representative of the community, the MRC guideline sees 
lay representation as non-scientific and seems to have an additional category 
of person as being the community representative.  The justification for having 
non-scientific but other professional categories of people as lay representation 
is for there to be strength in the voice of the lay representatives.  This 
sentiment is echoed by Sengupta and Lo when they refer to recruitment of 
“assertive” lay members who will not be easily intimidated by scientific 
members (Sengupta, 2003: 217).  The suggestion from the National Bioethics 
Advisory Commission (NBAC) to increase non-scientific representation to 
25% of the committee would also add strength to the voice of lay members on 
the committee. 
 
A distinction needs to be drawn between lay representation and community 
representation.  Lay representation on a research ethics committee usually 
refers to anyone who has no scientific or medical background.  It could 
therefore include lawyers, ethicists, priests or theologians.  In South Africa, 
these “lay” members are not always members of the community being 
researched.  They have a higher level of education than lay community 
members and while they play an important role in lending a multidisciplinary 
approach to the review process, they are not ideally suited to assess the 
patient information leaflets from the perspective of a community member.  
Often they also do not speak an ethnic language. 
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Community representatives, on the other hand, would refer to non-
professional, non-scientific members who belong to the community that is 
being researched. 
 
Generally they would be conversant in the same language as the research 
participants and they would share a similar culture. 
 
In most RECs in South Africa there is blurring of theses two different 
categories of representatives.  Often the lay person is taken to be the lawyer 
or priest with much higher levels of education than the average of the 
community being researched.  Often the priest is someone of the Christian 
faith with lack of representation of other religious sects in the community.  
Sometimes, the priest is also regarded as the “ethicist”.  In my opinion 
provision should be made for both categories of representatives – non-
scientific and community representatives on every committee. 
 
The roles defined for the lay/community member are two-fold: 
 
Firstly, it is felt that they lend a unique “community” perspective to the review 
process.  As representatives of the community, they provide insight into the 
relevance of a particular research project to the community.  They also 
provide input regarding the impact that they think the research will have on 
their community. 
 
The second role that these members fulfil relates to review of the patient 
information leaflet.  Most committees, in the absence of using an objective 
measure of readability of patient information leaflets, rely on lay/community 
members to review this document.  Experience abroad has shown that 
lay/community members help create clearer consent forms (Gillett, 2001: 1-6). 
 
On 10 May 1999, when the IRB at Duke University Medical Centre was 
suspended by the Office for Protection of Research Risks (OPRR), the 
violations specified included 
 
  108 
• Lack of a quorum at board meetings 
• Casual waivers of experimental rules 
• Insufficient public representation on the committee. 
• A Duke official who assisted with bringing research grants into the 
university was also an IRB member – a role potentially in conflict with 
declining unacceptable research (Greenberg, 1999: 1773). 
 
The role of community or “public members” on a committee is hence given 
significant weight.  
 
There is a correlation between those committees that have a lay member who 
speaks an ethnic language and the attention that the committee pays to 
review of translated documents.  The committees who focus mainly on 
English documents tend not to have lay representation from ethnic groups. 
 
In addition to these two roles, Sengupta and Lo suggest expanding the roles 
of non-scientific/lay members via education and training to assess benefits 
and risks of a study protocol from a patient’s perspective (Sengupta, 2003: 
217).  Such a role is confirmed by Gillett who has found that lay members 
encourage researchers to do a better job of explaining the risks and benefits 
to potential participants (Gillett, 2001: 1-6). 
 
Given the roles that the various chairpersons have assigned to lay/community 
members of the committee, it seems more likely that a lay community 
representative should be seen as a unique person making a contribution to 
the committee separate from the non-scientific members who have their own 
unique contribution to make.  It is also important that the dynamics of the 
committee are given attention.  It is important for lay members to be respected 
by scientific members, for their opinions to be respected and for their 
contribution to be elicited on every protocol. 
 
While the lack of scientific knowledge has been regarded as a disadvantage, it 
seems unfair to judge lay members in that regard.  It is mainly for the fact that 
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they do not have a scientific background that their role is defined and their 
function on the committees is not to review the science, but rather to 
concentrate on participant protection issues.  This in turn leads one to revisit 
the functions of the “ethics committee” – should the review of the science be 
split off from the ethics review?  This will be discussed in greater detail later in 
this chapter. 
 
6.5.2 Remuneration of Committee members 
 
Half of the 12 committees did not provide any of their members with 
remuneration for participation.  Of the remaining six, three provided 
remuneration only to independent members and/or community members, 
typically in the form of subsistence or travel costs.  Two provided a per-
meeting payment of approximately R600, while one provided members with 
R200 per protocol reviewed.  
 
Commentary on remuneration 
 
Remuneration of REC members is a long-standing, controversial issue that 
has not been addressed at most institutions in South Africa. 
 
On the one hand, it has been argued that payment of REC members will 
compromise the objectivity of their reviews and create conflicts of interest.  On 
this basis, it has become traditional both internationally and at most local 
RECs not to remunerate REC members.  On the other hand, REC members 
are often full time faculty members with numerous academic and clinical 
responsibilities.  The regular working day does not allow for protocol review, a 
process that is demanding more and more time and skill as protocols become 
more complex.  As such most REC members are conducting protocol reviews 
in their private time for which they are not compensated.  At the same time, 
REC members are not compensated in the form of “time off” from their 
academic or clinical responsibilities.  Furthermore, they receive little 
recognition for their efforts. Wood et al warn that 
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 lack of compensation or recognition communicates to IRB members a 
 devaluation of their commitment to ethical research. 
        (Wood, 2002: 6) 
 
It is hence not surprising that  
 
 Many IRB chairs are having difficulty securing and retaining IRB 
 members. 
        (Wood, 2002: 6) 
 
The issue of REC member remuneration hence needs to be revisited and 
ways of remuneration should be devised that are not linked to outcome of 
protocol review or the number of protocols reviewed thus eliminating the 
traditional argument of conflict of interest. 
 
6.5.3 Training and Development of members in research ethics 
 
Survey Data 
 
Figure 5: Research Ethics Training and Development of members 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
% Trained
0
10
20
30
40
50
60
70
80
90
100
1 2 3 4 5 6 7 8 9 10 11 12
Research Ethics Committees
Pe
rc
en
ta
ge
Trained Untrained
  111 
Interview Data 
 
There is a wide differential between the different institutions in terms of 
training of REC members.  While at two institutions all REC members have 
received training in research ethics, at other institutions none of the members 
are trained. 
 
Most of the training has been attendance of Good Clinical Practice (GCP) 
workshops.  Some RECs provide in-house training, time permitting, at 
meetings.  Some RECs circulate articles on Research Ethics to members. 
While funding is an on-going problem at most institutions, many RECs 
indicated that funding for training is available as a result of fees charged for 
protocol review.  Institutions with the lowest training levels are either not 
charging a fee for protocol review or are charging much less than the other 
RECs. 
 
Most chairpersons are committed to providing training for their members. 
 
Comments regarding training were as follows: 
 
We could do better but we are not doing so 
 
We sponsor anything on ethics…workshops or congresses or 
GCP…there are opportunities and we sponsor those…they can apply 
for funds and usually it’s not a problem 
 
For all members who have not received GCP training up to now, we 
plan to send at least two members a year for GCP training 
 
Two GCP courses are offered per year. We’ve strongly recommended 
that all members attend those GCP courses 
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Commentary 
 
While training varied widely from 0% on some RECs to 100% on others, on 
average 54% of REC members had received training in research ethics or 
GCP.  Surprisingly, only 20% of members had research ethics training on 
75% of the 89 IRBs in the United States survey in 2001 (De Vries, 2002). 
 
Definite and urgent training needs exist at some institutions.  However these 
institutions are conducting very little contract research and hence cannot build 
up funds like those RECS who charge a review fee. 
 
The nature of the training is unclear. GCP training is offered at major centres 
in South Africa by a number of different organisations – some private, some 
institutional.  However, there is no national system for accreditation of the 
various training courses.  Most GCP courses are designed for study teams, 
contract research associates and experienced researchers.  There are no 
GCP courses specifically aimed at REC members. However, a basic GCP 
course over two-three days is a good starting point for any REC member 
reviewing clinical trials.  A diploma in research ethics is available at the 
University of Cape Town as part of the International Research Ethics Network 
for Southern Africa (IRENSA) program.  A Masters course and modular short 
courses are available at the universities of Pretoria and Kwa-Zulu Natal in 
their combined program – the South African Research Ethics Training 
Initiative (SARETI).  The diploma course enrols 8 South African REC 
members a year out of 184 members who sit on the major RECs.  There are 
REC members who sit on purely academic RECs and smaller RECS who are 
not included in this survey.  Hence there may well be more than 200 REC 
members in South Africa.  While the modular courses in the SARETI program 
are suitable for REC members very few members have the time to spend on a 
masters course in research ethics.  
 
Surprisingly, similar concerns regarding training exist in the United States. 
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Training requirements are enforced for NIH related research only.  No 
curricular requirements are specified.  Hence there is no assurance that 
important ethical issues are included in the training courses.  The NIH has 
three computer –based courses: 
 
1. an hour long course for researchers and key personnel in NIH 
Intramural Research Programs 
2 a course for NIH IRB members 
3. a course for anyone involved in human participants research (Wood, 
2002: 7-8). 
 
Hence training curricula and accreditation remain a pervasive problem 
nationally and internationally. 
 
6.5.4 Ethics Review System 
 
At present all RECs in South Africa, both institutional and private are local 
RECs.  There are no regional or national RECs.  An INHREC has been 
established but is as yet not a statutory body as explained in the introduction 
to this chapter. 
 
a Committee Structure 
 
Nine of the ten RECS surveyed assess both clinical trial and academic 
research.  One REC has the review process divided into three separate 
committees – one to review clinical trials, one to review academic/human 
research and one to review animal research. 
 
The private RECs review both the science and the ethics of clinical trials 
submitted by researchers in the private health sector.  There is hence no pre-
existing distinct scientific review.  All REC functions rest with the full 
committee. 
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b Ethical Review – the science or the ethics or both? 
 
All RECS in South Africa are reviewing both the science and the ethics of 
submitted research projects.  Where the science is concerned, there appears 
to be “double review” especially at institutional ethics committees where each 
academic department has a Scientific Review Committee that screens the 
project from a scientific perspective before it is submitted for ethics approval. 
However, once the project reaches the ethics committee, both the science 
and the ethics are reviewed.  The diligence with which this is done depends 
on the review mechanism employed by the committee.  This can be illustrated 
as follows; some committees allocate each project to three reviewers – two of 
whom are members of the REC and one of whom is an external reviewer 
usually an expert in the field of the project.  One of the REC reviewers 
concentrates on the science while the other looks at the ethics. 
 
The use of an expert in addition to committee members ameliorates the 
discomfort felt by some clinical members who have to review protocols 
outside their field of expertise.  It also contributes to a discussion on the 
standard of care for a particular study as the expert is more familiar with 
current standards.  Some RECs are overwhelmed with the statistical design of 
studies that are submitted especially after the placebo debate that resulted in 
more equivalence studies being submitted. 
 
Commentary 
 
More sophisticated demands are being made of REC members in terms of the 
scientific review of protocols. This is better appreciated if one considers the 
elements of a scientific review: 
 
What needs to be considered in a scientific review: 
 
• Importance and novelty of the scientific question 
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• Strength of the scientific design and methodology feasibility of the 
research as designed 
• Appropriateness of the statistical analysis plan 
• Estimate of the probability of meeting the enrolment goals 
• Need for, and structure of a Data and Safety Monitoring Board (DSMB) 
• Assessment of the thoroughness of the evaluation of the relevant 
literature and previous studies, if available 
• Strength of the qualifications of the investigator to carry out the protocol 
and the facilities available to him or her 
• Appropriateness of the inclusion/exclusion criteria 
• Dissemination plan(to enrolled participants and via publication) 
 
Adapted from Responsible Research – Institute of Medicine, 2003. 
 
As is evident in the above guide for scientific review, emphasis is now being 
placed on assessing whether research is relevant, necessary and 
methodologically sound.  This translates into a need for investigators to 
conduct a systematic review of the literature and justify why their project is 
being conducted.  This approach in clinical medicine is referred to as 
Evidence Based Medicine (EBM).  In the research setting this is referred to as 
research synthesis - which refers to the: 
 
aggregation and integration of the results of related primary studies 
with the purpose of drawing conclusions from the totality of the relevant 
evidence. 
                (Savulescu, 1996: 1390) 
 
This is important to ensure that research protocols are not answering 
questions that have already been addressed thereby subjecting participants to 
unnecessary risks and wasting scarce resources.  Such information is also 
essential to judge the need for a placebo-controlled trial. 
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As a result, REC members need to have the ability to evaluate systematic 
reviews submitted to support an application to conduct research (Savulescu, 
1996: 1391). 
 
Additional skills are also required in terms of evaluating trial design, 
comparators and clinical or surrogate endpoints (Garattini, 2003: 1199).  In 
the absence of a statistician or epidemiologist the duties of scientific REC 
members are becoming increasingly difficult. 
 
The advantages of splitting the review into a scientific one and an ethical one 
are as follows: 
 
1. The multidisciplinary team on the ethics committee would be better 
able to concentrate on the issues related to participant protection. 
2. Lay and community members would feel more comfortable on the 
committee as most lay members cannot really participate in scientific 
review. 
3. The review process from the ethics perspective will be accelerated. 
4. A more thorough ethics review will ensue as will a more thorough 
scientific review. 
5. Currently overworked ethics committees will not be unnecessarily 
burdened with protocols. Any project that does not meet scientific or 
statistical standards will not reach the ethics committee. Bad science is 
unethical and hence it is an ethical pre-requisite that such studies are 
screened out before excessive time and resources are spent on review 
of other components like the informed consent form etc. 
 
What are the disadvantages of separating ethics and scientific review? 
 
1. The process may be seen as prolonged requiring more human 
resources – however many RECs are top heavy in terms of 
scientific/clinical members and these excess members could be split off 
to conduct scientific review as a scientific subcommittee. 
2. If not well co-ordinated, could increase review time overall. 
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3. There are conceptual objections to splitting scientific and ethics review. 
4. Membership of an REC may be perceived to be “less prestigious”. 
 
Current trends appear to be in favour of splitting scientific and ethics review 
thereby enhancing the individual review of each aspect (Institute of Medicine, 
2003). 
 
c. Interim National Health Research Ethics Committee (INHREC) 
 
Interview data 
 
• Right now they are not making an impact. Perhaps with time it will  
serve as a watchdog for the different RECs…and see if standards are 
being maintained. 
 
• I hope is that it will serve a facilitatory role to “get ethics committees 
together to formulate guidelines not rules”.  Guidance with HIV 
studies in general and HIV Vaccine studies in particular would be 
welcome. 
 
• A “policing role” will not be welcome and “interference” with 
committee composition and functioning will not be acceptable. 
 
• That’s now the “big daddy” of all the ethics committees: the 
“watchdog” of ethics committees. I think that accreditation is 
important.  Provision of training and support and working together as 
team would be a positive feature.  If however, the role is “policing, it 
will not go off that well.  If the plan is to dictate to everybody… people 
will resign from the ethics committees and they won’t be interested. 
 
• Some RECs felt there was not adequate involvement of RECS in the 
document from the Dept of Health (SAGCP).  The document was 
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circulated too late with inadequate time for feedback and comments. 
They felt “bulldozed into the process”. 
 
• All universities in South Africa are not represented here. 
 
• INHREC will play an important role for accreditation.  There are 
committees without standard operating procedures and membership 
lists or the full committee does not review the protocol. 
 
[The national committee will be good for this but] “they must just not want 
to interfere too much” – “on whether members should get paid or not and 
how much they’re allowed to get paid and how much they’re allowed to 
ask for a protocol, because it differs”.  It is not the “place of the INHREC 
to set limits because every committee functions on a different basis and 
we all don’t have the same resources”. 
 
• The INHREC will “control all ethics committees”.  It will be a place where 
researchers and participants can complain.  It will serve to “standardise 
ethics committees” and prevent “committee hopping”. I “hope that it will 
police committees”. 
 
• [INHREC is seen as] the Department of Health’s attempt to monopolise 
ethics control, which in my view has failed.  The Constitution very 
explicitly protects academic freedom, scientific research and universities. 
 
[The problem could arise that] government department controlled ethics 
control would get into all sorts of arguments that are extraneous to the 
real ethics debate including politics. 
 
• Registration with the INHREC would be important. Our university is 
represented on the INHREC. 
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Commentary 
 
Those committees with representation on the INHREC are positive about its 
role – those that are excluded feel suspicious and are negative about the 
possibility of policing.  The affiliation with the Department of Health is a source 
of serious concern. 
 
Comments from the Chairperson of the INHREC: 
 
 The Ministry of Health and the Interim National Health Research Ethics 
 Committee have been working for a couple of years on a set of 
 guidelines for research ethics.  It is hoped that these will be completed 
 and published within the next few months.  The Committee will also 
 make available a document outlining the requirements for registration 
 of Research Ethics Committees around the country when the National 
 Health Bill becomes the National Health Act. 
 
 As soon as the Act has been passed, I anticipate that the INHREC will 
 no longer be functional and that a National Health Research Ethics 
 Council will be appointed.  The regulations on a National Health 
 Research Ethics Council to be established in terms of Section 77 of the 
 National Health Act will indicate how the Council will be constituted, 
 how nomination of members will take place and the process whereby 
 appointments will be made by the Minister of Health.  The Regulations 
 will also indicate the terms of reference of the Council 
        (Benatar, 2004: 2). 
 
At present, the INHREC is an interim national body. It has not as yet impacted 
on local RECs in any way.  The plan is, however, to develop a system of 
accreditation for all RECs in South Africa.  Based on this system of 
accreditation, RECs will be classified as level one or level two RECs.  Level 
one RECs will be allowed to review minimal or low risk studies only whereas 
level two RECs will be allowed to review moderate to high risk studies as well. 
How this determination of risk is to be made remains unclear.  On the whole, a 
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national body in South Africa will be a positive addition to the ethics review 
system and provided it is fairly and appropriately constituted and efficient, it 
will assist greatly in achieving standardisation in research ethics review in the 
country. 
 
6.5.5 REC workload and review procedures 
 
Meeting frequency 
 
Figure 6: REC Meeting Frequency 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three-quarters of the committees met either monthly or fortnightly, with the 
remaining three meeting only quarterly.  
 
The mean number of members required for a quorum was seven, with wide 
variation (between 17% and 78% of the total membership) in the proportion of 
members required to form a quorum.  
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Protocol Review 
 
Private RECs review both the science and the ethics of protocols. Institutional 
RECs usually have a scientific review before the protocol reaches the REC 
but review both the science and ethics again. 
 
RECs circulated review documents to all their members.  Eleven of the 12 
reported that each protocol was discussed at a meeting of the committee. The 
remaining one committee divided itself into two sub-committees.  Protocols 
were also divided between the two sub-committees.  Only problematic 
protocols were discussed at a full meeting. 
 
The number of reviewers per protocol varied from one to 13; the mean was 
five.  One REC using three reviewers per protocol explained that while each 
member reviews one protocol in detail, he or she is expected to read only a 
summary of the other protocols submitted for the meeting.  That summary is 
provided by the investigator. 
 
Other RECs allocate each protocol to two reviewers – one reviews the 
science in detail and the other reviews the ethical issues. 
 
Ten of the 12 reported requiring consensus to decide on a protocol, while the 
remaining two required voting. 
 
Workload 
 
The average number of protocols reviewed per meeting varied from four to 30, 
with a mean of 12.  This included both clinical trials and academic research for 
all RECs except one.  The latter REC processes only clinical trials while 
academic research is processed by a separate REC altogether.  This is the 
only institution in South Africa that has three different RECs, one for clinical 
trials, one for human research (academic) and one for animal research. 
  122 
The mean estimated number of protocols reviewed during 2002 was 135, with 
a range from 30 to 360 (the total number of protocols reviewed during 2002 by 
the 12 committees was estimated at over 1600). 
 
Six RECs had data for the number of protocols rejected during 2002.  The 
rejection percentage for these six committees ranged from 0% to 10% with a 
mean of 4,52%. 
 
Efficiency of protocol review time 
 
Figure 7: Protocol Review Time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The average time from protocol submission to response was five weeks, with 
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Review Charges 
 
One-third of the committees (four of twelve) reported no charge for 
submissions, of the remaining eight which did charge investigators submitting 
a protocol, the average cost was approximately R2700 (range, R2000 to 
R5500). 
 
Infrastructure and administrative staff 
 
Nine of the 12 committees reported having an office dedicated to the 
committee’s activities.  One committee reported having no staff dedicated to 
the committee’s operations.  Of the remaining 11 committees, most (n=9) had 
at least one full-time staff member, with three committees reporting three full-
time staff members. 
 
Commentary on Workload and Review Procedures 
 
It is evident that the various RECs around the country are functioning at 
completely different levels.  There is wide variability in how the different RECs 
are resourced in terms of infrastructure and administrative staff. 
 
Historically disadvantaged institutions have the following factors in common:  
 
1. either no administrative staff or one part-time person 
2. no dedicated offices at the time of the survey. 
3. quarterly meetings 
4. review the lowest number of protocols in the country 
5. have the longest delay from date of submission of protocols to date of 
 approval  
 
Many tertiary level educational institutions are judged not only on the basis of 
their undergraduate and postgraduate teaching programs but also on their 
research output.  There is hence the vicious cycle of fewer clinical trials being 
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conducted at institutions with a poor research record, perpetuating both 
institutional and investigator funding deficits. 
 
The one private REC that meets fortnightly is able to review protocols in ten 
days.  This is in keeping with the turnaround time at private IRBs in the United 
States.  However, such a meeting frequency is only possible with fulltime 
members in the private sector. 
 
While almost all RECs in South Africa review all protocols at a fully constituted 
meeting of the committee, it was a concern that one REC does not do this. 
This committee’s review system bears a notable resemblance to the John’s 
Hopkins IRB that reviewed the Hexamethonium study.  The Office for Human 
Research Protections was “particularly concerned that that protocols had 
been extensively reviewed by subcommittees of the IRB but not by the full 
committee”. 
                            (Savulescu, 2002b: 3) 
 
In keeping with international trends the number of protocols rejected by RECs 
in South Africa is very low.  The mean of 3,8% compares with the 3% of 
rejected protocols in Spain (Dal-Re, 1999: 269).  A similar situation has been 
described in France where 9% of protocols were rejected or where significant 
modifications were requested.  This was interpreted as RECs being very 
kindly disposed to investigators even though the converse view is commonly 
held.  The French study queried whether the low rate of rejections was related 
to the dominance of physicians and scientists on the committees.  There was 
also the possibility that all protocols are not submitted to the ethics committee 
as this was not compulsory at the time (Isambert, 1989: 451). 
 
On the whole, complaints levied against RECs remain a global phenomenon. 
Investigators, sponsors and REC members themselves regard the experience 
of ethical review as being extremely frustrating.  The review system has been 
described as “time consuming, repetitive and inefficient” (Wood, 2002: 1).  In 
South Africa, RECs that meet quarterly contribute to significant delays in the 
review process.  A protocol review time of 10 weeks is long enough but does 
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not reflect the total time till final approval as most initial reviews require 
amendments by investigators prior to final approval.  South African RECs   
share common problems in the review process with their counterparts 
globally, with the problems being accentuated at some historically 
disadvantaged institutions.  These issues will be discussed further in chapter 
eight where the major challenges facing ethical review will be discussed and 
solutions proposed. 
 
6.6  Commentary   
 
 A remarkable outcome of the quantitative survey is the wide range of 
variability amongst RECs in South Africa. This lack of consistency is reflected 
in a wide range of structural and procedural issues related to ethical review. It 
is also one of the major reasons for “ethics committee shopping” in South 
Africa. This phenomenon occurs when sponsors and/or investigators submit 
protocols to a number of different RECs simultaneously or in succession until 
a favourable outcome is achieved with one of the RECs who may be more 
lenient than the others. Such leniency in review may be related to a number of 
factors such as inadequate constitution of the REC, rapid review time, or 
inadequate training and education of REC members. It may also be related to 
differences in policy on substantive review issues such as approval of 
placebo-controlled studies but this will be discussed in detail in chapter seven.  
 
At one level it is interesting to note the differences in RECs highlighted by the 
quantitative survey. At a more complex level it is important to acknowledge 
that variability in committee composition, variability in education of REC 
members and variability in review procedures impact significantly on the 
review process as a whole. The phenomenon of “REC shopping” results in a 
serious breach of research participant protection. It is thus imperative that 
consistency in REC structure and function is established – a role anticipated 
both by and for the new national body – the INHREC. However, until such 
time as this body is officially established other national initiatives must be 
implemented and these measures will be discussed in chapter eight.   
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The second significant finding in this survey relates to the crucial relationship 
between REC composition and the ethics review system. This pertains to  
both the scientific component and community advocacy on RECs. The rapidly 
expansive and intensive level of scientific review of research protocols that is 
becoming necessary underscores the importance of a new look at scientific 
review on all RECs. On the one hand, most RECs appear to have a stronger 
and more dominant scientific membership compared to non-scientific 
membership. However, the actual scientific expertise may be incomplete in 
terms of meeting all the requirements of scientific review in the 21st century. 
This refers specifically to the paucity of pharmacological and statistical 
representatives on RECs. While institutional RECs are stronger in terms of 
scientific review and have the potential to expand their expertise, private 
RECs and smaller RECs may be particularly vulnerable to deficiencies in the 
scientific review process. On the other hand, the conspicuous lack of 
community representation reflects the insignificance accorded to community 
and patient advocacy in the review process. These findings have important 
implications in terms of reconsidering the review system with a possible view 
to restructuring. This will be explored further in chapter eight.  
 
While the quantitative survey has provided an indication of the status of the 
major RECs in South Africa in terms of structure and function, the qualitative 
component will delve into the substantive research ethics issues that South 
African REC chairpersons are deliberating currently. The results of the semi-
structured interviews will be presented and discussed in chapter seven.              
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Chapter 7 
 
Substantive Ethical Review Issues in 
South Africa 
 
 
7.1 Introduction 
 
Qualitative research methods involve the “systematic collection, organisation 
and interpretation of textual material derived from talk or observation” 
(Malterud, 2001: 483).  The goal of qualitative research is the development of 
concepts that help to understand the social phenomena in natural rather than 
experimental settings, with an emphasis on meanings, experiences and views 
of all participants (Pope, 1995: 42-45). 
 
Much of qualitative research is interview based.  These interviews may be 
structured, semi-structured or in-depth. In structured interviews, a structured 
questionnaire containing fixed choice questions is administered by an 
interviewer who is trained to ask questions in a standardised manner.  In 
depth interviews, on the other hand, are far less structured and may cover 
only one or two issues.  Semi-structured interviews are conducted on the 
basis of “a loose structure with open-ended questions that define the area to 
be explored, at least initially, and from which the interviewer or interviewee 
may diverge in order to pursue an idea in more detail” (Britten, 1995: 251-52). 
 
The semi-structured interview was chosen for this study because I anticipated 
interviewing the chairpersons of all major RECs in South Africa.  These 
individuals are located throughout the country and have very busy schedules 
hence I was aware that I would have only one opportunity to conduct the 
interview.  The chairpersons are also experienced clinicians or scientists in 
senior faculty positions who are accustomed to efficient use of their time.  
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Most indicated that they would have only one hour available for the interview.  
According to Bernard, a semi-structured interview should be employed when 
one is aware that one may have only one opportunity to conduct the interview 
(Bernard, 2002: 205). 
 
Hence, the qualitative component of the empirical research took the format of 
semi-structured interviews.  This part of the research sought to answer the 
following question:  What is the nature and extent of substantive ethical 
problems being faced by RECS in South Africa? 
 
The interviews were conducted by the author during 2003 and 2004.  All major 
institutions, both private and public, with RECs were contacted.  Appointments 
were secured with the chairperson of each REC.  Where the chairperson was 
unavailable, the interview was conducted with the vice-chair. 
 
In qualitative research, sampling strategies are determined by the purpose of 
the research project (Britten, 1995: 253).  Similarly, sample sizes are 
determined by factors such as depth and duration of interview and what is 
feasible for a single interviewer.  The method of sampling used was 
purposive, that is, respondents were chosen deliberately.  A total of nine 
interviews were conducted covering ten RECs.  This was because one person 
interviewed was responsible for chairing both a university REC and a private 
REC.  Two RECs from the quantitative research components were excluded: 
UNITRA and University of Western Cape due to the emphasis on academic 
research and not clinical trials at these institutions.  The focus of this 
dissertation is largely directed towards the ethical issues currently being faced 
in the review of clinical trials in South Africa.  Hence all RECs reviewing 
clinical trials located in faculties of Health Sciences were included. 
Committees reviewing academic research only were excluded.  Where RECs 
were reviewing clinical trials and academic research, the interview focussed 
on clinical trial issues only.  Within the ten RECs, the Chairperson was chosen 
for the semi-structured interview as he or she represented the longest serving 
member on the REC with the most intimate involvement with and exposure to 
the range of substantive ethical review challenges being faced at the moment.  
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This also represents the person who takes final responsibility for the 
functioning of the REC. 
 
An interview guide was used to prompt discussion on a wide range of ethical 
challenges being faced by RECs in South Africa.  The interview guide was 
prepared in advance based on the doctoral candidate’s own experience as a 
member of an REC, as a clinical investigator and as a Trainer in Good Clinical 
Practice (GCP).  It was also based on an extensive literature review of current 
controversial ethical review issues. 
 
All interviews were conducted by the doctoral candidate to ensure uniformity 
in the conduct of the research. Interviews were conducted in accordance with 
the guide but flexibility was allowed to encourage rapport and spontaneity.  
The researcher remained open to the possibility that the concepts and 
variables that emerged might be very different from those that might have 
been predicted at the outset.  In a qualitative research interview, the aim is to 
discover the interviewee’s own framework of meanings and the research task 
is to avoid imposing the researcher’s structures and assumptions as far as 
possible (Britten, 1995: 252). 
 
It was very important that the interviewer appeared to be non-threatening and 
non-judgemental.  Most RECs are sensitive about the nature of the work that 
they are doing as a result of frequent clashes with investigators and sponsors.  
The RECs that are less resourced than others also felt they were being 
compared or policed and this had to be avoided.  One REC had to be assured 
of anonymity in the event of publication of results of this survey. 
 
A unique challenge posed by a qualitative interview (as opposed to 
quantitative research) is the effect of an investigator on a study. A 
researcher’s background and position will affect what is chosen as a subject 
for investigation, the angle of the investigation and the method deemed most 
adequate for this purpose.  This is referred to as reflexivity.  Reflexivity starts 
by identifying preconceptions brought into the project by the researcher.  As 
an REC member, a clinical investigator and a GCP Trainer it was impossible 
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to enter into the study without preconceptions.  Reflexivity was introduced into 
the analysis by an awareness of the preconceptions that I brought into the 
project by identifying and recording my frame of reference and theoretical 
framework before initiating analyses to look for data for competing 
conclusions (Malterud, 2001: 484). 
 
The way in which the interviewer is perceived by interviewees is also 
important in terms of race, gender, class and social distance (Britten, 1995: 
253).  During the course of these interviews the effect of both race and gender 
of the interviewer were significant.  This was obvious in the discussions 
around REC composition in terms of race and gender.  Given the historical 
background of South Africa and the emphasis on transformation, including 
where composition of RECs is concerned, some chairpersons of REC that are 
predominantly white male dominated were uncomfortable in admitting this to 
an Indian female interviewer and in responding to questions regarding a plan 
to change this. 
 
Each interview took approximately 40 to 60 minutes.  Interviews were audio-
taped and transcribed verbatim.  Analysis of the texts was based in a 
grounded theory approach.  This approach refers to a set of techniques for: 
 
1. identifying categories and concepts that emerge from text, and 
2. linking the concepts into substantive and formal theories. 
 
This technique is widely used to analyse ethnographic interview data 
(Bernard, 2002: 462-76). 
 
The procedure for analysis involves: 
 
1. reading and re-reading the text to become familiar with the content 
2. identification of the main issues emerging from the text 
3. formulating themes on the basis of the emerging issues 
4. reformulating themes to do justice to the text, while excluding prejudice 
and bias 
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5. developing a conceptual or theoretical framework to provide new 
meaning to and understanding of the theme 
 
6. continuing with the process until the text is exhausted 
                   (Meulenberg-Buskens, 1996) 
 
Themes were identified, some of which were predetermined, and manually 
colour coded.  These themes were then “decontextualised” – where part of the 
data was “lifted out and investigated more closely, together with other 
elements across the material” that deals with similar issues (Malterud, 2001: 
486).  Data was collated by the doctoral candidate.  The collated data for each 
theme was organised into sub-themes where applicable.  Where responses to 
a particular question or approaches to a specific problem varied widely, the 
range of responses is presented reflecting extreme positions at either end of 
the spectrum.  The average position is also reflected.  Innovative suggestions 
and new themes are indicated.  For each theme, commentary is provided after 
the interview data is presented.  The commentary reflects a critical appraisal 
of the data and contextualisation of the theme in terms of international 
debates.  This represents recontextualisation where the data that was 
temporarily removed from its context for the purposes of analysis is returned 
to its place in terms of the bigger research question.  
 
Emergent Themes and Ideas  
 
Based on interview data a number of themes were extracted from the 
transcriptions.  These pertained to both initial review and continuing review of 
research – two functions that must be fulfilled by a REC.  Initial review refers 
to the review process that occurs from submission of a protocol to the 
committee until approval is granted.  Continuing review occurs once the 
protocol has been implemented and spans the period from study initiation till 
study closure.  Issues that arose in the initial review that were common to all 
the interviews were as follows: 
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1. Informed Consent 
2. Placebo Use/Standard of Care 
3. Declaration of Helsinki 
4. Post Trial Treatment Provision 
5. Participant Remuneration 
6. Review of HIV Vaccine Trials 
 
Issues relating to continuing review while the trial is in progress included  
  
1. Adverse-event reporting 
2. Monitoring  
 
In addition to the predicted themes that arose, some new ideas were raised 
sporadically by some REC chairpersons and not others.  These will be 
referred to as emergent ideas and included the following: 
 
1. Ethics Review System Structure 
 
The interviews exposed the candidate to different structures of the ethics 
review system compared to the structure existing at the candidates institution.  
These structures will be discussed later. 
 
2. Private Sector Research 
 
Most questions in the interview guide were framed in the context of 
institutional RECs.  Interesting and unanticipated data emerged from some of 
the private RECS that were interviewed. 
 
3. Audit of RECs 
 
The concept of audit of RECs was raised by one of the interviewees as a 
result of his committee having underwent an audit process.  This was specific 
to one REC and did not emerge in other interviews. 
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These emergent ideas will be discussed at the end of this chapter after the 
initial and continuing review themes have been discussed. 
 
7.2 Themes related to Initial Review 
 
7.2 .1 Informed Consent 
 
Interview Data 
 
1. Concern was expressed regarding the length and complexity of patient 
information leaflets (PILs) by most REC Chairpersons.  However a 
complete and thorough PIL is preferred by half RECs surveyed.  Half of 
these RECs request a lay summary for the patient.  There are 
requirements in terms of the information that must be contained in 
PILs.  Most RECs have templates for PIL documents.  Checklists are 
provided to investigators to ensure that all essential elements of 
informed consent are provided to participants.  Assistance is available 
from REC members with drafting of the form if required. 
 
We prefer a complete document. Much information is lost if 
documents are abbreviated. We do not request a summary of 
the document. 
 
We would like to see the full ethical consent form 7 to 14 pages. 
I think that is important both in terms of the learning process of 
the committee members, and in terms of what is done 
internationally.  But, secondly, because of the very nature of our 
society, we’d like to see a much more simplified form 
encompassing the important aspects. So we always in fact ask 
for a simplified form in lay language. 
 
I think that especially for trials it is very important that the details 
must spell out everything you want to do. 
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  We request a lay summary. 
 
The one thing that we’re trying to do with the informed consent 
document is to keep it short, but it must have all the relevant 
information. 
 
2. Translation requirements for PILs and informed consent forms differ on 
the various RECs.  Of the ten ethics committees surveyed, four (40%) 
only review the English version of the PIL.  They do not request 
translations, back translations or certified translations.  These RECs 
maintain that translation is the sole responsibility of the investigator. 
 
A further four RECs (40%) request translations and check the 
translations.  This responsibility falls on the lay members who are able 
to read and correct the ethnic translations. 
 
Two RECs (20%) request translations but do not check them. 
Translations must be done by a certified translator and a back 
translation must be submitted but these are not checked.  These 
committees do not have members from ethnic groups and translations 
are, on the whole, the responsibility of the investigator.  Hence 60% of 
RECs surveyed do not check translated versions of PILs at all. 
 
Translations are problematic – Often the written language and 
verbal language differ. Rather give your research assistant 
training when they administer the document as to the essence of 
the document. English documents are verbally translated. 
 
We have projects which were translated by people from 
language departments at universities and they [community 
representatives] just said to us: ’But our people will not 
understand this, this is not the language that’s being spoken in 
this specific community’. 
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3. Apart form the content of PIL, the language used often results in PILs 
that are not user-friendly especially for educationally disadvantaged 
participants.  There are frequent spelling and grammatical errors on the 
forms and the use of academic and technical language.  Having a lay 
community member to assess PILs is regarded as being important. 
However, this REC does not have lay representation. 
 
Except for one REC, no use is made of objective measures like the 
Flesch and Fry readability scores to assess readability of PILs.  This 
REC uses these scores erratically. 
 
Most RECs depend on reviewers to assess readability and had 
comments similar to the following: 
 
As far as readability is concerned the members decide on that 
or, you know members will comment on whether they think this 
was too long or too difficult. 
 
  We rely on reading it. 
 
  I don’t think there’s an objective way that we use as such…the 
  various members of the committee review the informed  
  consent. 
 
  The lay member reads I and we make sure it is user friendly. 
 
  …it seems that it is difficult to get the forms to be user- 
  friendly…sponsors are unhappy to change the forms. 
 
4. Interesting comments: 
 
 Emphasis on the process rather than the forms: 
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We certainly can improve our informed consent process but it is 
not going to come form improving our consent forms. 
 
 Linguistic expert as committee member 
 
We have requested the board to appoint a linguistic specialist 
which  they haven’t done as yet so...people in the committee just 
check the translations. 
 
 Tests of comprehension as part of informed consent process: 
   
A little test needs to be done and of they can answer ten 
questions they can sign informed consent. 
 
 Empirical research into the informed consent process by RECs: 
 
I think there should be more studies on informed consent like 
they did in Natal. To see what patients actually understood. 
 
I think the committee should conduct some research themselves 
on what happens in the informed consent process. 
 
 Independent Witness to the informed consent process 
 
 [A witness] must be present for each patient… irrespective of whether 
 the patient can read or write and the witness must sign. 
 
Commentary on these findings: 
 
The most widely accepted source of evidence for the safety, tolerability and 
effectiveness of treatments is the randomised controlled trial (RCT).  The main 
reason for this is a scientific one: properly conducted RCTs produce valid data 
that contributes to generalisable scientific knowledge.  However, in the 
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process, the interests of participants may unavoidably be subjugated for the 
common good (Edwards, 1998: 1209). 
 
Informed consent is fundamental to the ethics of randomized controlled trials 
and is a critical component of the research process. Defined as “an 
autonomous authorization by individuals of a medical intervention or of 
involvement in research” (Beauchamp, 2001: 78), the concept of informed 
consent is based on the principle of respect for autonomy. In general 
autonomy is defined as self-regulation or the capacity for self-determination. 
 
We might ask why such respect is owed to persons?  Kant argued that such 
respect acknowledges the unconditional worth of all persons, where each 
person possesses the capacity to determine his or her own moral destiny.  Mill 
was more concerned with the “individuality” of autonomous agents.  He 
argued that individuals should be allowed to develop according to their own 
convictions as long as the freedom of others was not impinged upon.  He also 
believed that we are sometimes obligated to persuade others when they have 
false or ill-considered views (Beauchamp, 2001: 63-64).  This may be viewed 
as a form of justified paternalism, especially in the medical setting when the 
“best interests” principle is invoked. In the research setting, this could be 
rather controversial, where persuasion of patients to participate in research 
must be strongly guarded against. 
 
In the early history of research ethics informed consent was viewed primarily 
as a way to minimize the potential for harm.  However, in the mid-1970s, the 
primary justification for informed consent was to promote autonomous choice 
(Beauchamp, 2001: 77).  Hence, informed consent is enshrined in all major 
guidelines for the ethical conduct of biomedical research (International 
Conference on Harmonisation, 1997) and (WMA, 1996). 
 
The main concern about consent is the way the process can fail, either 
because consent is not sought, or because participants may not adequately 
understand the issues involved.  Given the central role of informed consent in 
the ethical conduct of clinical and epidemiological research, it is important to 
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understand the factors that may be associated with problems in the consent 
process.  
 
The amount of information contained in informed consent documents and 
PILs is the subject of considerable debate on RECs throughout South Africa. 
International regulations specify the various elements that should be included 
in a PIL. CIOMS outlines 26 elements, ICH-GCP lists 20 and SAGCP lists 16. 
Given the litigious climate that most health care professionals currently work 
in and in view of the fact that this is extending to the research environment, 
current opinion is that these forms are intended to protect the researcher 
rather than the participant.  Informed consent, however, is as much a legal 
requirement as a moral requirement.  
 
The Code of Federal Regulations has summarized the essential elements of 
informed consent in what they refer to as the “Common Rule”.  It is essential 
that a study participant clearly understands that he/she is participating in a 
research study and that this is distinct from treatment.  This is very important 
to establish at the outset to avoid therapeutic misconception (Lidz, 2002: 55-
57).  It is also important that all the risks and benefits of participating in the 
study are clear to the patient.  Consensus has not been reached in South 
Africa regarding the extent to which risks should be specified – all possible 
risks or only material risks. CIOMS 2002 comments on information regarding 
risks as follows under guideline six: 
 
 In complex research projects it may be neither feasible nor desirable 
 to inform prospective participants fully about every possible risk. They 
 must however, be informed of all risks that a ‘reasonable person’ would 
 consider material to making a decision about whether to participate…. 
 
The Association of the British Pharmaceutical Industry (ABPI) favours the 
provision of all “pertinent” information.  The participant should be aware of 
alternative treatments and how these may be accessed in the event of non-
participation.  It is essential that the participant is aware of the voluntary 
nature of the participation and the freedom to withdraw at any time without 
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usual treatment being compromised.  In the event of research related injury, 
compensation should be clarified.  Confidentiality must be ensured and 
waivers of confidentiality indicated in terms of sponsors, monitors and auditors 
who may need access to medical records in the course of the study.  Finally 
adequate contact details of the investigator must be available to the 
participant should the need arise for questions, queries or other issues that 
may arise.  The Department of Health and Human Services in the United 
States hence regards these elements as crucial to the informed consent 
process.  Any further information is necessary when appropriate (Department 
of Health and Human Services, 2001). 
 
The South African Department of Health, in their SAGCP guideline, adds a 
further eight elements.  They would like the purpose of the study explained as 
well as the concept of random assignment.  All trial procedures including 
invasive procedures must be outlined.  The experimental nature of drugs and 
the study must be clarified. 
 
Participant responsibilities must be mentioned including any expenses that will 
be incurred by participants in the course of the study.  Remuneration for 
participation in the study must be stated.  The sponsor’s identity as well as 
any conflicts of interest the investigator may have will need to be disclosed. 
 
The ICH-GCP guideline includes all of the above elements and adds on the 
following four elements: duration of participation must be conveyed to 
participants, the number of subjects enrolled in the study must be indicated, 
termination of participation must be outlined and the fact that participants will 
be supplied with new information that surfaces during the conduct of the trials 
(International Conference on Harmonisation, 1997). 
 
The CIOMS 2002 guideline discusses a total of 26 elements, ten of which do 
not appear in any of the aforementioned guidelines.  Four of these elements 
refer to post-trial issues.  Participants need to be informed that information 
relating to the results of the trial will be made available to them when the study 
is over. It should also be specified when and what treatment will be available 
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when the study is over.  This reinforces article 30 of the Declaration of 
Helsinki 2000 that is currently the subject of intense debate internationally and 
nationally. This will be discussed later in the chapter. 
 
The fate of biological specimens taken during the course of the study must be 
delineated and additional consent sought for further use.  Finally, the 
monetary gains that might accrue if a commercial product is developed as a 
result of the study should be discussed. 
  
Other issues pertain to clarifying the dual role played by the investigator and 
the extent to which the investigator will provide medical treatment in the 
course of the study.  The next two issues relate to participant rights - the right 
of access to medical records should be declared and the issue of whether the 
right to compensation will be legally guaranteed in the host country. 
 
This is the only guideline that requires participants to be informed that a REC 
has approved the study.  The final comment related to genetic testing and is 
usually contained in a separate consent form if genetic testing is to be done, 
so it will not be considered further in the context of a general consent form 
(CIOMS(Council for International Organisations of Medical Science), 2002). 
 
What is very clear about the description of the elements contained in all the 
different guidelines is the manner in which the information provided to 
participants becomes progressively more comprehensive. 
 
If one were to take the 20 elements in the ICH-GCP guideline and add the 
nine relevant elements from CIOMS (excluding the genetic testing element), 
one would have an exhaustive list of 29 elements!  This could easily fill ten - 
twelve pages of a patient information leaflet.  It would indemnify the 
investigator completely in terms of his/her responsibility to provide information 
relating to the trial. It is interesting that a number of RECs preferred such a 
comprehensive document. 
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In the current climate of research litigation such a position is tenable (Mello, 
2003: 40-45).  If we consider the three major cases where participants have 
died in the context of research form 1996 to 2001, all three cases had 
inadequate informed consent forms and in all three cases the deficiencies 
were related to information about risks.  In the case of Nicole Wan, the 
consent form did not mention the “possibility of death” (Day, 1998: 450).  After 
Jesse Gelsinger died, it emerged that adverse events detected in other 
human trials and in prior animal studies were not shared with him (Sibbald, 
2001: 1612-14).  In the Ellen Roche study the investigation revealed that the 
informed consent form was deficient in many respects.  Hexamethonium was 
described as “a medication that has been used during surgery as a part of 
anaesthesia; this is capable of stopping some nerves in your airways from 
functioning for a short period” (Steinbrook, 2002: 1000).  All the side-effects of 
hexamethonium were not listed.  The section on risks stated that 
hexamethonium “may reduce your blood pressure and may make you feel 
dizzy especially when you stand up”.  Pulmonary toxicity was not mentioned.  
The experimental nature of the drug was not clarified, instead it was referred 
to as “medication” (Steinbrook, 2002: 717).  The OHRP (the organisation that 
regulates institutions and other entities that conduct or oversee studies 
involving human subjects in the United States) criticized. 
 
 IRBs for approving informed consent documents that inadequately 
 described the purpose of the research, the nature of the experimental 
 design, and the risks- most notably death. 
        (Steinbrook, 2003: 629) 
 
It is evident that RECs in South Africa, like RECs elsewhere are overly 
concerned with the documents involved and the indemnity it provides to both 
researchers and RECs alike rather than the process of obtaining informed 
consent.  In fact only one interviewee discussed informed consent beyond the 
forms.  Informed consent has evolved from being viewed as an “event” to 
being viewed as a “process”.  Even though the focus has shifted from the 
researcher’s obligation to disclose information to the quality of the participant’s 
understanding and consent, many RECs still focus on disclosure 
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(Beauchamp, 2001: 77).  While this is a considerable improvement over 
previous informal procedures of obtaining consent, many critical issues 
relating to the process remain unresolved.  For example, it is uncertain how 
much of the information provided is actually understood and used by 
participants in the decision-making process (Taub, 1986: 7).  When one is 
dealing with educationally disadvantaged research communities, enhancing 
comprehension of trial related information becomes an ethical imperative. 
 
Therefore, while some RECs prefer a comprehensive document they also 
attempt to accommodate the patient by insisting on a summary in lay terms for 
the patient.  This is essential as, from the participant’s perspective, a 
comprehensive form could be daunting and incomprehensible if one is dealing 
with an educationally disadvantaged participant.  However, a summary in itself 
is insufficient. 
 
In South Africa, translation of informed consent documents is extremely 
important as the majority of study participants have an indigenous language 
as their first language.  Two factors impact negatively on the ability of a REC 
to process translated documents – lack of representation of ethnic groups and 
lack of lay, community membership. 
 
Most of these documents are written in academic language by sponsors or 
Contract Research Organisations (CROs).  Sometimes language departments 
of universities are used and the translated version is very academic.  Hence 
the comments of one of the lay members on an ethics committee in South 
Africa:  
  
 Our people will not understand this.  This is not the language that is 
 being spoken in this specific community. 
 
Depending on certified translations is grossly inadequate.  In SA, it is the duty 
of every REC to ensure that the English version is user friendly and that the 
translated version has been checked by a committee member.  The 
suggestion of having a linguistic expert on the REC is hence a good one. 
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Shifting the responsibility for the translation to the investigator is an abrogation 
of the committee’s duty to protect vulnerable study participants who eventually 
take home the written consent form to discuss with their families. 
 
Most RECs review the English version of the patient information leaflet at a 
minimum.  It is important that this version is reviewed thoroughly so that 
translated versions are user-friendly.  Readability of patient information 
leaflets is a very important but very neglected concept.  In order to enhance 
understanding of informed consent forms and patient information leaflets, it is 
essential that these documents are highly readable.  Research in South Africa 
often uses very complex and detailed patient information leaflets written in 
academic language, sometimes imported from developed countries.  This 
occurs in spite of the fact that a major concern with readability of informed 
consent forms exists in developed countries like the United States, where 
almost half of American adults read at or below the 8th grade level (Paashe-
Orlow, 2003: 725).  In South Africa we have the additional challenge of 
enrolling patients who are both educationally disadvantaged and unfamiliar 
with many complex research concepts.  Hence, significantly more attention 
should be paid to patient information leaflets and the informed consent 
process in South Africa. 
 
Most RECs depend on reviewers to assess the documents raising issues of 
subjectivity.  This is a concern where RECs have mainly scientific members 
accustomed to reading academic journals and who fail to read the document 
from the patient’s perspective.  This highlights the need for an objective 
measure of readability.  All except one REC was aware of and was using an 
objective method intermittently to assess readability of PILs. 
 
Flesch and Fry readability scores to assess readability are well documented in 
the literature (Paashe-Orlow, 2003: 721-26) and (Grundner, 1978: 773-75). 
 
The Flesch readability formula calculates the syllable count and the word 
count of the average sentence length in three one hundred word paragraphs 
in a PIL.  These counts are then fed into a formula that produces a score.  The 
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lower the score, the more difficult it is to read and understand the material. 
The Flesch-Kincaid system is widely available for computerised use as it is 
embedded in Microsoft Word (Paashe-Orlow, 2003: 725).  The Fry scale 
provides a measure of the grade level reading ability required for 
understanding of the written material (Morrow, 1980: 56-58). 
 
Given the tendency of RECs to prefer comprehensive consent forms and 
patient information leaflets, it is sometimes charged that RECs may 
inadvertently contribute to the complexity of the documents.  A study to 
assess the readability of informed consent templates provided by RECs to 
investigators found that readability of the templates ranged from a 5th grade 
reading level to a 10th grade level (mode, 8th grade).  The reading level 
generally aimed for is a 6th grade reading level though the authors of the study 
advise a reading level aimed at grade four to ensure promotion of the 
autonomy of most potential participants to engage in the research (Paashe-
Orlow, 2003: 725).  It is important for readability to be assessed and ensured 
in South Africa for comprehension to improve.  
 
Apart from making informed consent documents more readable, tests of 
comprehension are an important component of the informed consent process. 
While this was suggested by one of the REC chairs interviewed, there is a 
growing body of literature exploring this topic (Taub, 1984: 17-21) and (Silva, 
1988: 1-5). An empirical study conducted in Haiti found that only 20% of study 
participants receiving information as a single event from the physician-
investigator passed an oral multiple choice test of comprehension while 80% 
of participants receiving the trial information over a seven - ten day period 
from a counsellor were able to pass the test.  The second group received the 
information in small doses, verbally with the use of pictures and anatomical 
models (Fitzgerald, 2002: 1301-02). 
A systematic review of all empirical studies conducted from 1966 to 2004 has 
been conducted by Flory and Emmanuel. Interventions used to convey trial 
related information in 42 trials were reviewed. Twelve studies used various 
forms of multimedia in place of or in addition to standard IC forms, 15 trials 
used enhanced IC forms, 5 studies evaluated the use of extended discussions 
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with participants, 5 trials used tests of understanding and feedback and 5 
trials used miscellaneous methods in various combinations. Criteria used to 
judge these studies included whether they were randomized or not, whether 
they were simulated or conducted as part of a real trial, sample size and 
whether the study had been published. Overall, the use of multimedia did not 
improve understanding in 13 of the 15 trials. Where enhanced IC forms were 
used, in 9 out of 15 studies understanding had decreased while in 6 of the 15 
studies understanding improved. Reducing the length of the form was found to 
be most beneficial. Extended discussion improved understanding in 3 out of 5 
trials. The test/feedback method made a significant impact but was flawed 
methodologically. In the miscellaneous category, there were new methods 
such as a dry run of trial related procedures or a combination of methods but 
this did not impact significantly on results. Overall, it was advised that 
multimedia were best used to standardize information across trial arms. It was 
also felt that there might be benefit in illiterate populations but due to the 
expense of such methods they should be used if proven to be of benefit. The 
best method identified was the use of person-to-person contact in the context 
of extended discussions. On the whole, IC sub-studies did not negatively 
impact on enrollment in parent studies (Flory,2004). None of the studies 
included in the systematic review were conducted in South Africa or in other 
African countries. Hence it is imperative that such empirical research is 
conducted in Africa. 
 
While comprehension of informed consent is critical the need for a culturally 
sensitive consent process cannot be sufficiently stressed in South Africa. 
In South Africa, as in most parts of Africa, there are, a number of issues to 
consider: family or spousal consent is often required by participants in addition 
to their own consent, written consent may be problematic, explanation of 
scientific concepts may be difficult. 
 
The Nuremberg Code, since 1947, has advised that consent be “voluntary”, 
“legally competent”, “informed” and “comprehending” (The Nuremberg Code, 
1996).  Since the late 1950s, however, the term “informed consent” has been 
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used (Levine, 1991: 207) – Law Med & Health Care.  The Declaration of 
Helsinki makes reference to first person informed consent. 
 
It has been charged that individual informed consent is a western construct 
based on the Western notion of personhood. In particular, the American 
notion of personhood is “markedly rational, and also legalistic – prototypically 
expressed in the language of rights” (De Craemer, 1983: 19-34).  This view is 
supported by Nhlanhla Mkize, a South African clinical psychologist based at 
the University of Kwa-Zulu Natal and contributing author of the book “Critical 
Psychology”.  According to him, unlike the Western concept of personhood 
that defines a person as rational, autonomous, individual, separate from 
others, the traditional African notion of personhood is relational, 
communitarian and extended.  Reciprocity and interdependence are reflected 
in the Nguni notion of ubuntu.  The family or community are regarded as the 
moral agent as a result of the family being the most important aspect of 
identity.  A horizontal and vertical dimension of being is described where a 
person is connected to the living, the ancestors and those yet to be born.  A 
deep respect for elders is cultivated and the authority of these elders is vested 
in a socio-moral responsibility to promote community and familial interests 
(Mkhize, 2004: 46). Christakis comments that an African might find it “difficult 
to see how the interests of the subject conflict with the interests of the society 
except, of course, if the society is not his own” (Christakis, 1988: 31-37).  
Shutte, a South African philosopher, echoes these sentiments in his work on 
Ubuntu. He concurs with both Christakis and Mkhize. In traditional Africa, the 
interest of the subject and of society are necessarily congruent.  This is in 
keeping with the Nguni belief that “umuntu ngumuntu ngabantu” – a person is 
a person through persons.  Each individual member of the community sees 
the community as themselves, as one with them in character and identity.  
There is no room for a separation between the individual and the community.   
People see themselves as “potential persons” who become fully human to the 
extent that they are included in relationships with others (Shutte, 1999). 
 
Michele Barry, in 1988, in anticipation of the cultural issues that would 
influence HIV/AIDS research in Africa argued that the concept of personhood, 
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in some central African cultures, is defined by one’s tribe village or social 
group. 
 
 Whereas in Western terms selfhood emphasizes the individual, in 
 certain African societies it cannot be extricated from a dynamic system 
 of social relationships, both of kinship and of community as defined by 
 the village. 
                        ( Barry, 1988: 1083)  
 
In such a setting, an investigator may need to approach community elders for 
their consent before attempting to obtain informed consent from individual 
persons.  While her comments refer to central Africa, similar views are 
expressed in South Africa and elsewhere in Africa. 
 
These alleged differences in conceptions of personhood have impacted on 
perceptions of how informed consent should be sought in Africa.  This has 
ranged from perceptions that consent should be sought from family elders and 
community leaders instead of individuals, to obtaining individual consent in 
addition to family or community consent. Empirical work from Senegal 
illustrates the use of community consent instead of individual consent followed 
by the employment of individual consent two years later. In 1990, a study 
using a safer, acellular Pertussis (whooping cough) vaccine was initiated in a 
rural community in Senegal. Village chiefs were informed of the study and the 
project proceeded. In 1992, as a result of debate on issues of consent in the 
medical literature and on recommendation from the institutional review board, 
an information campaign was launched and verbal individual informed 
consent was sought. The introduction of an individual consenting procedure 
was evaluated later in the study to assess the feasibility and validity of 
seeking individual informed consent. In the pilot study 4 of the 55 mothers 
interviewed refused to participate in the study on the new vaccine, as they had 
opted to use the well known pertussis vaccine. These informed refusals were 
considered to be a sign of full understanding that the mothers had a choice in 
study participation (Preziosi 1997:370-373). 
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In 1999, a study conducted in the Gambia on a Haemophilus Influenzae type 
B vaccine also looked at differences in informed consent in urban as opposed 
to rural communities. Amongst the urban participants, 2% of the sample 
indicated that the village chief should be involved in informed consent 
decision-making and a further 2% indicated that a religious leader or imam 
should involved. In the rural community, 23% of the participants indicated that 
the village chief should be involved in the decision-making process while 15% 
indicated that the imam should be involved. None of the participants in either 
setting was prepared to accept that a community leader could make a 
decision on their behalf ( Leach 1999: 139-148). 
 
Ijsselmuiden argues that “there is no single African culture”.  Furthermore, 
extensive changes have occurred in traditional lifestyles as a result of 
urbanization, education and industrialization (Ijsselmuiden, 1988:831). As a 
result, communities that have undergone urbanisation would be in a position 
to provide individual informed consent. This is illustrated in the study by Leach 
et al. 
 
In South Africa, the requirement for spousal and family consent differs as one 
moves from urban to rural communities.  In many urban communities the 
human rights culture has become firmly entrenched and some individuals 
would be prepared to consent without consulting family members or 
community leaders.  In rural communities, however, tribal leaders, family 
elders and spouses may need to be consulted as well. 
 
It is hence important that investigators in South Africa are familiar with the 
preferences of the communities they research.  Provision must be made for 
spousal and/or family consent in the informed consent process when 
requested.  This would require adequate time being devoted to the process 
and adequate time being allowed for participants to consult with family 
members prior to participation.  This may require a “mandatory waiting period” 
before consent forms can be signed.  In Uganda, a 48 hour waiting period is 
granted for participants to discuss their participation in trials with family 
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members and return to the research site to authorize their participation (Loue, 
1996: 49-50). 
 
Culturally specific linguistic issues relating to informed consent have been 
discussed in Chapter Four in the context of vertical transmission trials and the 
terminology used to describe placebos both in South Africa and Thailand.  
This problem was also encountered in Uganda when participants were being 
prepared for HIV vaccine trials.  Culturally and socially familiar analogies were 
employed to describe trial related concepts - “air supply” was used to describe 
placebo, “wrapping” was used to explain blinding and “lottery” was used to 
describe randomization (Mugerwa, 1999: 227).  In a rural community in 
Senegal, investigators conducting a trial on a new pertussis (whooping cough) 
vaccine for children used an agricultural example to explain randomisation.  
Farmers in the area were familiar with the evaluation of fertilizers or seed 
varieties on randomized plots and this was used as an analogy (Preziosi, 
1997: 370-71). 
 
Requirement for written informed consent can be impractical in some 
developing communities where cultural issues relating to affixing a signature 
to a form result in verbal consent being preferred for research.  In the 
Ugandan context, study participants might be afraid of the “potential 
consequences” of signing a document that “confirms their connection to 
foreigners” (Loue, 1996: 50).  One would sign for a house, for example, but 
not for research.   This has implications for what medical journals would 
regard as ethical.  There are also implications for what ethic committees 
would regard as waivers of informed consent and how a witness can be used 
instead of a signed consent form. 
 
The suggestion by one of the REC chairpersons to encourage empirical 
research into informed consent is a valid one.  There is a paucity of empirical 
research into informed consent in developing countries and in South Africa in 
particular. In South Africa, only two studies have been published to date.  The 
first study assessed informed consent in a population of women attending an 
antenatal clinic in Durban, Kwa-Zulu Natal.  These women had been invited to 
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participate in a perinatal HIV transmission study. 88% of the women felt 
compelled to participate in the study. 28% of women perceived the research 
to be integral with service at the hospital.  This study concluded that the 
consent was informed but not voluntary (Abdool Karim 1998: 637-40). 
 
The second study was conducted in Bloemfontein.  Here the objective was to 
assess whether informed consent for participation in a trial investigating the 
effect of vitamin A on vertical transmission of HIV was informed and voluntary. 
Despite the participants having eight years of schooling or more, they had 
“poor knowledge about the most basic details of the trial”.  However, the 
informed consent study was conducted more than a year since the study 
commenced and recall bias could have been a contributory factor.  The 
authors concluded that subjects’ participation could not be seen as informed.  
Regarding the voluntary nature of the consent, the same study found that 
although the respondents believed that their participation was voluntary they 
were clearly aware of the lack of alternative sources of care (Joubert, 2003: 
582-84). 
 
The third empirical study conducted in South Africa, currently unpublished but 
being peer-reviewed, examined the knowledge and perceptions of the 
informed consent process among individuals who had participated in influenza 
vaccine trials in two Cape Flats communities.  
 
Four to 12 months after completion of the trials, participants were contacted to 
return to participate in the informed consent study that assessed 
understanding of trial procedures and the informed consent process.  The 
questionnaires covered key issues including: the purpose of the study, 
awareness that the study was not part of routine treatment, the voluntary 
nature of participation and freedom to withdraw, randomization, placebos, as 
well as participant remuneration. 
 
334 Participants, representing 93% of original clinical trial sample, completed 
the informed consent questionnaire.  The mean age of respondents was 68 
years, the median level of education was grade eight.  Only 21% of the 
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sample understood that they were allocated randomly to the different 
treatment arms. Only 19% of the sample involved in the placebo-controlled 
study understood the concept of placebo as inactive medication.  The study 
concluded that while a good general understanding of trial concepts was 
demonstrated, the concepts of randomization and placebos were poorly 
understood.  This study also has the disadvantage of having been conducted 
long after the actual informed consent process was conducted. Informed 
consent in a developing community in South Africa may often be “less than 
informed” and innovative ways to improve understanding of the research 
process must be instituted (Moodley, 2004). 
 
What all three studies have in common is evidence that the informed consent 
process in South Africa is far from satisfactory.  Data such as this provides 
useful information to investigators and REC members alike to devote 
increased attention to the question of informed consent in South Africa.  What 
is also evident is that the timing of such projects is important.  While concerns 
exist regarding the timing of two of the three studies described some 
consolation can be derived from the study conducted on elderly patients in 
Sweden where it was found that 26% of study participants understood the 
randomisation process (Bjorn, 1999: 263-67).  However, a test of 
comprehension should be instituted after the informed consent process but 
prior to enrolment. 
 
It is clear that RECs will need to assess IC documents more carefully. It has 
even been charged that IC documents that are complex when submitted to 
the REC become even “longer and less readable” after REC review.  In a 
study to assess the effects of the local review process on consent forms from 
two major clinical trials, the changes made to the forms by the local REC were 
analysed.  Findings included a mean increase in reading level of 0.9 (p< 
0.001).  A mean of 46,5 changes were made by the REC, most ( 85,2%) of 
which involved alterations to wording without affecting meaning.  Errors were 
commonly introduced relating to protocol presentation or an informed consent 
element (Burman, 2003: 245). 
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Litigation in the context of research is increasing internationally.  Recent 
deaths and lawsuits have attracted increased attention to this phenomenon.  
Large groups of patients enrolled could mean class actions against 
investigators, sponsors, institutions, REC members (Mello, 2003: 40-45).  It is 
hence not surprising that RECs focus excessively on the comprehensive 
content of forms rather than how understandable they will be to participants. 
However, a recent complaint lodged against a research investigator in South 
Africa, coupled with a threat of litigation, indicates the need for RECs to pay 
more attention to comprehension of the informed consent process.  A 66 year 
old gentleman, one of 12 participants in a trial of the drug “Caduet”, a drug 
used to treat both hypertension and hyperlipidaemia, experienced worsening 
in his renal function a week after the drug was administered.  He claimed that 
he “could not understand the contents of the form” and that he was not 
advised or educated about the drug. His 26 year old daughter, had the 
following to say about the consent process: My father had no schooling history  
and not even I, a university graduate, could understand the jargon in that 
consent form. The case is being investigated by the REC that approved the 
study (Sewchurran 2004). 
 
It is clear that both the documents and the process related to informed 
consent can be considerably improved in South Africa.  This will be discussed 
in further detail in Chapter Eight. 
 
7.2.2 Placebos and Standard of Care 
 
Interview data 
 
The range of responses to placebo-controlled studies varied from extreme 
laxity to extreme caution with the majority of RECs exercising moderate 
caution within reason.  These middle-of-the-road RECs appear to be handling 
the issue of placebo controlled trials on a case-by-case basis. 
 
Except for the one committee that demonstrated a lack of awareness of the 
ethical and scientific issues related to the use of placebos in research, there is 
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an acute awareness of the risks to participants involved in placebo controlled 
trials.  Most committees are extremely alert when a submission is received 
involving a placebo and will approve such a study only if no standard of care 
exists and if the study will not place participants at greater than minimal risk.  
However, one committee raised the concern that equivalence studies (as 
opposed to placebo controlled studies) requiring an extremely large sample 
size would expose more people to an experimental drug with its inherent and 
undetermined risks. 
 
Most committees appear to employ very strict criteria when reviewing 
placebo-controlled studies.  One committee is particularly diligent in assessing 
the risk benefit ratio, sample size and follow-up and requesting a motivation 
from investigators for the use of placebo.  Another committee uses the 
placebo waivers provided by the Declaration of Helsinki as guidance. 
 
If there is a placebo, that trial is scrutinised. The committee is very, 
very strict. 
 
 We shudder…if it’s a placebo control we shudder. 
 
For trials with active controls you need more patients. Theoretically, 
this increases the risk of exposure of patients. 
 
[for HIV studies] we’ll never use a placebo, I mean if we receive a study 
with a placebo, I think there will be a lot of questions about that. 
 
In the context of controlled trials, establishing a standard of care is critical.  
While some committees have not reached consensus on this issue as yet, 
most Committees refer to the best available standard of care in the public 
health sector in South Africa as the benchmark.  The standard is determined 
by expert reviewers in the various medical disciplines as well as by 
pharmacists in their capacity as committee members. 
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The control group must receive the best available standard in South 
Africa. Declaration of Helsinki asks for best proven. 
 
[Standard of care] depends on the expert reviewer and it stretches 
across from the treatment of Asthma to the treatment of Leukaemia. 
 
…in South Africa it is best available and affordable standard of care. 
This is clearly illustrated in HIV research. 
 
…if you have an HIV trial, the patient must get the standard treatment, 
in other words if it’s not available in the state sector, I mean you must 
make it available for your study. 
 
Well, the best available treatment in South Africa, at least. I mean, if 
you’re working in a private hospital – its run on first world sort of 
medicine, not exactly America or Europe- but the standard of care is  
really high, so it must be the best available treatment that’s acceptable 
in the country. 
 
Personally I’m just scared that the research in this country is going to 
be killed if you require too much from sponsors, and I think it is already 
happening. 
 
 
Commentary 
 
Doctors Lurie, Wolfe and Angell opened a Pandora’s box of ethical dilemmas 
in 1997 when they critically appraised the placebo controlled HIV vertical 
transmission trials in developing countries around the world (Angell, 1997: 
847-49). Since then the debate has been fuelled by researchers and ethicists 
from the developed and developing world.  This has been described in detail 
in Chapter Four. 
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Enormous controversy was raised by the attempt to amend the guidance 
regarding treatment for control groups in the Declaration of Helsinki (DOH) in 
2000.  The attempt to change the standard of care from “best proven” to “best 
available” was thwarted by activists from developed and developing world 
countries alike.  It is hence extremely interesting that even though the 
standard of care outlined in the DOH 2000 now refers to the “best current” 
treatment being provided to members of a control group, most ethics 
committees in South Africa subscribe to the “best available in South Africa” 
standard.  
 
This is consistent with the findings of Kent et al in their systematic review of 
clinical trials conducted in Sub-Saharan Africa and published from January 
1998 to November 2003.  They wanted to establish whether these trials had 
employed the “best current” standard of care in their control groups.  Trials 
included were in the fields of HIV, Tuberculosis and Malaria – as these 
illnesses represent a high burden of disease in Sub-Saharan Africa. Overall, 
only 16% of trials employed the “best current” standard of care.  Their 
explanation of their findings was as follows: 
 
 investigators who design and conduct these studies, and ethics 
 committees who review and approve them, consider trial design in the 
 context of the local level of care rather than the international standard 
 of care. 
                  (Kent, 2004: 240) 
 
It is evident that most RECs are hesitant to obstruct research in South Africa – 
there is an unspoken fear that pharmaceutical companies will take their 
research to other less stringent developing countries if South Africa insists on 
a standard of care that will render the conduct of research in the country very 
expensive.  A similar argument is invoked by Wendler when he refers to the 
effect of a ban on research that is not conducted using the worldwide best 
treatment in the control group.  He believes that insistence on use of the 
worldwide best standard would 
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 block important research designed to improve health care for the 
 world’s poor. 
            (Wendler, 2004: 923) 
 
The Declaration of Helsinki is prided as being a document that sets an 
international standard of care for participants all over the world.  However, this 
declaration sets a standard of care that is extremely narrow. 
 
Article 29 states that: 
 
The benefits, risks, burdens and effectiveness of a new method should 
be tested   against those of the best current prophylactic diagnostic and 
therapeutic methods.  This does not exclude the use of placebo or no 
treatment, in studies where no proven prophylactic, diagnostic or 
therapeutic method exists. 
                  (Declaration of Helsinki 2000) 
 
Controversy abounds about whether “best current” refers to best current 
global standard or best current local standard?  This is not clarified in the 
Declaration of Helsinki.  The fulcrum of this conflict revolves around the 
“relevant reference point” – a global reference point versus a local reference 
point (London, 2000: 379-97). 
 
More important however than the dispute over the relevant reference point is 
whether we consider the standard to be de facto or de jure, where de facto 
refers to a standard of care set by the actual medical practices of a community 
and the de jure standard refers to a standard set by the judgement of experts 
in the medical community according to the diagnostic and therapeutic 
practices that have proven to be most effective in a particular disease.  This 
concept is supported by the current trend in medical practice referred to as 
evidence based medicine.  This is important where the term “best proven” is 
used - as is the case in the Declaration of Helsinki 1996 and in the 2000 
version where placebo may be permitted when no “proven” standard exists. 
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Here too a local de jure standard would involve expert opinion from the local 
community while a global de jure standard would refer to international expert 
opinion.  
 
London’s article is based on the Declaration of Helsinki 1996 that refers to the 
“best proven” standard of care.  The attempt to change the 1996 version to 
“best available’ did not materialise and so the 2000 version reads “best 
current”. 
 
Similarly, the Declaration does not specify whether it is best current locally or 
best current globally.  Can there be a best current locally? – I think not.  It 
seems most likely that best current would refer to the best international 
standard, especially since the Declaration of Helsinki is an international 
document.  In fact, criticism that could be leveled against London’s arguments 
includes a query of the existence of a local de jure standard.  He himself 
maintains that even local experts in a local community would be aware of the 
best proven or best current standard of care even if it were unaffordable in the 
region.  To me it is the toss up between adopting a local de facto standard of 
care – practiced due to financial constraints, not for lack of knowledge of the 
best standard - and a global de jure standard – established as the best proven 
treatment globally based on the principles of evidence based medicine.  As 
such research must be conducted and designed based on the research 
question that exists in a particular country or region. If for financial reasons, a 
particular treatment is unaffordable, new cheaper treatment could justifiably 
be tested against placebo. 
 
The placebo debate can only use this international guideline as a point of 
departure. In addition, further considerations need to be made.  Hence, the 
WMA subsequently issued a clarification on this article that reads as follows: 
 
A placebo controlled trial may be ethically acceptable, even if proven 
therapy is available for compelling and scientifically sound 
methodological reasons or where the method is being investigated for a 
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minor condition and patients who receive placebo will not be subject to 
any additional risk of serious or irreversible harm. 
        (Declaration of Helsinki 2000) 
 
Guideline 11 of CIOMS 2002 specifies choice of controls in clinical trials: 
 
• Placebo may be used: 
 
• When there is no established effective intervention; 
 
• When withholding an established effective intervention would expose 
subjects to, at most, temporary discomfort or delay in relief of 
symptoms; 
 
• When use of an established effective intervention as comparator would 
not yield scientifically reliable results and use of placebo would not add 
any risk of serious or irreversible harm to the subjects. 
 
The commentary on this guideline refers to temporary discomfort as a 
headache and to minor risk where the group that would receive placebo has 
only a slightly raised blood pressure or a modest increase in cholesterol. 
 
The explanation provided for use of placebo when scientifically reliable results 
would not be achieved refers to the instance when an established effective 
intervention is not sufficient to provide a scientifically reliable comparison with 
the intervention being tested. 
 
The various footnotes that have been added to these international guidelines 
imply that placebo controlled trials need to be considered on a case-by-case 
basis taking context into consideration.  This is an example of the transition 
from a rule-based approach to ethical decision-making to a situational 
approach sensitive to cases based in reality rather than abstraction, to the 
consideration of context rather than the blind application of rules. 
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It is also evident that these guidelines are focusing their definition of a 
standard of care only on the drug that will be used.  Benatar and Singer 
however allude to an expanded concept for standard of care.  This includes 
equitable access to research, expenditure on total care and therapeutic drugs 
shown to be most effective in other locations.  It extends to similar facilities, 
access to technology, general medical care, follow-up and on-going care. 
Finally, care includes research personnel of the same culture and language 
group as participants, who are equivalently qualified and trained as developed 
country sites to conduct research (Benatar, 2000: 824). This too reflects a 
postmodern influence on ethical deliberation, using a holistic approach to the 
conduct of research rather than a focused scientific, technical approach 
divorced from the bigger picture. 
 
Excessive reliance has been placed on international declarations to 
define what is ethical, but declarations, like constitutions, need to be 
interpreted. 
        (Benatar, 2000: 824) 
 
The standard of care debate remains incomplete because the standard of 
care has not been adequately defined.  Furthermore the assumption has been 
made that the standard set by developed countries can be considered to be 
the norm (Benatar, 2000: 824).  The debate over the vertical transmission 
trials in developing countries bears testimony to this.  
 
This in turn draws attention to the enormous problems of global inequity 
where health care is concerned.  There is a palpable gap in standards of 
health care between the developed north and the resource-depleted south 
(Benatar, 1998b: 295-300).  At a local level, the discrepancy in the standard of 
care between private health care and state health in South Africa sets 
different standards for research conducted in the different health sectors. 
 
The question is: should research participants in different parts of the world or 
even in different parts of the same country be subjected to different standards 
of care? 
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In South Africa, the best available and sustainable standard in the public 
health sector is used as the benchmark where research is conducted in public 
health care settings. The best available standard in the private sector would 
constitute an unfair inducement to participants who would normally have 
access to public sector health care. If however, research is being conducted in 
the private sector, the standard of care used in the control group would of 
necessity be the private health care standard of care as no patient with 
access to private health care would settle for treatment that is less than he or 
she would otherwise have access to. 
 
Given the inequities in health care, innovative proposals have been compiled 
since the debate. 
 
Dan Wikler of Harvard University, proposes the following: (Wikler, 2004). 
 
 All [control participants] should be offered care that is no worse than 
 what they should have received had the study not been done. 
 
The rationale for his proposal is as follows: accepting placebo use in a trial 
because basic treatment is not affordable represents “taking advantage of 
another’s misfortune” and that is “exploitative” as would be the case if using 
the non-availability of treatment for HIV/AIDS in a developing country were the 
reason to justify a placebo arm in a trial. 
 
In setting a standard of care for the control group he suggests using the World 
Health Report 2000 which provides a performance assessment of 191 Health 
systems.  This would entail a comparison of the research site with all other 
countries with similar resources.  The treatments provided by those countries 
could be ascertained and subjects could be assured of treatment provided by 
most of the highest ranking countries.  This approach permits research on 
affordable therapies and does not deny people in developing countries care 
that they should receive.  Wikler also highlights the disadvantages of such a 
proposal. It does not address the problem of international misdistribution of 
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wealth or high international drug prices.  My concern would be related to the 
following factors: 
 
1. Who calculates the drug regimen for this “developing country standard 
 of care”?  
2. Some developing countries are manufacturing their own generics – 
 Brazil, Thailand and India are such examples. Would a pharmaceutical 
 company testing a new drug be comfortable to pay for a generic 
 manufactured in another country for use in the control group?  
3. What happens to study participants after the trial – do they return to a 
 state of “no treatment” if that is the local standard of care? 
4. Placebo use in a clinical trial must be justified by a good scientific basis – 
 as the HIV vertical transmission trials in developing countries including 
 South Africa were.  
 
Wendler et al argue that a standard of care that is “less than the worldwide 
best” should be acceptable provided the following conditions are met: 
 
1. scientific necessity 
2. relevance for the host community 
3. sufficient host community benefit 
4. subject and host community non-maleficence 
        (Wendler, 2004: 923) 
 
Benatar suggest similar justification when he advocates using “the highest 
achievable standard of care” (Benatar, 2000: 825). 
 
Use of the best current international standard of care would require a 
separation of considerations of treatment and research into two separate and 
distinct entities.  By implication, research would have no relationship 
whatsoever to the local de facto standard of care.  In that case the same 
standard of care would apply to research irrespective of where in the world the 
research is conducted.  If the research question requires a placebo controlled 
study design, that study should be conducted anywhere in the world with 
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placebo. If a study required comparison to the “gold standard” in treatment for 
a particular disease, this would be provided by the sponsor to the control 
group at any site in the world.  This would require the adoption of what Alex 
London describes as the global de jure standard of care.  All research, even 
that conducted in developing countries, would then be generalisable to 
developed countries where the best standards of care are available. It is an 
idealistic model but one that is wide open to exploitation. 
 
This will be discussed further in Chapter Eight.  
 
7.2.3 Adherence to the Declaration of Helsinki (DOH) 
 
Interview Data 
 
There was a wide range of variability in the response of REC Chairpersons to 
this document.  
 
At one extreme, it was evident that the Chairperson had not heard of the 
document and was completely unfamiliar with its contents. 
 
 I would like to have some information on it because I can remember it 
 vaguely, but it hasn’t been an issue that I have had to go over recently. 
 
On the other hand, a Chairperson was familiar with more than just the 
standard of care issue in article 29.  He was aware of the waivers for placebo-
controlled trials and he commented on post-trial treatment (article 30) as well. 
 
Most RECs believed that the DOH might be too idealistic for SA as many 
REC’s are struggling to actually implement the standard of care part of the 
guideline.  On the other hand while the DOH was regarded as an idealistic 
document it was regarded as a good document in view of the waiver for 
placebo trials depending on risk.  The standard of care is “best current” but in 
SA it is best available and affordable standard of care. Post-trial treatment 
must be contracted in depending on type of patient, disease, exposure.  This 
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REC required researchers to sign a separate form regarding the DOH and 
insisted on adherence to the declaration.  Conversely an REC stated that 
sponsors do not take it seriously because most of them do not accept the 
2000 version.  Investigators don’t know the declaration. He viewed this as a 
failing on the part of the REC for not insisting on investigator training.  The 
REC had made GCP training for all investigators compulsory.  Another REC 
had the following requirement regarding the DOH:  In the informed consent 
form the investigator has to specify that she/he is following the 1996 version 
and not the 2000 version if a placebo-controlled trial is being conducted.  
Other RECs accepted the 2000 version only and not the 1996 version.  The 
Medical Research Council (MRC) has adapted the DOH to South African 
conditions in the MRC booklet on research ethics.  They do not insist that 
investigators abide by the DOH 2000 version.  Instead they prefer 
investigators to indicate in their submissions to the MRC that they have read 
the MRC guidelines. 
 
Most RECs list a host of guidelines that they refer to from time to time. 
However, in-depth knowledge of these guidelines is lacking.  Where 
inconsistencies exist in the different guidelines, much confusion results. 
 
It was interesting to note that a significant number of RECs were not aware of 
the contents of the local SAGCP guideline 
 
Commentary 
 
On the whole, most interviewees were not able to engage in an in-depth 
debate on the DOH.  In spite of being aware of the standard of care debate 
and the reference in article 29 to the “best current” care for the control group, 
most RECs had decided on “best available” care rather than “best current”. 
This supports the view of Lie et al in their claim that “the Declaration of 
Helsinki has lost its moral authority” with regard to the standard of care 
controversy (Lie et al, 2004: 190-93). 
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The comment from one REC that sponsors and investigators do not take the 
DOH seriously is echoed in Levine’s claim that “many researchers routinely 
violate the requirements of the declaration”.  He goes on to add that “such 
routine violations and the attitudes associated with them tend to undermine 
the authority of the entire document” (Levine, 1999: 531). 
 
Most RECs in South Africa have adopted a local standard of care for control 
groups in defiance of Helsinki 2000.  Is this proof of ethical imperialism that 
has failed? Most Western documents are based on universal principles and 
concepts and do not take cultural and country specific issues into 
consideration. 
 
Some RECs insist on the 2000 version of the declaration being quoted in the 
protocol and the patient information leaflet.  The distinction drawn between the 
1996 and 2000 versions of the declaration are only valid if all the differences 
between the two documents are acknowledged.  While most RECs in South 
Africa insist on the 2000 version, they are not acutely aware of the full extent 
of the differences between the versions.  The difference in article 29 relating 
to the standard of care relates only to a change from “best proven” to “best 
current” method for the control group.  The full extent of the changes from 
1996 to 2000 include the following: 
 
Article One Medical research involving human subjects includes research on 
identifiable human material or identifiable data. 
 
Article Eight Some research populations are vulnerable and need special 
protection.  The particular needs of the economically and medically 
disadvantaged must be recognized.  Special attention is also required for 
those who cannot give or refuse consent for themselves for those who may be 
subject to giving consent under duress, for those who will not benefit 
personally from the research and for those for whom the research is combined 
with care. 
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Article Nine Research Investigators should be aware of the ethical, legal and 
regulatory requirements for research on human subjects in their own countries 
as well as applicable international requirements.  No national, ethical, legal or 
regulatory requirement should be allowed to reduce or eliminate any of the 
protections for human subjects set forth in this Declaration. 
 
Article 13 This independent committee should be in conformity with the laws 
and regulations of the country in which the research experiment is performed.  
The committee has the right to monitor ongoing trials. 
 
Article 19 Medical researchers is only justified if these is a reasonable 
likelihood the populations in which the research is carried out stand to benefit 
from the results of the research. 
 
Article 27 Negative as well as positive results should be published or 
otherwise (made) publicly available. 
 
Article 29 The benefits, risks, burdens and effectiveness of a new method 
should be tested against those of the best current prophylactic diagnostic & 
therapeutic methods.  This does not exclude the use of placebo or no 
treatment, in studies where no proven prophylactic, diagnostic or therapeutic 
method exists. 
 
Article 30  At the conclusion of the study, every patient entered into the study 
should be assured of access to the best proven prophylactic, diagnostic and 
therapeutic methods identified by the study. 
 
Hence the REC that insists that adherence to the 1996 version is quoted only 
for placebo-controlled studies is incorrect in their interpretation of the new 
version and the change in version is irrelevant for placebo-controlled studies. 
If anything, the 2000 version with the waivers for placebo-controlled trial would 
be more relevant. 
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On the whole most RECs are adhering to a range of different local and 
international guidelines and most would prefer a single guideline.  Of all the 
international guidelines, the CIOMS document is the most comprehensive and 
relevant.  Regarding the range of local guidelines, rationalisation of guideline 
use in South Africa is a priority. 
 
7.2.4 Participant Remuneration 
 
Interview Data 
 
All ethics committees are unanimous on the issue of avoidance of inducement 
to participate by paying research participants large sums of money.  There is 
consensus on providing remuneration for travel and food for the day only 
based on the historical adoption of the reimbursement model in South Africa. 
This will be detailed below in the commentary. 
 
There is however, lack of clarity on what the actual amount should be per visit.  
Traditionally, ethics committees in South Africa have allowed an amount of 
R50 ($8) per study visit.  Some committees prefer that this amount not be 
reflected in the patient information leaflet as it will influence the decision to 
participate, especially where very poor vulnerable populations are being 
researched.  One committee stipulates that the amount should be disclosed in 
the PIL.  A recent recommendation by the Medicines Control Council (MCC) 
to investigators in South Africa requires that participants should receive R150 
($24) a visit for expenses incurred in participation in research and that this 
should be documented in the patient information leaflet read by the participant 
before deciding whether to participate in the research study.  This has caused 
considerable uncertainty amongst researchers and ethics committees alike. 
 
One committee maintains that an allowance for travel will differ depending on 
the distance being traveled and that the reimbursement for travel should be 
calculated on a case-by-case basis. 
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Commentary 
 
There is controversy regarding the appropriate remuneration for research 
participants in South Africa.  Most international and national guidelines on 
health research ethics vaguely warn against unfair inducement of individuals 
to participate in research but are otherwise silent on this issue.  The most 
comprehensive guideline referring to participant remuneration is that of the 
Council for International Organisations of Medical Sciences (CIOMS).  
Guidelines Four (1993 version) and 11 (2002 revised draft) refer to 
‘inducement to participate’. 
 
Guideline Four states, inter alia, that 
 
 subjects may be paid for inconvenience and time spent, and should be 
 reimbursed for expenses incurred, in connection with their participation 
 in research. 
 
Guideline 11 states, inter alia, that  
 
 subjects may be paid or otherwise rewarded for inconvenience and 
 time spent.  
 
The guideline also details acceptable and unacceptable recompense, 
remuneration of guardians of incompetent participants and remuneration in 
the event of withdrawal from a study. 
 
The notion of participant remuneration ranges from the promotion of research 
as a socially responsible activity, with no payment at all but rather recognition 
for the time and effort of participants (Russell, 2000: 126-30), to the view that 
a wage payment model should be used in which research subjects are paid 
an hourly wage based on that of unskilled workers (Andersen, 2002: 359-76).  
A number of different payment models are possible.  Dickert describes three 
models: a market model, a wage-payment model and a reimbursement model. 
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The market model is grounded in traditional libertarian theory based on the 
principle of supply and demand.  As such payment may be high for research 
that offers little benefit to participants yet involves risky or uncomfortable 
procedures.  Payment may also be high when subjects need to be recruited 
very quickly or when few people are eligible for a particular study. 
 
The wage-payment model is based on the notion that research participation is 
similar to other forms of unskilled labour.  As such a fairly low, standardized 
hourly wage can be paid.  This may be increased depending on risk or 
burdensome procedures.  A completion bonus is permissible using this model. 
 
According to the reimbursement model, payment is provided simply to cover 
the subject’s expenses.  This is based on the view that research participation 
should not require financial sacrifice on the part of participants.  Usually this 
includes reimbursement for travel, meals and parking (Dickert, 1999: 198-
203). 
 
In South Africa the reimbursement model has been applied and consensus 
has been reached on this amongst all RECs as is reflected in the interview 
data.  Our choice of this model can be justified as follows: South African 
research participants are often poor and can barely afford travel costs to a 
hospital or clinic for non-research purposes.  Participation in research requires 
more frequent visits than routine treatment requires and participants will not 
be able to travel to the research site if they are not reimbursed for their travel 
expenses.  Obviously these expenses vary depending on where the 
participant lives.  Research visits also require that participants leave home 
very early and spend the day at the research site – hence they must be 
reimbursed for their meals for the day.  In settings where the therapeutic 
misconception is a common phenomenon, the reimbursement also serves to 
distinguish research from treatment where no payment occurs. 
The market model and the wage payment model would not work in South 
Africa.  The market model would unfairly induce participation in research and 
the wage model, given our very high rates of unemployment, would also serve 
to lure desperate patients to the research site with negative sequelae.  
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Participants would underestimate the degree of risk involved in a study based 
on their need to earn a wage for the day.  Logistic problems would be created 
at research sites with patients queuing and demanding an opportunity to be 
“hired” for research purposes. 
 
The reimbursement model, on the whole, works well in South Africa.  
However, the amount of money that participants should receive for their 
participation is highly contentious.  A balance has to be achieved between a 
rate of payment that is high enough not to exploit subjects and low enough 
that it does not create an irresistible inducement (Beauchamp, 2002: 547-64).  
The ethical concerns involved in participant remuneration have received 
attention in the international literature, yet surprisingly little research attention 
has been paid to this question in the South African context where research is 
frequently and unavoidably conducted on vulnerable populations. While many 
researchers have a strong opinion on the remuneration of study participants, 
there is little understanding of how participants themselves perceive 
remuneration for research. 
 
A semi-structured cross-sectional study was conducted by the doctoral 
candidate and a colleague on 334 individuals from the Bishop Lavis and 
Elsies River communities in the Western Cape who had participated in two 
pharmaceutical industry-sponsored trials of an intranasal flu vaccine during 
2001 and 2002 was conducted in 2003.  For their participation in these trials, 
participants received R50 ($8) at each of three scheduled study visits and an 
additional R20 ($3) for unscheduled ‘illness’ visits over a 12-month follow-up 
period.  For this study, individuals were interviewed in their home language 
(English or Afrikaans) by an independent researcher four - 12 months after 
completing the vaccine trial.  All participants gave informed consent before 
being interviewed.  The mean age of the 334 participants was 68 years (range 
60 - 80 years) and the majority were female, with a mean educational level of 
Grade Eight.  All the participants received R50 ($8) per study visit (R150 or 
$24 altogether), although several received up to R200 ($32) for additional 
interim visits.  The majority of those interviewed (N = 281, 84%) felt that the 
compensation they received for participation in the trial was adequate, 
  170 
although a minority (N = 36, 11%) recommended that the compensation per 
visit be increased to a median of R100 ($16) per visit (range R70 - R200 or 
$10 - $32 per visit).  In open-ended questions regarding compensation, 
participants stated that they used the money received in a range of ways, 
primarily to purchase food for their families, to transport themselves or a 
family member to a clinic or hospital, or to meet cost-of-living expenses 
generally. 
 
While drawn from a small sample within a particular community, these results 
indicate the complexity of a blanket compensation policy — as is being 
requested by the MCC —for participants in biomedical and epidemiological 
studies. In this setting, the standard of R50 ($8) per visit for three study visits 
spread over 12 months was deemed acceptable, yet it is likely that other 
communities may have substantially different standards — some greater, 
some lesser.  And while there are sometimes concerns regarding the use of 
cash as compensation, these participants used their compensation to meet 
basic needs (Moodley, 2003: 677-78). 
 
Generally, identifying the most appropriate level of compensation for 
participation in a particular study, as well as what form it should take, is an 
important and sometimes daunting task for researchers.  The establishment of 
a single national guideline to be applied across all types of research 
throughout the country may be difficult.  However, current literature suggests 
that research ethics committees should have written policies on participant 
remuneration and that these should be prorated and contextualised to the 
research population in question (Dickert, 2002: 368-73). 
 
In general, health research ethics guidelines regard the issues of participant 
remuneration as residing fairly in the domain of the research ethics committee 
involved. In South Africa, however, the regulatory agency, namely the MCC, 
has decided to take this matter into its domain.  Is it the mandate of the MCC 
to review the patient information leaflet and informed consent documents, 
especially where participant remuneration is concerned, or is this a role of the 
local ethics committee? Perhaps this is a matter that will be resolved by the 
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annual meeting of chairpersons of RECs or by the National Health Research 
Ethics Council.  
 
While the importance of payment has been described as a potential way of 
unfairly inducing a patient to participate, less attention is paid to other aspects 
of trial participation that may influence both the recruitment and retention of 
study participants.  Many of these other factors may have more import in 
developing countries than in developed world settings. 
 
In South Africa, research in the public sector is often conducted at sites such 
as clinics and hospitals that conventionally offer treatment. It is therefore not 
unusual for research participants to be drawn from these centres where they 
regularly present for chronic care.  To facilitate the research process, 
participants are given a card to allow them privileged access to the research 
clinic thereby avoiding the usual delays involved at a state health facility.  This 
translates into a saving of many hours of waiting in queues to be admitted to 
the hospital and to gain access to hospital folders.  This reduction in waiting 
time is seen as compensation for the inconvenience incurred in the clinical 
trial and is necessary to ensure that trial conduct is efficient.  The availability 
of dedicated staff at the research clinic results in participants receiving 
personalised attention that they would otherwise not receive in a busy 
outpatient setting.  Research often requires more intensive and more frequent 
medical examinations and hospital visits.  In addition the need for telephonic 
contact in a research study may increase the perception on the part of the 
participant of personalised attention.  During study visits sites may provide tea 
and refreshments to participants during their long wait for research related 
investigations and procedures.  In some instances, the medication being 
provided as part of the trial may not be otherwise available at the state health 
facility and is perceived as an enormous benefit.  Consider the HIV related 
trials held in South Africa prior to anti-retroviral provision by the government. 
Any medication that is received in the course of the trial also bypasses 
traditional waiting time at the dispensary that can usually be anything from 
one to two hours depending on the clinic or hospital.  Sponsors sometimes 
provide small token gifts – sanctioned by the REC - during the course of the 
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trial.  On the whole, there are many ways in which study participants in 
developed countries may perceive their involvement in research to be 
beneficial even though the trial itself is not designed for individual benefit. 
 
Having mentioned all the above factors, I have not even started with the issue 
of therapeutic misconception that is a dominant feature amongst trial 
participants who do not fully comprehend the research process. 
 
Hence, it important that participant remuneration is seen in context of other 
trial related benefits and that the payment in itself is kept within reasonable 
limits. 
 
At present some RECs have adopted the MCC specified amount, other RECs 
remain uncertain.  This is matter that must be resolved in South Africa and 
options for resolution will be discussed in chapter eight. 
 
7.2.5 Post-Trial Treatment 
 
Interview Data 
 
Policy regarding the provision of treatment to participants after the trial is 
largely undeveloped in South Africa. 
 
While it is regarded as an important consideration in the research process by 
all ethics committees, the responses ranged from strict insistence that it is 
incorporated in the protocol to extreme uncertainty and discomfort with 
implementation. 
 
Most committees require that provision is made for post-trial treatment 
provision, especially so if the treatment is unavailable in South Africa or if it is 
a new or novel treatment that has proven to be effective.  Under these 
circumstances, if alternate treatment is available, one REC was comfortable 
that the investigator ensure that the patient knew how to access alternate 
treatment. 
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HIV research and Oncology trials have set a precedent regarding post-trial 
treatment. This has not extended to other types of research as yet.  The 
duration of treatment after the trial has not been established.  For HIV 
research it appears to be till treatment failure or death. 
 
However, the fear exists that if insistence is placed on post trial treatment 
provision, South Africa will lose research projects to countries where this is 
not strictly enforced. 
 
While ethics committee shopping occurs within South Africa, research site 
shopping occurs in the developing world as a whole especially when a specific 
country implements stringent rules. 
 
Commentary 
 
At the time of conducting the qualitative research interviews, post trial 
treatment had not been seriously deliberated on RECs in South Africa.  It has, 
however, posed a significant problem with the emergence of HIV/AIDS.  Prior 
to government antiretroviral rollout programs – that is- prior to 2003, clinical 
trials on anti retroviral treatment represented the only hope for many patients 
in terms of accessing care.  RECs have been faced with the dilemma of 
approving trials where at the end of the study participants would receive no 
treatment or they would have to revert to less effective treatment.  Some 
RECs have adopted policies such as “trial subjects must continue to receive 
the antiretroviral treatment after the trial ends until they cease to benefit or are 
enrolled into another trial” (Cleaton-Jones 1992: 887).  Drug companies were 
not impressed with this decision.  Their argument was that informed consent 
is provided by participants who then have no claim to treatment beyond the 
trial.  Cleaton- Jones, however, contested this based on his view that South 
Africa has “large numbers of people insufficiently educated to understand the 
implications of what they are consenting to” (Cleaton-Jones 1992: 887). 
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In the last few months, post-trial treatment has become a global issue under 
considerable debate at the World Medical Association (WMA). 
 
 At the conclusion of the study, every patient entered into the study 
 should be assured of access to the best proven prophylactic, diagnostic 
 and therapeutic methods identified by the study. 
            (Declaration of Helsinki 2000) 
 
The focus on post-trial issues was stimulated by “parachute” or “safari” 
research that had been occurring in Africa without consideration for capacity 
development or sustainability of treatment tested during a clinical trial.  The 
intention was to ensure that study participants’ treatment and care would not 
be abruptly halted at the close of a study.  It was also envisaged that 
participants who had borne the burdens of research would benefit from the 
research in some way. 
 
The current controversy regarding article 30 of the Declaration of Helsinki 
2000 revolves around the concept of the “best proven” method and whether a 
single study could provide conclusive proof of the best agent.  There is also 
concern that pharmaceutical companies will not conduct research in 
developing countries if provision of treatment after the trial is a requirement.  
The World Medical Association (WMA) set up a working group to consider the 
controversy surrounding article 30 and developed the following proposal: 
 
Proposed Changes to article 30– WMA meeting Sept 2003: 
 
Before undertaking a study, the physician should make every effort to 
ensure that all patients entered into the study will have access to any 
available prophylactic, diagnostic or therapeutic method that the study 
proves to be the most effective and appropriate for such patients, once 
it has been approved by the appropriate authorities.  When informing 
the patient about the study the physician will explain the treatment 
options after the study and how they relate to the patient’s condition 
and will state explicitly if it is foreseeable or likely that the sponsors will 
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not be able to provide effective and appropriate treatment to the patient 
after he or she leaves the study.  Any arrangements for the 
continuation of treatment beyond the study, or the reasons for their 
absence, should be described in the study protocol that is submitted to 
the ethical review committee. 
 
This amendment was not accepted at that meeting.  The Argentinean Medical 
Association objected to the amendment on the basis that it “strongly weakens 
the spirit of the declaration” (Sibbald 2003: 169).  The Brazilian Medical 
Association was concerned that the change “might weaken the intent and 
provisions of paragraph 19 that states that: 
 
 Medical research is only justified if there is a reasonable likelihood that 
 the populations in which the research is carried out stand to benefit 
 from the results. 
                    (Declaration of Helsinki 2000) 
 
On the other hand, the amendment was accepted by the United States 
Department of Health and Human Services and multinational pharmaceutical 
companies (Canadian Medical Association Journal – Editorial 2003).  The 
British, Croatian and Mexican medical associations also supported the 
change.  
 
While opinion is divided on article 30, the WMA rules require at least 75% 
approval for documents dealing with ethics.  As a result a WMA work group 
was constituted to explore this issue further.  Their suggestions included the 
following: 
 
1. to add a preamble explaining that the Declaration of Helsinki is a set of 
ethical guidelines, not laws or regulations;  
2. to add a note of clarification that reaffirms the intention of paragraph 30 
but avoids the possibility of misinterpretation; 
 
3. to make no changes or additions to the Declaration.  
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The WMA work group, in their draft report, argue that article 30 should remain 
unchanged.  Their official report back is expected in May 2004 (Frankish, 
2003: 963).  According to Dr Delon Human, secretary general of the WMA, 
 
 The aim of this paragraph is to guarantee that research participants are 
 not worse off after a study than they are during the study.  The WMA’s 
 primary consideration has always been that the best interests of 
 patients be served, but also that no good ethical research should be 
 restricted.  At the same time, the WMA is adamant not to compromise 
 the ethical principles that the medical profession stands for. 
   (www.wma.net/e/ethicsunit/pdf/wg-doh-jan2004.pdf) 
 
Unlike the Declaration of Helsinki 2000, the CIOMS 2002 guideline, on the 
other hand, specifies benefit to the community.  Guideline 10 deals with 
research in populations and communities with limited resources: 
 
 Before undertaking research in a population or community with limited 
 resources, the sponsor and the investigator must make every effort to 
 ensure that: 
 
 any intervention or product developed, or knowledge generated, will 
 be made reasonably available for the benefit of that population or 
 community. 
 
While Helsinki refers only to study participants as recipients of benefits 
CIOMS refers to the population or community.  
 
The discrepancy inherent in these two documents creates confusion and 
makes it difficult for RECs to implement them.  On the other hand, a synthesis 
of the two guidelines could assist in considering the concept of post-trial 
benefit in broader terms. 
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The concept of post-trial treatment is better operationalised if the concept of 
post-trial benefit is explored.  What provisions can be made after a study is 
over? 
 
1. Knowledge gained can be disseminated. 
2. The study drug or intervention can be made available to participants. 
3. The research clinic can be converted into a primary health care clinic 
for the community in the area. 
4. Research staff may be employed for a period after the trial to provide 
primary health care services to the community. 
5. Capacity development of research staff and community advisory board 
members can be instituted. 
6. Equipment from the trial site may be donated to the institution or health 
care service. 
 
It has been argued that investigators and sponsors have no responsibility to 
provide non-research related treatment to study participants or communities 
(Richardson 2004: 25-33).  I would like to argue that investigators and 
sponsors have a moral obligation to provide treatment to study participants 
who develop co-morbidity during the course of the study if a country lacks 
infrastructure or medical supplies to treat such co-morbid illness.  Participants 
also deserve to be treated for chronic illness that predated their enrollment in 
a trial. In practice it is extremely difficult to ignore co-existing disease even in 
the context of a clinical trial.  If, however, one can rely on a robust referral 
system to provide such care to a study participant, that represents an ideal 
situation, often non-existent in developing countries.  In essence I am 
advocating the use of research to address inequities in health care systems in 
multinational research where there is a wide gap between health care 
services between sponsor and host countries.  Justification for such an 
approach could be invoked from a Rawlsian theory of justice where persons 
should receive an equal distribution of certain goods like health care services.  
Norman Daniels refers to “a positive societal obligation to eliminate or reduce 
barriers that prevent fair equality of opportunity, an obligation that extends to 
programs to correct or compensate for various disadvantages.  It views 
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disease and disability as undeserved restrictions on persons’ opportunities to 
realize basic goals” (Beauchamp 2001: 233-234).  Hence article 30 of the 
Declaration of Helsinki, referring to post-trial treatment, can be expanded to 
include post-trial benefits to developing country health care infrastructure. 
Coupled to this, however, is engagement of governments to commit 
proportionally to health care infrastructure. 
 
These issues must be discussed at the start of a study and negotiated 
between investigator, sponsor and ministries of health.  Once agreement has 
been reached, post-trial benefit should be specified in the protocol or 
application form to the ethics committee. However, in calculating the risk-
benefit ratio of a study, risks to participants must be balanced against benefits 
to participants during the trial. At no stage should risks to participants during 
the trial be balanced against benefits to participants or communities after the 
trial. Post-trial benefits will be discussed further in Chapter Eight where 
resolution is sought. 
 
7.2.6 Review of HIV Vaccine Trials 
 
Interview data 
 
RECs varied in their response to how the review of HIV vaccine trials would 
be managed.  At one end of the spectrum, an REC indicated that HIV vaccine 
trials would be reviewed like any other trial protocol.  On the other hand, it was 
indicated that the ethical issues inherent in the vaccine trials are too intensive 
and extensive for one local REC to handle and should be decided at a 
national level within SA.  Most RECs did not have a specific policy to deal with 
these trials except for the MRC committee who had been intimately involved 
with the development of a specific guideline on the Ethics of HIV Vaccine 
trials, one of the booklets in their series of five booklets outlining ethics in 
research.  Two RECs were familiar with the guidelines on HIV Vaccine trials 
contained in the Department of Health’s SA GCP - 2000 guideline.  One 
committee intended to follow international guidelines. 
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Three RECs indicated the need to invite HIV experts and ethicists to update 
their RECs on HIV Vaccines prior to reviewing such protocols.  At the time of 
conducting the interviews two RECs had received protocols for a phase one 
trial. These protocols had, however, presented the RECs with a challenge in 
terms of treatment of participants who would seroconvert during the trials.  
While two RECs had initially approved this phase one trial, both RECs 
subsequently withdrew approval after it was discovered that the sponsor did 
not intend to provide seroconverters with antiretroviral treatment (Altenroxel 
2002).  This set into motion intensive discussion around this point in SA 
around 2001-2002.  It is therefore not surprising that six of the RECS 
interviewed were acutely aware of the consensus that had been reached on 
the obligatory provision of antiretrovirals to seroconverters.  It was only after 
sponsors agreed to provide antiretroviral treatment to participants who 
seroconverted during the HIV vaccine trials that the two RECs involved 
granted approval for the conduct of phase I HIV vaccine trials in SA in 2003.  
 
Two RECs indicated that they would like community preparedness programs 
in place at HIV vaccine trial sites and that willingness to participate in studies 
should be conducted on these communities.  Protocols would need to include 
this information before RECs could review such protocols. 
 
Commentary 
 
HIV vaccine trials are fraught with ethical concerns both internationally and 
locally.  Two phase one vaccine trials were approved and started in SA during 
2003. These are safety trials on small groups of healthy volunteers.  At 
present approximately 30 candidate vaccines are in phase one trials globally 
(Esparza, 2004).  In the United States and Thailand, two large phase three 
efficacy trials have been conducted (Choopanya, 2004). 
 
Debate culminated in the UNAIDS Document released in 2000 in which 18 
guidance points dealing with the ethics of HIV Vaccine Trials were outlined 
(UNAIDS, 2000). 
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The fascinating way in which science and ethics are related has been borne 
out in the HIV vaccine trials.  Prior to conducting the clinical trials, the ethical 
issues and concerns were overwhelming.  Ethical deliberation helped to clarify 
some of the concerns.  However, the actual conduct of phase one, two and 
three trials has helped to further clarify many perplexing concerns. 
 
When deliberations on HIV vaccine trials first began in South Africa in 1998, a 
decision was taken to test only clade C vaccines in South Africa as this was 
the clade most prevalent in South African.  It was argued that South African 
communities should bear the burdens of research for a vaccine that they 
could later benefit from.  This was a very clear attempt to protect our 
communities from exploitation where sponsors from developed countries 
would test a vaccine here that would never be used on our communities in 
future.  Here too, science helped to change this rule when it was discovered 
that cross-clade reactivity might occur and hence other vaccine clades might 
also benefit South African populations.  At present we have both a clade C 
and a clade A vaccine in phase one trials in SA. 
 
The ethical issue that has received considerable attention to date relates to 
the care of participants who seroconvert during the course of trials.  The 
ethical dilemmas inherent in the provision of care to these participants centre 
around the moral responsibility of sponsors/investigators to provide care to 
such volunteers. 
 
This moral responsibility is two-fold.  Firstly the responsibility to patients who 
are screened out of the vaccine trial as a result of their being HIV positive and 
secondly, the responsibility of sponsors to participants who seroconvert during 
the trial. 
 
According to guideline 21 of the CIOMS 2002 document,  
 
 External sponsors are ethically obliged to ensure the availability of:  
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• health- care services that are essential to the safe conduct of the 
research ; 
 
Commentary on guideline 21 states 
 
although sponsors are, in general, not obliged to provide health-care 
services  beyond that which is necessary for the conduct of the 
research, it is morally praiseworthy to do so.  Such services typically 
include treatment for diseases contracted in the course of the study.  It 
might, for example, be agreed to treat cases of an infectious disease 
contracted during a trial of a vaccine designed to provide immunity to 
that disease, or to provide treatment of incidental conditions unrelated 
to the study. 
 
By extrapolation it would seem plausible to assume that the sponsor has no 
responsibility to those HIV positive volunteers identified during the screening 
process.  However, the commentary continues to add that volunteers who  
“cannot be enrolled in a study because they do not meet health criteria” for 
admission to the investigation - as would be the case with HIV positive 
volunteers who are screened out of trials – “should, as appropriate, advise 
them to obtain, or refer them for, medical care”.  The commentary also 
indicates that sponsors and investigators should refer those “subjects or 
prospective subjects who are found to have diseases unrelated to the 
research”.  Hence it is imperative to ensure that a robust referral system is in 
place in the community before research commences. 
 
Falling short of stating a moral obligation on sponsors to provide care for HIV 
positive volunteers, Guidance point 16 of the UNAIDS document indicates that 
 
Sponsors need to ensure care and treatment for participants who 
become HIV-infected during the course of the trial. 
 
While there is no consensus on the standard of care that should be offered, a 
comprehensive care package is referred to and Guideline 16 suggests the 
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provision of the best proven standard of care as an ideal, but the provision of 
the highest attainable standard of care in the host country as a minimum. 
 
In South Africa, research and care are integrally linked and often conducted at 
the same sites due to resource constraints.  As such, it is impossible to 
conduct research without making provision for care, whether this is care for 
illnesses related to the research or unrelated morbidity. 
 
The options to the sponsor in the provision of care range from a volunteer 
specific approach on the one hand to community wide provision of care on the 
other hand. 
 
A volunteer specific approach could involve provision of care at trial sites 
independent of existing host country ARV programs.  The standard of care 
provided could be that of the sponsor country or the host country. 
 
Another volunteer specific option would be the provision of a higher standard 
of care funded by a trust fund financed by the sponsor but administered by the 
local government as suggested by Tucker in the South African setting 
(Tucker, 2003: 995).  Such a scheme is both innovative and interesting.  
However, offering private medical care to participants who seroconvert will 
represent an inducement to participate.  Such a scheme is individualistic and 
will benefit only trial participants who seroconvert.  It will also be costly and 
hence limited to a period of a minimum of ten years as is outlined in the 
proposal. 
 
However a more pragmatic and morally sound option would involve 
collaboration of the sponsor with local governments, working to strengthen 
existing infrastructure, in particular, existing ARV rollout programs.  In this 
way, sponsor funding will assist to raise the standard of care to the highest 
attainable level in a developing country.  Communities and not only volunteers 
will benefit. Inequity between trial volunteers and community members will be 
eliminated so it will not serve as an unfair inducement to participate.  Such an 
approach will also make provision for the referral of HIV positive volunteers 
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who are screened out of the trial.  The results of the first phase three trial 
conducted in Thailand indicated that 1570 participants had to be screened out 
of the trial due to their pre-existing HIV positive status.  This represents a 
large number of patients who would have to be cared for, highlighting the 
importance of good health care infrastructure that must exist concurrently with 
the conduct of HIV vaccine trials.  In fact, the HIV positive patients who are 
screened out represent a much larger challenge than those who seroconvert 
during the trials.  The Thai study had 105 seroconverters in the vaccine arm 
and 106 seroconverters in the placebo arm a total of 211 out of 2500 
participants who were enrolled in the study. 
 
Given the current challenges being faced in South Africa with ARV rollout with 
only 16 out of a possible 66 sites being active, coupled with the need to train 
at least 14000 permanent health staff to sustain the program, financial 
assistance from research sponsors is indispensable.  In exchange, trial 
participants, both those who are screened out and those who sero-convert 
during trials, could be assured of prioritized access to such programs.  It is 
imperative that pragmatic solutions are found for the care of HIV positive 
vaccine trial participants in South Africa.  It is the responsibility of the sponsor 
to assist to “ratchet the standard upward” rather than attempt to create 
“utopian” standards that are neither attainable nor sustainable (Benatar, 2000: 
824-26). Sponsors argue that research initiatives cannot be used to reduce 
health care inequities. However, given the minimal options that exist to 
improve health care in developing countries, research remains the only 
currently viable option.  
 
The above arguments pertain to the situation where HIV positivity is regarded 
as a primary end-point in an HIV vaccine trial and where those who sero-
convert are regarded as falling outside the parameters of the study. 
 
If, however, we look at the use of surrogate end points in a vaccine trial, 
retention of HIV positive trial participants will become an important 
consideration and the moral obligation of investigators to these study 
participants will change. 
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While much attention has been focussed on treatment of seroconverters in 
trials it is clear that this issue affects less than 10% of participants enrolled in 
clinical trials.  On the other hand, informed consent procedures are going to 
affect all trial participants and attention needs to be focussed on this ethical 
issue in South Africa. Suggestions to improve the informed consent process in 
South Africa will be discussed in chapter eight. 
 
The inclusion of children and adolescents in HIV vaccine trials is a current 
source of concern in South Africa. According to the current classification of 
research into therapeutic and non-therapeutic research in South Africa (MRC 
guideline) HIV prevention trials would fall squarely into the non-therapeutic 
category.  As such, according to the National Health Bill, non-therapeutic 
research requires consent from parents/legal guardians, the children involved 
and the Minister of Health.  Consent from children under the age of 18 years 
for research purposes is a new concept in South Africa.  Traditionally, assent 
has been obtained from children under the age of 18 years for the purposes of 
research.  Ministerial consent for such research could prove to be a logistical 
problem resulting in enormous time delays in initiating urgently needed 
research in South Africa.  The delegation of this function to the National 
Health Research Ethics Council, when it becomes a statutory body, is a 
possible solution.  Consensus is being reached that children and adolescents 
must be included in HIV vaccine research on the proviso that the vaccine has 
first been demonstrated to be safe in adults – one of the tenets outlined in the 
Belmont report in chapter three.  In addition, it has been argued that if phase 1 
and 2 trials can demonstrate no significant difference between adult and 
adolescent responses to the vaccine, it may be possible to obtain licensure for 
adolescent use without conducting phase 3 trials on adolescents ( McClure 
2004: 732).  The view on research on children in the United States differs 
markedly from the protectionist view South Africa has adopted. The 
Revitalization Act of 1993 and policy established by the National Institutes of 
Health (NIH) and implemented since 1998 adopts the view that researchers 
need to justify reasons for not including children in research.  In South Africa, 
the emphasis has been on justifying why children are included in research 
whenever this has been the case.  Unlike the South African situation where 
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research on children is classified as therapeutic and non-therapeutic, the 
United States approach has focussed on risk (Miller 2003:102).  The 45 Code 
of Federal Regulations part 46 developed by the Department of Health and 
Human Sevices (DHHS) outlines 3 major risk categories:  
 
1. Research involving minimal risk 
2. Research involving more than minimal risk with direct benefit to the 
children 
3. Research involving more than minimal risk with no direct benefit to the 
children but research that will produce generalisable knowledge. 
 
The need to include children and adolescents in HIV vaccine research in 
South Africa has resulted in many ethical issues being revisited – the 
emerging autonomy of the adolescent, beneficence - as such research will 
benefit children as a class and the principle of justice which requires that 
children are not excluded from research.   
 
In a multicultural setting like South Africa, different concepts of autonomy of 
the child exist.  At a meeting in Kwa-Zulu Natal in July 2004 hosted by the HIV 
AIDS Vaccine Ethics Group (HAVEG) to explore the issue of inclusion of 
children and adolescents in HIV vaccine research, an interesting view was 
expressed by Black community members regarding the autonomy of the child. 
In some communities, a person is regarded as a child as long as he or she is 
dependent on parental support and is still living at home.  Under such 
circumstances, consent would have to be sought from parents before 
participating in research even if a person were over the age of 18 years.  By 
extrapolation it would then be impossible for a child or adolescent younger 
than 18 years to participate in research without parental permission.  There is 
a great deal of empirical research that is necessary in South Africa to inform 
the development of guidelines for conducting research on children and 
adolescents where HIV/AIDS is concerned.   
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7.3 Continuing Review: The Ethical Issues 
 
The responsibility of the REC does not end with approval of a research 
protocol.  Hence, the interviews also included questions on two important 
functions that the REC must fulfill once a trial is initiated.  This includes 
adverse event reporting and monitoring.  According to the ICH_GCP 
guideline, a Serious Adverse Event is defined as  
 
Any untoward medical occurrence that at any dose results in death, is 
life-threatening, requires inpatient hospitalisation or prolongation of 
existing hospitalisation, results in persistent or significant 
disability/incapacity or is a congenital anomaly/birth defect.   
   (International Conference on Harmonisation, 1997) 
 
Good clinical practice requires investigators and/or sponsors to report serious 
adverse events to sponsors and to RECs (International Conference on 
Harmonisation, 1997). 
 
7.3.1 Adverse Event Reporting 
 
Interview data 
 
[Adverse event reporting] - That’s a nightmare, I think for any and every 
ethics committee. 
 
This sums up the view of all RECs in South Africa.  This is largely due to the 
huge number of adverse events that are reported both from the local site and 
from international sites.  All adverse events are not related to the study drug 
and all are not serious. 
 
In most RECs the role of reviewing adverse events has been assumed by the 
chairperson.  
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In four out of ten RECs surveyed, this function is delegated to a specific 
person/s: 
 
Either the vice chair or specific REC member has this responsibility.  
Alternatively a subcommittee has been established comprising two REC 
members. In one instance a manager of the REC performs this duty. 
 
In two out of the four cases this person/committee does not review protocols 
at all. 
Four RECs have developed ways to cope with this enormous administrative 
burden: 
 
Consensus exists regarding the importance of having a system in place to 
deal with this problem.  Such a system can be manual or electronic. 
 
These RECs have an electronic database to process adverse events.  This 
works well provided the adverse event reports contain all the information 
required by the electronic system.  The computer is able to flag the adverse 
events and generate a letter to the investigator when ten or more adverse 
events are detected on a study.  However, the nature of the adverse event, its 
relevance and severity must be interpreted by a clinician.  Hence one cannot 
rely solely on the electronic system to fulfil this function. 
 
One of the four RECs also uses a colour coded sticker system to identify 
adverse events according to severity and relationship to study drug. 
 
Two RECs have developed their own forms that facilitate the data capture of 
these adverse events. 
 
How could the reporting of adverse events be improved? 
 
Most RECs prefer to have only those adverse events that are related to the 
study drug reported to them. 
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We should demand of the sponsors that we only review adverse events 
that they think are related 
 
It would also simplify the work of local RECS if adverse events from South 
African sites are reported separately from those occurring at international 
sites. 
 
The idea of the NHREC assisting with multicentre studies was suggested.  It 
was felt that it would be worthwhile to have a dedicated person attending to 
adverse events at a national level. 
 
Consistent submission of adverse events by investigators would facilitate the 
work of RECs in this regard. 
 
Some pharmaceutical companies complicate the work of REC’s.  The majority 
of RECS regard adverse event reporting to be the responsibility of 
investigators, not sponsors and prefer for investigators to follow simple rules 
to minimise the burden created by adverse event reporting. 
 
Commentary 
 
There is wide variation in how different RECs are coping with this very difficult 
yet important function of adverse event reporting.  It is a vital way in which the 
health of research participants should be monitored and protected by an REC 
yet it is fraught with logistical problems at all levels.  A very valid concern 
exists regarding the level of protection that is being afforded to study 
participants.  It is argued that the current process fulfils the “bureaucratic 
requirement of data dissemination” but may not result in enhanced safety for 
participants in clinical trials” (Liauw, 2003: 426-428). 
 
Most RECs, already overburdened with protocol review are looking for ways 
to simplify the adverse event reporting function.  While the use of an electronic 
database is good, it cannot fully appreciate the significance of an adverse 
event.  Those systems that react after only ten adverse events are reported 
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may appear to be efficient, yet in some clinical situations two adverse events 
of a particular nature, especially if related to the investigational drug, may be 
too many.  This was clearly illustrated in the Ellen Roche case study where 
the first study participant developed a cough that was not reported to the REC 
and the second participant (Ellen Roche) also developed a cough but 
subsequently died.  If dependence were being placed on a computer to 
monitor adverse events, nine people could easily have died before the 10th 
adverse event had been flagged by the computer! 
 
A consistent complaint from all RECs surveyed was that safety reports from 
sponsors do not situate the adverse event in the wider context of the clinical 
trial.  Hence it is difficult for the significance of the adverse event to be 
evaluated in context. 
 
Data Safety and Monitoring boards (DSMB) represent a mechanism to 
monitor interim data in clinical trials to ensure safety of participants.  The 
members of these boards are experts in the field of interest but are 
independent of the clinical trial itself (Slutsky, 2004:1143-1147).  Liauw argues 
that data safety monitoring boards are in a better position to make judgements 
about safety, especially in relation to causality as they have access to more 
complete information.  The major liability for adverse events in investigational 
clinical drug trials lies with the sponsor.  As such, sponsors should take 
responsibility for establishing effective, independent data safety monitoring 
boards. RECs should insist that the data safety monitoring board process 
should be more transparent.  Protocols should state whether or not an 
independent monitoring board is being established and the membership of the 
board as well as its terms of reference should be disclosed.  The sponsor’s 
internal operating procedure for handling adverse events should also be 
disclosed (Liauw, 2003: 426-428). 
 
The current regulations and guidelines that define a serious adverse event 
includes any hospitalisation excluding those for elective procedures and 
scheduled operations or investigations, during the conduct of a trial.  Often, 
sponsors and contract research organisations fail to bring this to the attention 
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of investigators at the start of a trial.  If, on enrolment of a participant, all 
elective procedures requiring hospitalisation for the duration of the study are 
documented in the source documents, these do not meet the definition of a 
serious adverse event when they occur and hence do not have to be reported 
as such.  This will considerably reduce the paper trail that already exists in 
adverse event reporting.  
In South Africa, the INHREC will have to seriously consider the role it will play 
in national and international multi-centre trials.  These studies entail a great 
deal of duplication of effort and reporting mechanisms.  According to Califf et 
al, traditional RECs “within single institutions, acting alone, typically are not 
constructed to assess reliably the safety of participants across multicentre 
trials” (Califf, 2003).  It is therefore not surprising that adverse event reporting 
and surveillance of multicentre trials is an area identified by local RECs in 
South Africa where the national committee can play an important role.  This 
needs to be negotiated with the INHREC before it becomes a statutory body 
so that provision can be made for this in their mandate.  In this regard, the 
latest guideline of the European Union that came into effect as of the 1 May 
2004 can be invoked.  The guideline referred to as 2001/20/EC is legally 
enforceable throughout the European Union.  In the context of multinational 
collaborative research with Europe other countries will also have to abide by 
the regulation.  The regulations relating to adverse event reporting are 
comprehensive.  Of particular import, is the development of a single national 
electronic database to expedite the reporting of suspected unexpected 
serious adverse reactions (SUSAR).  The efficiency of the system remains to 
be judged but it does represent a unique way of handling adverse event 
reporting at a national level (European Council and European Parliament-EU, 
2004). 
 
Ultimately, Good Clinical Practice training of all investigators will hopefully 
ensure standardised knowledge of adverse events and procedures for 
reporting to the REC that will contribute significantly to the role that the REC 
plays in participant protection.  The final responsibility for the protection of 
study participants should lie with the investigator who is medically trained and 
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in the best position to recognise adverse events timeously.  The REC can only 
play a secondary role in protection of participants once the trial is in progress. 
 
 
7.3.2  Monitoring of Research 
 
Interview data 
 
Only one REC is actively involved with monitoring at a very low level – two-
three site audits are conducted a year at random by REC members. 
 
Two other RECs have had limited experience with monitoring – one attempted 
to do telephonic monitoring but were dissatisfied with the experience.  Another 
REC had conducted one or two audits as a result of complaints. 
 
For most RECs the monitoring function is limited to annual reports from 
investigators and adverse event monitoring. 
 
Across the board, all RECs cite a lack of resources both financial and human 
to conduct a proper auditing function. 
 
However, all RECs would like to conduct monitoring and have the following 
plans in mind: 
 
1 Who should conduct the monitoring? 
 
One suggestion was that a separate subcommittee of the REC consisting of 
two REC members should be responsible for random on-site monitoring.  
These members should not be involved in protocol review at all.  Another 
suggestion was that a separate committee should be established to conduct 
monitoring. One committee suggested sharing the monitoring function with 
other RECs who are located geographically close together.  One REC had 
appointed a full time committee member with a mandate to conduct 
monitoring but the process had not started at the time of the interview. 
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2 Which sites should be monitored? 
 
Random monitoring was mentioned.  Some high risk sites were identified such 
as sites conducting a high number of clinical trials, high risk research such as 
HIV vaccine trials, and oncology and respiratory studies.  It was also thought 
that monitoring visits should be driven by complaints from participants and 
colleagues.  Some RECs had received complaints while others felt that 
participants are not aware that complaints can be lodged with RECs and the 
awareness of this fact needs to be increased through efforts of RECs.  One 
REC believed that academic research should also be monitored as these 
involved “less experienced researchers working with vulnerable populations”. 
 
3 What should the monitoring entail? 
 
Site visits were cited as essential.  Mention was made of speaking to study 
participants and of monitoring the informed consent process. 
 
4 How could this be operationalised? 
 
Although funding was a pervasive problem, one REC suggested building 
monitoring fees into review fees for clinical trials and building monitoring fees 
into academic fees for academic research. 
 
Commentary 
 
The extent and depth to which RECs conduct monitoring in South Africa is in 
keeping with international trends.  A multinational survey of REC monitoring in 
21 different countries revealed that only 11 countries were conducting 
monitoring and in most cases this involved only passive surveillance (quoted 
in Burgess, 2004:1). 
 
While there is consensus in South Africa regarding the relevance of a 
monitoring function of an REC, internationally, this issue is met with more 
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ambivalence.  On the one hand, proponents for monitoring regard this as an 
integral function and indeed, an obligation, of an REC. On the other hand, 
critics hold that monitoring represents a policing function that falls outside the 
domain of REC functions.  
 
Robert Levine has argued vehemently against routine monitoring. His 
arguments are grounded in two main objections.  Firstly, he charges that 
routine monitoring would erode the trust embedded in the relationship 
between RECs and investigators.  His second objection pertains to the high 
cost-benefit analysis of monitoring.  While the costs involved are high, 
monitoring does not “seem to catch many wrong doers anyhow”. (Quoted in 
Weijer, 1995: 1974) 
 
As a proponent of monitoring I wish to offer the following counter arguments.   
 
Many programs of human participant protection have routinely traded on 
investigator integrity.  RECs have very little knowledge of what actually 
happens to perfectly designed research protocols they approve.  Often they 
trade on the following assumptions: 
 
1 acceptance that researchers will do what they say they will do; 
2. a willingness to believe that informed consent in practice will meet up 
 to its moral rather than its legal obligations 
3. confidence that conflicts of interest can be eliminated ;and 
4. the desire to achieve participant protection will have a higher priority 
than the  pursuit of knowledge. 
                              (Adapted from Benatar, 1998: 221) 
 
However, in many instances, this trust in investigator integrity has been 
eroded by investigators themselves.  The Bezwoda case in South Africa 
(Weiss, 2000: 999-1003) and the Poisson case in Canada (Weijer, 1995: 
1973) – both involving research fraud on patients with breast cancer – are 
living examples and will be discussed in more detail in Chapter Nine. 
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The comment from one of the REC chairs interviewed also supports the 
notion of monitoring as a result of lack of trust in investigator integrity: 
 The Bezwoda case…should have taught us a lesson about monitoring 
 – we still do not monitor enough so we did not learn a lesson. 
 
While it may be argued that these represent isolated cases of breach of trust 
and hence cannot be used to establish a rule of universal monitoring, it is 
clear that in research on humans even a few cases of research fraud, 
especially in the magnitude of the Bezwoda and Poisson cases, is a few 
cases too many.  These cases in and of themselves are sufficient to erode not 
only trust in RECs but also erosion of public trust.  This in itself would destroy 
the research endeavour altogether.  This is echoed in the words of Schwarz: 
 
 If integrity and credibility of the [research] process is called into 
 question, our ability to produce new methods for the diagnosis and 
 treatment of disease will be compromised.  The ultimate penalty will be 
 paid in decreased benefits to public health.  It’s that simple as well as 
 that serious. 
                            (Schwarz, 1991: 760) 
 
This leads to the second counterargument to Levine’s objections to 
monitoring.  The cost benefit analysis of monitoring cannot simply be 
calculated in monetary terms.  Agreeably the costs involved are high, 
however, the benefits accrued in preventing just one case of scientific fraud 
are enormous as is evidenced by both the Bezwoda and Poisson cases.  It is 
true that it will not be possible to monitor all research projects, but a system of 
random monitoring will encourage researchers to comply with rather than to 
deviate from protocol specifications.  Such a system will not obliterate 
research fraud altogether but will serve to deter investigators in the vast 
majority of cases from committing fraud. 
 
Further support for the monitoring function of RECs is enshrined in some 
international guidelines relating to REC functions: 
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Article 19 of the 2000 version of the Declaration of Helsinki specifies: 
 
 The committee has the right to monitor ongoing trials  
 
The CIOMS 2002 guideline 2 refers to monitoring as follows: 
 
 The ethical review committee should conduct further reviews as 
 necessary in the course of the research, including monitoring of the 
 progress of the study. 
 
In spite of the controversy surrounding monitoring, a number of systems have 
been proposed to operationalise the monitoring function of RECs.  These 
include continuing annual review, informed consent monitoring, monitoring for 
adherence to the protocol, and review to identify unapproved activities (Heath, 
1979: 1-4).  A fifth category includes monitoring of data integrity (Weijer, 1995: 
1977-78). 
 
Continuing annual review: 
 
This is a minimum requirement for monitoring internationally and is by far the 
most that is being done in South Africa and elsewhere by most RECs.  Most 
REcs require that a report is submitted to the committee annually indicating 
the number of participants enrolled, the progress of the study and any adverse 
drug reactions.  If the adverse drug reactions are a source of concern,  The 
REC may suggest that a data safety monitoring board be appointed to monitor 
the study further.  Any new information that has been acquired by other 
studies should also be reported to the REC especially if such information 
disturbs the equipoise of the study. This might necessitate termination of the 
study. 
 
Consent Monitoring: 
 
Deficiencies in the informed consent process is a frequent finding when 
various regulatory bodies audit research.  A survey conducted by the Office 
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for Human Research Protection (OHRP) on 175 institutions in the United 
States found that 25 % of the institutions had a deficiency in the informed 
consent process (personal communication - Melody Lin deputy director of 
OHRP, 2004). 
 
Consent monitoring can range from a simple inspection of consent forms to 
observation of the process on site to testing participants’ comprehension of 
the process.  Faden et al reviewed consent documents for 214 research 
participants at the Johns Hopkins Oncology Centre over a three year period – 
March 1976 to March 1979).  The entire process took a total of 160 hours to 
complete (Faden, 1980:9-10). The IRB at Harvard University, School of Public 
Health has been conducting informed consent monitoring on site since 2003.  
Monitoring is conducted by a specific person to whom the task has been 
delegated.  He has travelled to Botswana and Nigeria to monitor the process.  
Some of his visits include sitting in on the interaction between investigator and 
participant with the permission of the participant (personal communication 
Jelal Hoosein). 
 
Monitoring for adherence to protocol 
 
This is a labour intensive process and is usually conducted by contract 
research organisations or sponsors to ensure adherence to Good Clinical 
Practice.  Most RECs in South Africa are inadequately trained and under-
resourced to conduct monitoring of this intensity. 
 
Review to Identify Unapproved Research 
 
This would have been the ideal way to detect the kind of research being 
conducted by Werner Bezwoda at the University of Witwatersrand.  However, 
it is uncertain whether this is indeed a function of a REC.  It is extremely 
difficult to determine which studies have not received REC approval.  I believe 
that this type of monitoring clearly falls outside the mandate of a REC. 
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Monitoring of data integrity 
 
This type of monitoring occurs when clinical trials are audited either in house 
by the sponsor or externally by a regulatory agency.  When this occurs, a 
REC may request a report of the audit.  However, in trials that are not audited, 
it remains an impossible task for a REC to conduct a full audit on a clinical trial 
– another function the REC is not mandated to conduct. 
 
Monitoring of research that has been approved by a REC is regarded as an 
integral function of RECs.  However, most RECs are unable to fulfil this 
function both nationally and internationally.  It is hence important that each 
REC develops a plan for monitoring based on expertise and resources 
available to conduct such monitoring. 
 
7.4 Emergent Ideas 
 
The new ideas that emerged in the course of the interviews pertained to 
research in the private health sector and audit of RECs.  They will be dealt 
with briefly as they represent largely unresearched areas that require further 
exploration in another study.  Research conducted in the private health care 
sector of South Africa is submitted to one of two private RECs for approval.  
Many private practitioners are inadequately trained to conduct research and 
most private practitioners conduct research on their own patients with whom 
they have a pre-existing therapeutic relationship.  This raises serious 
questions about voluntariness of participation by patients who are in a 
dependent relationship with their doctors.  An important issues raised in the 
interviews was the problem of some doctors billing their patients’ medical aid 
plans for research related investigations, drugs and consultations – a 
phenomenon referred to by one of the REC Chairs as “double-dipping”.  In the 
context of a clinical trial, all research related investigations, consultations and 
drugs are paid for by the sponsor.  Hence these items cannot and should not 
be charged to a medical aid. 
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The concept of audit of RECs is unique in South Africa.  Only one REC 
indicated that the REC had been audited by a private audit company.  This 
audit had been financed by the institution.  Eight other RECs had received a 
quality assurance visit by the Office for Human Research Protection (OHRP) 
in 2002 and were alerted to their short-comings.  However, all documentation 
related to that process was confidential and hence could not be made 
available to the interviewer. 
 
7.5 Commentary 
 
The in-depth interviews facilitated a process of engagement with the critical 
challenges facing REC chairpersons in South Africa.  There are widespread 
problems relating to both initial and continuing review both amongst 
institutional and private RECs.  In addition, there are issues of significant 
concern where private sector research is concerned and this represents an 
opportunity for future in-depth empirical and conceptual research.  Interesting 
links exist amongst the various themes identified in the course of the 
interviews.  Undoubtedly, informed consent receives a disproportionate share 
of the review process.  Standards of care and post-trial benefits share a 
common sub-theme – namely – both reflect the compromised position most 
RECs find themselves in when attempting to achieve a balance between 
protecting participants and promoting research.  They must choose between 
the following options: securing a global standard of care as well as post trial 
benefits and risk losing research, or settling for local standards of care and 
sacrificing post trial benefits in order to attract and maintain a vibrant research 
industry in South Africa.  The latter option would require that the universal 
standards aspired towards in the Declaration of Helsinki must, of necessity, be 
disregarded.  Participant remuneration and post trial benefits are two concepts 
that can be viewed as being inversely proportional to each other.  Increasing 
post-trial benefits could result in reducing in-trial participant remuneration 
thereby elimination the potential for undue incentives for participation.  
Enhancing post-trial benefits will contribute to an improved standard of care in 
developing countries.  It will also raise the ethics of trial participation closer to 
those aspired towards in the Declaration of Helsinki and other international 
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documents.  Ultimately all these issues will facilitate the ethical conduct of HIV 
vaccine trials in South Africa, a research priority for the third world.  Chapter 
eight situates the various challenges that emerged from the empirical 
research in a conceptual framework and proposes solutions to each of the 
major challenges that have emerged.  Recommendations for resolving the 
global challenges are also presented. 
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Chapter 8 
 
Towards National Standardisation 
 
8.1 Introduction 
 
Internationally it has been charged that there is “an impending, if not actual, 
crisis” in the review of human participant research (Wood, 2002).  In the 
context of the 4000 to 6000 IRBs in the United States, this is perhaps not an 
exaggeration. 
 
In South Africa, many of the problems that exist in developed countries are 
present but on a much smaller scale.  The empirical research conducted on 
the major RECS involved in clinical trial research in South Africa indicates the 
following: 
 
1 wide variability across the country in the ability of RECS to conduct 
 satisfactory ethical review. 
2 a number of problem areas in research ethics review: 
 2.1 at a structural level, 
 2.2 in the course of the review process, both during initial review 
 and continuing review or 
2.3 in deliberation of substantive research ethics controversies. 
 
These findings will now be considered in more detail:  
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8.2 Challenges in the Ethics Review System in South Africa 
 
8.2.1 General  
 
8.2.1.1 Variability in the Ethics Review System 
 
The Bantu Education Act of 1953 placed control of education of Africans in 
apartheid South Africa in the hands of the Department of Native Affairs 
(Perez, 2004: 765).  The Minister of the department, Dr H.F. Verwoerd, 
outlined his plans for the education of Africans as follows:  
 
 My department’s policy is that education should stand with both feet in 
 the reserves and have its roots in the spirit and being of the Bantu 
 society…There is no place for him (the Bantu)in European community 
 above the level of a certain form of labour. 
                  (Roux, 1964:394-395) 
 
As a result of The Bantu Education Act and a Bantu education policy that 
followed a system of inferior education for African people, the apartheid 
ideology was extended to higher education (Perez, 2004: 765).  It is hence not 
surprising that RECs at Black universities have been in existence for only one 
year, are under resourced, lack infrastructure and training of members and 
review very little contract research. 
 
The lack of standardization amongst the 12 RECs surveyed in terms of 
structure and the review process has its origins in the apartheid system in 
South Africa.  While the effects of the system have been widely recognized at 
a socio-political and economic level, the effects in academia have been less 
clearly defined and documented, especially where tertiary educational 
institutions are concerned.  This study, however, clearly demonstrates that the 
historically disadvantaged institutions have RECs that are in existence for one 
year while the historically advantaged institutional RECs have been 
established up to 30 years ago.  What defines the institutions that sit at the 
extreme opposite ends of the spectrum is simply a differential in terms of 
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historical government support to tertiary institutions serving students of 
different racial groupings. 
 
The large majority of institutions that have been in existence for ten years 
coincide with the change to a democratic government since 1994 and a 
greater awareness of participant protection and vulnerable communities. 
 
Hence the quality of ethics review in South Africa is divided along racial lines. 
While the burdens faced by REC members are enormous under the best of 
circumstances, including developed world RECs, these burdens are 
intensified in historically disadvantaged institutions in South Africa in terms of 
experience, infrastructure, administrative support, training and capacity 
development. 
 
The INHREC has a plan to divide RECs further in terms of level one and level 
two RECs. Level one RECS will be able to review high risk research while 
level one RECs will be able to review only low risk research.  Given the 
current situation with RECs in South Africa it is most likely that historically 
disadvantaged  RECs will only qualify for level one accreditation.  In the 
absence of redress aimed at raising the level of functioning of RECs at 
historically disadvantaged institutions, the INHREC system of accreditation 
will serve to perpetuate the injustices of apartheid. 
 
There are far-reaching consequences to the disparity in REC functioning. 
Level one RECs will only be able to review low risk research.  Most RECs 
review the research that comes to their own institutions.  From the data on 
workload at the various RECS, it is evident that historically disadvantaged 
RECs already have very little research activity at their institutions.  This will be 
reduced even further by an accreditation system that discriminates against 
disadvantaged institutions.  It is established that research is a major source of 
funding for institutions and investigators alike.  Hence low levels of research 
activity at historically disadvantaged institutions will impact on the ability of 
those institutions to build research funds both at an institutional level and at 
individual investigator level. 
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8.2.1.2 Lack of Communication amongst RECs 
 
RECs in South Africa function in isolation. There are no national policies in 
place to ensure uniformity in review requirements. RECs have not established 
a means of communication.  Such a situation lends itself to the phenomenon 
of REC shopping which impairs human participant protection. 
 
8.2.2  Specific Problems in the Review System 
 
8.2.2.1 Structural 
 
A.  Composition 
 
Most RECs except those at Black universities are white dominated.  Hence 
these RECs fall short of the requirements of the SAGCP guideline for RECs to 
reflect the demographics of the country.  Females are under represented at 
almost all RECs. Most RECs are top heavy where scientists and clinicians are 
concerned.  There is poor representation of pharmacologists and statisticians. 
 
Community representation is being confused with lay representation.  Lay 
members on RECs in South Africa are non-scientific professionals like 
lawyers or theologians.  All priests on REC represent the Christian faith.  This 
is unacceptable in a multi-denominational society like South Africa.  Except for 
the private RECS, very few members on institutional RECs are not affiliated to 
the institution.  This leaves the REC in a serious position of conflict where 
research conducted at the institution is reviewed by the institutions own REC. 
 
B. Committee & Review System Structure 
 
Most RECs in South Africa review both academic and clinical trial research at 
a monthly meeting.  This usually results in a large number of protocols per 
meeting, long meetings and an enormous workload for reviewers.  This is 
intensified where all REC members are reviewing all the protocols for the 
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meeting. One institution has three RECs – one to review human (academic) 
research, one to review clinical trials and one to review animal research.  
Different faculty members sit on each of these committees. During the 
interviews, one of the larger RECs alluded to such a system of review as 
being preferable. 
 
Scientific review is being conducted twice in most institutional RECs but only 
once at private RECs.  This could represent duplication at the level of 
institutional RECs and inadequate scientific review by private RECs. 
 
C. Administrative staff 
 
Most RECs have at least one person responsible for the administrative 
workload of the committee.  This is generally inadequate due to the enormous 
amount of administrative work in the REC. 
 
D. Infrastructure 
 
All RECs, except one, has a dedicated office for REC administrative work.  
This in itself is inadequate.  Storage of documents requires further space and 
a good storage system. 
 
E. Training and development of members 
 
There is wide variability in training levels of REC members.  Training ranges 
from 100% on some RECs to 0% on others.  Funding appears to be problem 
at some institutions.   
 
F. INHREC 
 
There is ambiguity about the role that this national body will play in the South 
African system of ethical review.  While there is a positive expectation in terms 
of education and training needs being met, there is a concern regarding the 
potential for a policing role.  The system of accreditation has been questioned 
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and there is a concern that registration of level one and level two committees 
will perpetuate the apartheid structures that still exist within universities in 
South Africa.  A wider role for the INHREC is anticipated by RECs in terms of 
its involvement in the review of multi-centre research and adverse event 
reporting.  These roles are not anticipated by the INHREC for themselves. 
 
G. Remuneration of REC Members 
 
There is wide disparity on the issues of payment of REC members.  There is 
lack of national consensus in this regard. 
 
8.2.2.2 Review Process 
 
A. Delayed review 
 
Delays in the review process are an international and national phenomenon. 
Compared to the delays internationally, South African RECs are actually more 
efficient than they are perceived to be with the range for review extending 
from ten days to ten weeks. 
 
Factors contributing to the delays are as follows: 
 
1. Double review of the science – most RECs are reviewing the science 
even though this has been done either by another committee or by a 
departmental review committee. 
2. The requirement by some RECs for all REC members to review all 
protocols. 
3. Infrequent meetings – those RECs meeting quarterly contribute more to 
the delay in the review process.  
4. Inadequate administrative staff – the enormous amount of paper work 
has to be processed and this delays the process if there are only part-
time administrative staff. 
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B.  Informed consent forms 
 
There is excessive focus on comprehensive content of informed consent 
documents.  At the same time very little attention is paid to readability and 
layout of forms and translation of forms.  There appears to be little concern 
with the impact of the forms on study participants with erratic policies 
regarding the provision of summaries for participants.  Only three out of ten 
RECs require summaries for participants. 
 
C. Adverse Event Reporting 
 
The definition of serious adverse events results in many routine and unrelated 
hospitalizations of participants being reported.  In the context of multi-centre 
studies adverse events at international sites are reported to local RECs. 
Inadequate information is provided rendering RECs incapable of 
contextualizing the adverse event.  Adverse events that are both unrelated 
and related to the investigational product are reported. RECs receive reams of 
paperwork and have attempted to create databases to facilitate the process. 
However, there data bases serve only to flag adverse events after ten or more 
events occur at a site.  A computer cannot assess the clinical significance of 
the event and hence unnecessary letter are generated by databases and sent 
to investigators.  Data safety and monitoring boards and RECs do not liaise in 
any way.  Ultimately, the reporting of serious adverse events in the way in 
which it is currently being done does not serve to promote the function of 
RECs to ensure the safety of study participants. 
 
D. Monitoring 
 
None of the RECs in South Africa is engaging in meaningful monitoring of the 
research that they approve.  If it is being done at all, it is being conducted in 
an erratic manner or at such a low level that it fails to adequately serve the 
purpose of quality control.  Most RECs are under resourced, both financially 
and in terms of personnel to execute this function.  As a result, the most of 
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this function that is fulfilled is the review of annual reports on studies from 
investigators. 
 
 
8.2.2.3 Substantive Review Issues 
 
A. Standard of care 
 
International guidelines that specify a universal standard of care for control 
groups in clinical trials have introduced conflict into the ethical review process 
in a developing country like South Africa.  On the one hand, RECs would like 
study participants to receive the best standard of care possible.  On the other 
hand, researchers and RECs in developing countries are in a compromised 
position with regard to sponsors in negotiating a universal standard of care.  A 
policy for an international standard would cripple the research industry in 
South Africa.  As a result, RECs are disregarding the Declaration of Helsinki, 
even though we are members of the World Medical Association.  This has 
been borne out, both in a systematic review of the standard of care used in 
research in Sub-Saharan Africa (Kent, 2004), and from the interview data in 
this study.  What has not occurred in South Africa is a clear expression of our 
decision – as considerable confusion exists amongst investigators, contract 
research organizations and sponsors regarding the standard of care policy in 
South Africa. 
 
B. Post-trial treatment 
 
Like the standard of care guideline, this is another guideline specified in the 
2000 version of the Declaration of Helsinki that is not being implemented, 
again, for fear of stifling the research industry in the country.  There is 
inconsistency in the recommendations of the Declaration of Helsinki and the 
CIOMS guideline.  This relates to the obligation to provide treatment to study 
participants only (Helsinki) as compared to communities that study 
participants belong to (CIOMS).  At an international level, this needs to be 
clarified.  However, at a local level, RECs need to reach consensus on a 
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reasonable plan for the post-trial period.  Firstly, the concept of post-trial 
benefit must be defined.  This can be viewed as a study drug or intervention 
proven to be effective in a narrow sense or on a broader scale as a 
contribution to infrastructure development or capacity development in South 
Africa. 
 
C. Remuneration 
 
There is lack of clarity on the amount that should be paid to research 
participants in South Africa.  It is also unclear whether the RECs or the MCC 
should make this decision. Inclusion of this information in informed consent 
documentation remains problematic. 
  
D. Guidelines 
 
The number of guidelines regulating research ethics is growing internationally 
and nationally.  Guidelines like the Declaration of Helsinki are simply being 
disregarded when implementation is not possible.  RECs make irrelevant 
specifications regarding which version of the declaration must be included in 
informed consent documentation and protocols, yet are themselves unclear of 
what the different versions espouse.  Selective application of some articles of 
the guidelines is unacceptable.  An obsessive dependence on guidelines in 
the ethical review process results in more attention being paid to a paper trail 
and beaurocracy rather than the business of research participant protection. 
Developing countries make insufficient contributions to the development of 
international guidelines.  Local guidelines are largely the result of “cutting and 
pasting” from international guidelines and do not reflect a country specific 
approach to the dilemmas being faced. 
 
E. HIV Vaccine Trials 
 
Most REC members have poor knowledge of the ethics and the science of 
HIV vaccine trials.  Hence the dependence on ”experts” to assist in their 
decision making. 
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F. Informed Consent Process 
 
Very little attention is paid to the informed consent process as such.  This 
aspect of human participant protection is subjugated to an obsession with 
documents with an emphasis on providing indemnity to investigators and 
RECs, rather than participants. 
 
None of the RECs in South Africa make reference to the process or have 
policies to highlight the process in any way.  There is no requirement for tests 
of comprehension. 
 
8.3 Resolution Options to Improve Research Review In South Africa 
 
8.3.1 Eliminating Variability and Achieving Standardisation 
 
Political and institutional redress are necessary to restore institutional inequity. 
South Africa has affirmative action programs and transformational policies in 
place since 1994 in an attempt to achieve equity. Ten years into democracy, it 
is quite apparent that this is a long term process that will be achieved with 
time. From the perspective of RECs in such institutions, however, the 
INHREC has a critical role to play in securing institutional commitment to 
support and improve the ethics review process. 
 
Most RECs in South Africa function in isolation.  It is important that a 
communication network is established amongst the various RECs in South 
Africa. As an interim measure, an electronic national newsletter has been 
established. This will be discussed in further detail later in this chapter as a 
recommendation. The INHREC will play the final role in introducing 
standardization by establishing criteria for all ethics committees in the country. 
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8.3.2 Changes to the Review System 
 
8.3.2.1 Structural Changes Recommended 
 
A. Composition 
 
1. Active attempts must be made to establish diversity in terms of race 
 and gender in REC membership. 
 
2. Where professional diversity is concerned, scientific membership 
 should include a pharmacist and a statistician/epidemiologist as far as 
 is possible. The National Bioethics Advisory Commission (NBAC, 2001) 
 in the United States recommended that non-scientists make up at least 
 25 % of an IRBs membership (National Bioethics Advisory 
 Commission(NBAC), 2001). 
 
The Institute of Medicine (IOM) report recommends that: 
 
 unaffiliated members, non-scientists and those who represent the local 
 community and or the participants’ perspective comprise at least 25% 
 of the membership 
       (Institute of Medicine, 2003: 9) 
 
This is however inadequate.  Combining non-affiliated, non-scientific and 
community members is problematic as each of the three categories of 
membership is already under-represented.  Furthermore, there is overlap 
between non-affiliated membership and the other two categories.  This 
precludes adding them together.  Non- affiliation must be viewed as a 
category that is distinct from professional categories of membership.  Hence 
the NBAC proposal for each category (non-affiliated and non-scientific) to 
represent at least 25 % of REC membership is a good starting point for South 
Africa. 
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3. Community representation of the populations most frequently being 
 researched in that region must be co-opted and trained.  Religious 
 membership, if any, needs to include more than one Christian priest. 
 
4. Non-affiliated or independent members – The National Bioethics 
 Advisory Commission (NBAC, 2001)  has advised that at least 25% of 
 IRB members are independent –that is – come from outside the 
 institution.  This is a good policy to implement in South Africa although 
 we should aspire towards having at least 50% of REC members 
 independent in the long term as the issues surrounding conflicts of 
 interest escalate. 
 
The SAGCP guideline is based on the ICH GCP guideline.  However, ICH 
GCP does not deal with conflict of interest where the REC is concerned.  This 
section has been added on to chapter eight of the SAGCP guideline on ethics 
committees.  The SA GCP guideline specifies that RECs must have clearly 
formulated policies regarding conflicts of interest and that these must be made 
known to all members and to investigators.  It also outlines the range of 
indirect and direct benefits that may place an REC member in a position of 
conflict.  
 
It is essential that such a policy is included in the standard operating 
procedures (SOPs) of all RECS in South Africa. 
 
As a result of the large proportion of scientific and clinical members on RECs 
in South Africa it is inevitable that some members play dual roles of 
investigators and REC members and submit their protocols to their 
institutional REC.  It is standard practice that the member may not contribute 
to the discussion or vote on his/her protocol and this is adhered to on all 
RECs surveyed.  However, the member often sits in on the discussion making 
it uncomfortable for colleagues to be completely honest and forthright about 
deficiencies that may exist in the submission.  It would hence be important to 
implement the policy of having members leave the room for the entire duration 
of the discussion of their protocols. 
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Historically disadvantaged institutions require increased institutional support in 
establishing dedicated REC offices and staffing.  Capacity development is 
also required. 
 
4. All RECs must ensure that all protocols except those that qualify for 
 expedited review are conducted at a full meeting of the committee. 
 
 
B. Review System Structure 
 
The current structure of the review system in South Africa given the current 
membership that is skewed in a scientific direction, could be enhanced in one 
of two ways: 
 
1. At all institutions, separate RECs could be established for clinical trials 
 review and for academic research review.  This model already exists at 
 one institution and works well.  Each REC would then have fewer 
 proposals to review and meeting duration would be significantly 
 reduced thereby increasing the efficiency and quality of the review 
 process.  Faculty members could then be spread across the two RECs 
 with no member sitting on both committees.  Each REC would conduct 
 both scientific and ethics review. 
 
2. Two RECs could be created divided according to medical speciality. 
 Each would then review both academic research and clinical trials 
 research in the specific disciplines.  This would enhance the scientific 
 review of protocols within specific disciplines as expertise would exist 
 on the REC and experience would grow with each specific discipline. 
 Members would also become familiar with clinical trial as well as 
 academic research.  Each REC would conduct scientific and ethics 
 review ( personal communication – Dr L. Horn, REC Manager) 
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Conceptually the issue of ‘scientific’ review and ‘ethics’ review lends a broader 
perspective to the review system structure in South Africa. 
 
All institutional RECs already have a double system of scientific review.  This 
might be a good idea given the scientific complexity of clinical trials.  However, 
if RECs were to be restructured to include more non-scientific members and 
fewer scientific members, a formal scientific review committee distinct from 
the REC might be a good idea.  This structure has been suggested by the 
Institute of Medicine in the United States.  They suggest a three-pronged 
review process of the science, the ethics and conflict of interest.  Scientific 
review could be conducted by a separate committee, a sub-committee or by 
using outside experts.  This would ensure that proposals that have scientific 
deficiencies do not reach the REC.  However, for those that do reach the 
REC, some consideration could still be given to the scientific merit of the study 
as ethical and scientific review are often interdependent.  The saving in time 
for the REC would result from a summary of the scientific adequacy being 
presented to them (Institute of Medicine, 2003: 77). 
 
A dedicated Conflict of interest review process is also suggested which would 
be a very good idea in South Africa given the fact that all institutional RECs 
are dominated by affiliated members. 
 
Further suggestions emerging from the empirical data include allocating 
distinct responsibility to sub-committees of the REC for adverse event reviews 
and monitoring. 
 
Private RECs appear to be conducting all aspects of the review process 
together but could benefit from considerations of restructuring their systems to 
improve the review process.  Given that some private RECs have a larger 
proportion of non-scientific than scientific members, they would benefit more 
from a distinct scientific review. 
 
In South Africa, the INHREC would be the overarching body of both private 
and institutional RECs. 
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Figure 8 outlines a possible structure that the review system in South Africa 
could assume. 
 
Figure 8: Ethics Review System Structure in South Africa 
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These models will be discussed in the REC network in South Africa till 
consensus is reached. 
 
C. Administrative staff 
 
All RECs require adequate administrative staff and achieving this requires 
institutional commitment.  At a minimum, requirements are as follows: 
 
1. an administrative manager 
2. an administrative assistant 
3. a secretary 
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4. a data capturer – if an electronic system is being used. 
 
These staffing requirements must be met at all RECs in South Africa. 
 
D.  Infrastructure 
 
All of the above staff members require office space.  In addition, it is essential 
that adequate space is available for storage of files in keeping with FDA 
requirements such as fire proof, flood resistant storage systems with adequate 
temperature controls.  It is the responsibility of all institutions to provide such 
infrastructure to ensure an efficient ethics review system. 
 
E Training and Development 
 
The Irensa training program sponsored by Fogarty International and located at 
the University of Cape Town offers a Diploma in Research Ethics.  It is an 
excellent program and will in the long term contribute significantly to capacity 
development for ethics review in South Africa.  However, it cannot meet the 
training needs of all members in the country.  As a basic requirement all REC 
members reviewing clinical trials must attend a Good Clinical Practice (GCP) 
Training course.  This in itself is insufficient, so on-going training programs 
must be attended.  Some tertiary educational institutions in South Africa have 
established Bioethics units or departments.  Each of these departments 
should have a mandate, and be provided with institutional support, to develop 
training programs tailored to meet the educational needs of REC members.  
 
F. INHREC 
 
This committee will become a statutory body in South Africa when the 
National Health Act is enforced later this year.  It will play a crucial role in 
standardising the ethics review system in the country, in accreditation of 
RECs and in establishing curricula to meet the educational needs of REC 
members.  However, it also has a crucial role to play in achieving equity 
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amongst institutions before implementing its accreditation criteria and prior to 
categorising RECs into level one and level two RECS.  
 
G. Remuneration of REC members 
 
A national policy must be established to ensure that all REC members are 
remunerated for their work.  This is essential as most REC members conduct 
protocol reviews outside of their working hours.  A fee should be established 
per meeting attended rather than per protocol reviewed.  This fee can be 
extracted from the protocol review fee that is charged by most RECS. 
 
8.3.2.2 Resolution Options for the Review Process 
 
A. Delayed Review 
 
The review process could be improved by: 
 
• Separating the review of clinical trials and academic research 
• Separating the scientific review from the ethics review. 
• Increasing administrative staff 
• Appointing a REC manager 
• Employing an electronic data capture system 
• Formulating clear policies to investigators so that complete 
applications are received in full and on time 
• Allocating each protocol to two or three reviewers for detailed review 
and providing summaries to other members 
• Allocating protocols to reviewers at least two-three weeks before the 
scheduled meeting 
• Sending the committee’s response to investigators electronically rather 
than via the postal system 
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B. Informed Consent Forms 
 
If RECs want more comprehensive forms they need to be aware of the 
possibility of complicating the form.  In addition readability should be improved 
rather than worsened.  This can be attempted by objectively using a well 
established readability score. In addition, community representatives on the 
REC can double check the form for ease of understanding.  There are also 
other issues that improve readability such as font size, use of bullets and 
spacing and emphasis of important issues.  These need to be considered. 
 
It is hence important that the most readable version of the patient information 
leaflet is translated, that the translation is checked by REC members familiar 
with the language and that a summary of the translated version is given to the 
participant.  
 
C. Adverse Event Reporting 
 
The definition of a serious adverse event must be revisited to include 
hospitalizations related to investigational products or trials procedures only. 
 
The gross inefficiency in the system of adverse event reporting results in the 
concern for safety of human participants being lost in excessive paper trials. 
The monitoring of safety would be much better served by a data and safety 
monitoring board with biannual reports only to the REC.  All multisite and 
international site adverse events should be submitted to a subcommittee of 
the NHREC where this function is fulfilled by dedicated staff.  Here too, only 
related adverse events must be submitted. 
 
D. Monitoring 
 
All RECs must make provision for monitoring.  Resources are better spent on 
monitoring than adverse event reporting systems.  While it is not possible to 
monitor all research approved by the REC, a small percentage of trials can be 
monitored at random and high risk studies can be routinely monitored. 
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In view of recent deaths of research participants and the current climate of 
litigation in research, it is essential that all RECs, in developing and developed 
countries alike, employ a more vigilant system of review of “high risk” 
protocols. 
Levine et al suggest a system of “special scrutiny” of high risk protocols using 
the following criteria: 
 
1. Where research involves translating new scientific advances to studies 
 in humans, especially when the intervention is novel, irreversible or 
 both. 
2 Where there is known or credible risk for significant harm 
3 Where the protocol raises ethical questions about research design or 
 implementation for which there is no consensus or there are conflicting 
 or ambiguous guidelines. 
 
8.3.2.3 Resolution Options to Improve Deliberation on   
  Substantive Issues in the Review of Human  Participant  
Research in South Africa 
 
A. Standard of Care 
 
Clear policy must be established regarding the standard of care in South 
Africa.  Most RECs are adhering to the best available in South Africa.  This 
can easily be justified as follows; 
 
An international standard of care enshrined in the international guidelines on 
research ethics would only be possible to implement if research were clearly 
separated from treatment and regarded as a separate entity.  As such 
international guidelines and principles would be applied to these research 
sites wherever in the world these existed.  It would then also be necessary to 
implement article 30 of the Declaration of Helsinki – provision of the most 
effective medication identified by the study to the participants after the trial.  
This would mean that research, irrespective of where in the world it is 
conducted would be generalizable to developed world settings.  This could 
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potentially lead to exploitation of developing world communities (where the 
drug would not be affordable for widespread use) for the benefit of developed 
countries. 
 
Implementing a local standard of care as comparator would result in locally 
relevant research.  Such research would provide answers to research 
questions relevant to developing world medicine such as the development of 
more cost-effective regimens. 
 
By moving away from the concept of best available to highest attainable 
standard in the public health sector we are clarifying the issues further. 
 
B. Post-Trial Treatment 
 
The Declaration of Helsinki has to date focused on provision of effective 
treatment discovered during the conduct of the trial to participants after the 
trial.  A broader conceptualization of the specification of the declaration could 
include provision of post-trial benefits rather than post-trial treatment.  This 
could include infrastructure, capacity development, equipment or treatment, 
whichever is the most practical to achieve. 
 
C. Remuneration 
 
All benefits to participation in clinical trials must be considered.  The payment 
of R50 per visit for regular trials is acceptable.  Where great distances must 
be traveled to the trial site, payment should be calculated on a case-by-case 
basis. Payments for illness visits must be carefully considered as these can 
impact on the scientific validity of studies. Participant remuneration can be 
balanced against post-trial benefits. As post-trial benefits increase, participant 
remuneration can be reduced but not below a threshold level that is necessary 
to reimburse participants for all expenses incurred as a direct result of their 
participation in the trial. 
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D. Research Ethics Guidelines 
 
There is a need for the research endeavour to be contextualised and for 
ethical decision-making to expand beyond didactic regulations and vague 
guidelines.  It is highly desirable that a different approach using context, 
particularity and scepticism needs to be embraced incorporating an ethics of 
responsibility on the part of researchers and REC members alike. 
 
Developing countries need to develop a voice to impact on international 
guidelines or develop local guidelines that override international guidelines 
with a Western paradigm.  The developing world must be encouraged to 
contribute to ethical discourse with a focus on locally relevant and responsive 
questions, taking into account indigenous knowledge systems and cultural 
influences on the ethics of collaborative research.  Different concepts of 
personhood need to be incorporated into the deliberation of ethical issues in 
developing communities but communities themselves must be given agency 
to participate in, contextualise and enhance the local review process.  It is 
highly desirable that such initiatives are informed by empirical and conceptual 
research into the wide range of ethical issues in human research in South 
Africa. 
 
South Africa needs to develop one guideline that is contextualized to our 
needs as a developing country and should be used by all RECs in the country. 
This will ensure uniformity of review.  The current SA GCP guideline is 
currently being modified.  This process must be thorough so that one 
comprehensive guideline exists. 
 
Finally it must be appreciated that guidelines are important but require 
interpretation and should be viewed as aspirational documents rather than 
rules that are rigidly implemented in the absence of ethical reflection and 
argumentation 
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E. Review of HIV Vaccine Trials 
 
It is imperative that all RECs in South Africa are exposed to a workshop that 
provides an update on both the science and the ethics of HIV vaccine 
research.  This will empower all RECs to review protocols.  It is important that 
the training reaches all RECs especially historically disadvantaged institutions 
as these institutions are located in areas of high HIV prevalence which are 
captive sites for phase three HIV vaccine trials. 
 
In South Africa, the challenge of HIV vaccine trials has prompted “special 
scrutiny”. 
 
The complexities involved in HIV vaccine research require a thorough and 
novel informed consent process which must be documented in the protocol. 
An appropriate test of comprehension should be conducted after the 
information giving but before authorization by participants.  In addition, the 
informed consent process should be monitored by ethics committees who 
approve the protocol. 
 
The recent experience of large phase three HIV vaccine trials in Thailand and 
the United States has highlighted the issue of placing large numbers of 
volunteers at risk of receiving an inefficient vaccine and precluding their 
participation in future trials of a more effective vaccine. 
 
F. Informed Consent Process 
 
Having fulfilled the legal requirements for the informed consent documents, it 
is essential that the ethical requirements of the informed consent process are 
fulfilled.  These include more attention to the process rather than the forms. 
Investigators need to document the process that will be followed.  It must be 
clarified when the detailed document will be made available to the participant 
to enable the participant to take the document home and read it at his or her 
leisure, allowing the involvement of family members in communities where 
family and spousal consent are culturally relevant.  Sponsors should therefore 
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be encouraged to have the patient information leaflets available at the trial site 
at least two weeks before enrolment.  Summaries should be given to 
participants initially followed by the comprehensive form.  There should be 
documentation of other modalities that will be used to convey the trial 
information such as videos or flip-charts or models. A formal test of 
comprehension should be an essential part of the process and should occur 
prior to enrolment.  Finally, empirical research in to the consent process 
needs to be encouraged in South Africa where a paucity of data exists. 
 
8.4 Summary of Major Recommendations 
 
8.4.1 National Association of Local RECs 
 
It is strongly recommended that a National Association of RECs is constituted 
as a matter of urgency in South Africa.  The mission of such an association 
should include the achievement of standardization of the ethics review 
process in South Africa to eliminate the wide range of variability that currently 
exists.  The association should have its own standard operating procedures 
and should meet at least annually, preferably six monthly.  One of its main 
functions should be aimed at achieving national consensus on the range of 
substantive research ethics issues relating to initial and continuing protocol 
review.  It should also work towards achieving equity of all RECs in the 
country. 
 
8.4.2 National Newsletter 
 
Eliminating inconsistency in the review system in South Africa requires a 
national effort to form a communication network between geographically 
distant RECs.  At most, local REC chairpersons will be able to meet annually. 
In the interim, a communication network is required to facilitate deliberation 
amongst the various REC members on a regular basis. 
 
In this way, REC members can be encouraged to discuss and debate the 
challenges facing them.  In an attempt to initiate this process, the chairperson 
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of the INHREC was approached to obtain support for the initiative.  
Thereafter, all chairpersons of the major RECs were contacted electronically 
and their support for the project was secured.  In May 2004 the South African 
Research Ethics Committee (SAREC) Newsletter was launched.  This is an 
electronic newsletter circulated on a quarterly basis to all REC members 
reviewing clinical trials in South Africa. 
 
8.4.3 National Health Research Ethics Council (NHREC) 
 
As soon as this body becomes a statutory entity in South Africa it will play a 
critical role in accreditation of local RECs.  In addition it has an important role 
to play in promoting educational and training activities.  Being directly 
associated with the Ministry of Health, it is also in a position to lobby for equity 
for all institutional RECs.  In addition, there is a potential role in reviewing 
multicentre research and in safety monitoring. 
 
8.4.4 National Research Ethics Guideline 
 
South Africa desperately needs to commence a process of synthesis where 
the various guidelines are concerned.  A single national guideline should be 
developed and implemented nationally.  
 
8.4.5 Research Ethics Training and Development 
 
There is an urgent need for widespread training of REC members, 
investigators and research participants.  Curricula must be specified and 
training programs must be accredited.  South Africa is fortunate to have two 
good programs fro research ethics training.  However, investigator training, 
requires a great deal of attention.  A wide range of GCP training courses are 
available in South Africa.  None of these have been accredited and a lack of 
standardization of training requirements exists.  Curricula reform and 
standardisation of training requirements must be specified. 
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8.4.6 Participant Advocacy 
 
While RECs are charged with the responsibility of protecting research 
participants, it is being argued that agency of individuals, groups and 
communities needs to be recognized and strengthened.  Expanding REC 
membership to include participants drawn from vulnerable communities is 
important and deserves serious attention in South Africa.  The development of 
education programs in research for participants is also important. 
 
8.4.7 Research Ethics Review System 
 
RECs should decide on adopting one of two options for an effective review 
process: 
 
i. If dual review of the science and the ethics of protocols is to continue, 
 the scientific membership of RECs must be strengthened.  This will 
 require a pharmacologist and a statistician on every REC.  Additionally 
 a person skilled in literature review is essential 
 
ii. If splitting the scientific and ethics review is to be considered, a distinct 
 process must be set up for scientific and statistical review.  Only 
 protocols that have passed scientific review will be sent to the REC 
 with a summary of the scientific review.  
 
 
8.5 Commentary 
 
This chapter reflects the major challenges facing the REC system in South 
Africa at the time of the survey. These challenges have been identified 
collectively from both the quantitative and qualitative research undertaken. 
The quantitative survey discussed in chapter six highlighted a number of 
inequities amongst RECs in South Africa at a national level. The qualitative 
interviews discussed in chapter seven illustrate the ethical challenges faced 
by RECs in South Africa as a result of global inequities in health care. 
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At a national level, the deficiencies outlined are extensive and have been 
addressed to different extents according to the magnitude of the problem. The 
main problems, however, relate to variability in structure and function of 
RECs. This variability is a function of the inequities in higher education which 
is a legacy of the apartheid system in South Africa. Institutional RECs at 
historically disadvantaged institutions are significantly under resourced 
compared to RECs at historically advantaged institutions. This impacts on 
training and capacity development of REC members and investigators. This, 
in turn, impacts on the amount of contract research that is conducted and 
reviewed at these institutions. Such inequities must be addressed at a political 
and institutional level with the implementation of redress procedures to 
alleviate the imbalances. 
 
At a national level, another major deficiency relates to the lack of 
communication between RECs and a lack of standardization and consensus 
on a variety of issues. Such a situation exposes vulnerabilities in the REC 
system and lends itself to “REC shopping”. This in turn compromises human 
participant protection. A number of national initiatives have been described to 
achieve standardization. 
 
At an international level, inequity in health care services exists between 
developed and developing countries. This impacts on multinational research 
between well resourced sponsor countries and resource depleted host 
countries. The qualitative research component has reflected the complex of 
substantive challenges encountered in research ethics in South Africa largely 
as a result of health care inequities. This is indicative of the interdependence 
of health care and health research as complimentary public goods. Most 
international research ethics guidelines draw a distinction between health care 
and research. The only guideline that relates research and health care as a 
“morally praiseworthy” endeavour, is the CIOMS guideline and this has been 
discussed at length in the context of HIV vaccine research.  
Responsibility of researchers with respect to health care provision ranges 
from no responsibility to partial responsibility. The National Institutes of Health 
is a perfect example of the former option. This institution provides funding for 
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research expenses only. Even compensation for trial related injury is not 
included. Treatment issues fall squarely outside the domain of the research 
project. On the other hand, some sponsors demonstrate partial treatment 
obligations. This includes some oncology and HIV related research where 
compassionate treatment is provided beyond the scope of the trial. 
It is evident that the interdependent relationship between research and health 
care is being ignored. To do so creates ethical challenges to developing 
countries that remain perpetually unresolved. It is thus essential to revisit this 
concept in an international forum. 
 
Ultimately, if the national and international challenges described are 
addressed and REC function is raised to an acceptable and efficient level in 
South Africa, will this guarantee human participant protection? The next 
chapter examines the role played by investigators in the review process and 
their contribution to participant protection.  
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Chapter 9  
 
Participant Protection – Who’s 
Responsibility? 
 
 
 
9.1. Introduction 
 
If the assumption is made that an efficient ethical review system can be 
established, is this adequate to afford human participants protection?  The 
Bezwoda case study has shown us that even in the presence of robust ethical 
review, participant protection can be compromised by individual researchers 
who evade the system of ethical review or by researchers who deviate from 
protocols that have already been approved by RECs.  What went wrong in the 
Bezwoda case?  Did the REC fail to protect the participants or did the 
investigator do so? 
 
9.2. The Bezwoda Case (Weiss, 2000: 999-1003) 
 
Werner Bezwoda was professor of Haematology and Oncology at the 
University of Witwatersrand since 1992.  In 1995 he announced that high-
dose chemotherapy with bone-marrow transplantation increased survival in 
patients with metastatic breast cancer.  In May 1999, he presented the results 
of a second trial on high dose therapy at the American Society of Oncology 
meeting.  Again he concluded that women receiving high dose treatment had 
longer survival rates than women on normal dose therapy.  Four other papers 
presented at that conference by other scientists failed to show a benefit. 
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A team approved by the United States (US) National Cancer Institute visited 
South Africa in 2000 to audit Bezwoda’s results in preparation for the conduct 
of large-scale confirmatory trials in the United States (Farham, 2000: 553). 
Findings: 
 
1. Bezwoda presented data on 154 patients at the conference – only 151 
 patients were listed in the enrolment register.  Records for 58 patients 
 were produced. 
2. There were discrepancies in eligibility of patients including age, tumour 
 category and number of axillary nodes involved.  Only 20 of the 58 
 patients met eligibility criteria. 
3. The presentation indicated that 36% of the study population were white 
 women. Only 7% were actually white.  The majority of patients were 
 black women. 
4. There were discrepancies in dosages of drugs used.  Patients in the 
 control group had not been given the treatment specified in the 
 presentation. 
5. Deaths in the high dose treatment group were under stated. 
 
As a result of the above findings, the study was invalidated (Weiss, 2000: 999-
1003). 
 
On 31 January 2000, Peter Cleaton Jones – Chairperson of the REC at Wits, 
received a letter from Bezwoda in which he acknowledged scientific 
misconduct. 
 
In a letter to the president of the American Society of Clinical Oncologists on 4 
February 2000, Peter Cleaton-Jones indicated that: 
 
 …there have been serious ethical violations as well as misconduct 
 and…the study is discredited and must not be used as a basis for 
 further trials. 
        (Farham, 2000: 553) 
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Bezwoda claimed that he had not submitted his protocol to the REC at Wits as 
he regarded the study as being retrospective. 
 
9.3. The Poisson Case Study (Weijer, 1995: 1973-1980) 
 
Like Bezwoda, Dr Possion was also involved in a breast cancer study at St 
Luc Hospital, Montreal, Canada between 1977 and 1990.  This was the 
largest and most prestigious breast cancer study in the world where two 
different modalities of therapy were being compared – radical mastectomy as 
opposed to lumpectomy.  Due to the dilemma created in patients by the offer 
of radical mastectomy, recruitment was slow.  His site, however, recruited 
19% of all patients on the study.  As a result, attention was drawn to his site. A 
number of violations were detected at his site.  These included falsifying data, 
pressurising patients to participate, subjecting patients to unnecessary risk by 
placing them on cardiotoxic chemotherapy regimens even though he was 
aware of pre-existing cardiac disease in these patients.  He had falsified data 
on 99 of the 1511 patients he had enrolled at his site.  After results of this 
study were published in an international journal, all sites had to be re-audited 
and results re-published excluding his results.  Fortunately, this did not impact 
on the overall results of the study. 
 
Commentary on Bezwoda and Poisson 
 
While these appear to be two isolated cases of research fraud, the extent of 
harm caused has far reaching consequences.  Firstly there is the actual 
maleficence exhibited towards patients directly involved in the trial.  In the 
second place, there is a level of maleficence towards potential patients who 
would have been recruited into larger trials to confirm Bezwoda’s initial 
findings.  In both the Poisson and Bezwoda cases, data presented was initially 
included in the body of knowledge used by other clinicians, surgeons and 
oncologists in the choosing a treatment modality for cancer patients based on 
evidence based medicine principles.  Both studies had been published in 
international journals. 
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Furthermore, the erosion in public trust caused by these two events is 
immeasurable.  One of the major reasons patients participate in research is 
based on the relationship of trust between doctor and patient.  Commenting 
on this a gynaecologist based in Kenya had the following to say: 
 
 I would like to emphasize that most patients consent to nearly anything 
 if asked by a trusted authority – in this case a medical person who is 
 supposed to know what is best for the patient. 
      (Temmerman, 1992: 1102). 
 
 
Researchers are under enormous pressure to conduct research and produce 
results.  Often, their careers are linked to grants which depend on an ability to 
convince a sufficiently large number of participants to enroll in research 
projects.  There is also a need to publish in order apply for promotion and 
apply for continued financial support.  Research, as such, is conducted not 
only to produce generalizable knowledge but also to earn a salary and career 
advancement.  It is therefore not surprising when researchers look for “short 
cuts to attractive answers” and this clouds the investigator’s judgement about 
what is and is not appropriate What both these cases demonstrate is that in 
the absence of researcher integrity and trustworthiness, even well functioning 
RECs cannot protect participants.  In the absence of RECs, the individual 
researcher and his or her integrity remains a crucial factor. (Altman, 1985:21). 
 
It is claimed that “the primary virtue in health care is integrity” (Beauchamp, 
2001: 35). Moral integrity entails living and acting in accordance with moral 
and ethical norms. The central element of this virtue is the consistent 
application of a set of values. Integrity demands a willingness to make 
sacrifices in order to defend these values. Integrity demands the 
acknowledgement that there are more important goals and values than the 
promotion of self interest (Gilligan 1997: 6-14). It is evident that both 
investigators had not established a certain moral threshold beyond which they 
were not willing to compromise their values and principles.  Both cases 
demonstrate a serious lack of integrity. 
  231 
 
Prior to 1966, each individual investigator bore responsibility for protecting the 
rights of human subjects participating in research (Taub, 1986: 7).  The 
advent of RECs from 1966 onwards transferred a greater share of this 
responsibility from individual investigators to the committees.  Responsibility 
shifted from a virtue based system of protection to a principle based system of 
REC protection. As early as 1969, Jonas described the researcher as “an 
interested party (with vested interests, indeed, not purely in the public good, 
but in the scientific enterprise as such, in “his” project, and even in his career)” 
and this makes him also “suspect”.  This precarious and conflicted position of 
the researcher “calls for particular controls by the research community and by 
public authority” (Jonas, 1969: 120).  Such controls generally mitigate the 
problem but do not eliminate the problem completely. 
 
 
Research fraud has highlighted the importance of a return to virtue ethics in 
addition to a principle based review system.  Most guidelines have 
emphasized medical and scientific training of investigators.  Very little mention 
has been made regarding researcher integrity: 
 
 The experiment should be conducted only by scientifically qualified 
 persons.  The highest degree of skill and care should be required 
 through all stages of the experiment of those who conduct or engage in 
 the experiment. 
       (The Nuremberg Code, 1996) 
 
The Declaration of Helsinki (2000) 
 
 Medical research involving human subjects should be conducted only 
 by scientifically qualified persons and under the supervision of a 
 clinically competent medical person.  The responsibility for the human 
 subject must always rest with a medically qualified person and never 
 rest on the subject of the research, even though the subject has given 
 his or her consent… 
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      (World Medical Association, 2000) 
 
Council for International Organisations of Medical Sciences 
 
 The responsible investigator is appropriately qualified and experience, 
 and commands facilities to ensure that all aspects of the work will be 
 undertaken with due discretion and precaution to protect the safety of 
 the subjects. 
        (CIOMS, 1993) 
 
ICH GCP: 
 
 Each individual involved in conducting a trial should be qualified by 
 education, training and experience to perform his or her respective 
 tasks 
   (International Conference on Harmonisation Good Clinical 
   Practice: Consolidated Guideline, 1997) 
 
The earlier guidelines (Nuremberg and Helsinki) stress scientific qualifications 
of the investigator. CIOMS alludes to participant protection in addition.  ICH-
GCP specifies that the research team should be trained, not just the 
investigator and GCP encompasses both scientific training and the ethical 
issues inherent in participant protection. 
 
In South Africa, the regulatory agency, The Medicines Control Council has 
declared GCP training compulsory for all clinical investigators. 
 
Conventional GCP courses focus on rules and procedures.  This is 
inadequate to foster a commitment to the conduct of ethical research.  
Attention must be focused on GCP curricula in South Africa to complement 
rule based teaching with a strong research ethics component including the 
importance of scientific integrity. 
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Commentators in current literature are highlighting the importance of 
investigator responsibility.  Hence both an ethics of responsibility and virtue 
ethics needs to be revisited where investigators are concerned.  A return to 
the practice of self-experimentation might also encourage a higher level of 
investigator responsibility and a deeper level of commitment to participant 
protection in the conduct of clinical trials. 
 
 It is not enough to ask society for unquestioning trust, nor can it be 
 assumed that scientists are different from other human beings and 
 totally incapable of error, deceit, misrepresentation or bias. The 
 scientific community must be vigilant for this, since nothing less that the 
 viability of the biomedical enterprise is at stake. 
 
   (Schwarz R.P.Quoted in Weijer et al, 1995: 1979) 
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Chapter 10 
 
Conclusion 
 
The recent crisis described in research ethics review systems in the United 
States have dominated the literature since 1996.  This must be seen in the 
context of an extensive review system currently in existence in the United 
States, which has approximately 4000 to 6000 IRBs all operating at a local 
level. 
 
While many similar concerns are shared in South Africa, the scope of the 
problem is distinctly different.  At present we have approximately 20 RECs in 
total, some of whom are currently undergoing mergers as a result of 
institutional changes as part of a rationalization process in higher education in 
the country.  In many respects, there is no sense of crisis where ethics review 
is concerned in South Africa.  There are extensive deficiencies in the system, 
but they are more contained and can be addressed. 
 
RECs in South Africa, in common with their equivalents globally, are 
overwhelmed with administrative duties, bureaucratic procedures and 
paperwork.  This impacts negatively on their ability to engage in the 
substantive ethical issues underlying human participant research.  It is hence 
imperative that all procedural functions that do not adequately contribute to 
participant protection are rationalized. 
 
While some problems encountered in South Africa are similar to those 
challenging developed countries, there are problems that are unique to 
developing countries. This is related to the complex of reasons that motivate 
the conduct of research in a developing country as compared to a developed 
country.  A host of questionable reasons are forwarded for conducting 
research in Africa: 
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 Lower costs, lower risks of litigation, less stringent ethical review, the 
 availability of populations prepared to co-operate with almost any study 
 that appears curative in nature, anticipated under-reporting of side-
 effects because of low consumer awareness, the desire for personal 
 advancement, and the desire to create new markets for pharmaceutical 
 agent and other products 
                    (quoted in Ijsselmuiden, 1992: 833) 
 
While all multinational research is not underscored by such motivations, it 
remains an important priority to establish a robust ethical review system to 
ensure the protection of vulnerable communities.   
 
In establishing a robust ethical review system, a number of national and 
international factors have been identified. At a national level, equity must be 
established amongst the various institutions. In addition, standardization must 
be achieved via a national association and a national communication network. 
Given the current REC membership in terms of professional representation 
and the growing demands in terms of scientific review, the ethics review 
system as a whole must be revisited. As the non-scientific and community 
representation increases, it will become necessary to consider adopting a 
distinct scientific review process that is not repeated at the level of the ethics 
committee. Distinct scientific review that precedes ethics committee review is 
being promoted as an important new trend in the review of research abroad. A 
similar measure in South Africa will represent a major paradigm shift for ethics 
review locally, and will be met with enormous resistance. In the long term, 
however, it may be a necessary and serious consideration for South Africa. 
 
South Africa is home to millions of vulnerable communities – so termed for 
socio-economic reasons but also as a result of educational disadvantage.  
As a result, RECs are overly but perhaps unavoidably concerned with 
informed consent at the peril of other important components of the review 
process like the relevance of the research, scientific validity and the risk-
benefit ratio, inter alia. Informed consent documentation as well as the 
informed consent process must be considerably amended to accommodate 
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the special needs of participants in developing countries. At the same time, 
more emphasis must be placed on reviewing research projects submitted to 
RECs in the context of research priorities that exist in South Africa. 
 
The interview data in this study clearly shows that RECs in South Africa are 
operating from a position of compromise in conducting their function of 
research participant protection.  They have one of two options at present – 
maintain a position of compromise and retain the research industry in the 
country or set stricter criteria for sponsors and the pharmaceutical industry 
who wish to conduct research in South Africa and risk losing research 
projects.  Given the global inequities in health care, research in a developing 
country must of necessity be viewed as a means to reducing such inequities.  
It has been established by the 10/90 report that only 10% of all available 
research funding is spent on 90% of the world’s burden of disease – most of 
which exists in developing countries.  The implication of this data means that 
a significant proportion of research that is conducted in South Africa and other 
developing countries is intended to benefit populations in developed 
countries.  How then can the principle of justice be fulfilled – how do the 
populations who bear the burdens and risks of research benefit from such 
research?  It can be argued that the concept of post-trial benefit presents a 
unique and valid opportunity to increase the benefits to populations being 
researched. Improvements in infrastructure secured in this way will contribute 
to improved health care for communities and for other research projects. 
 
At an international level, a new conceptual framework must be created to 
incorporate research and health care in a complimentary and interdependent 
relationship. Such a paradigm shift would place obligations on sponsors and 
researchers to contribute to health care in developing countries in imaginative 
ways.  Such contributions will not only elevate standards of primary health 
care in developing countries, they will also create robust referral systems for 
co-morbid and non-related illness arising in a wide spectrum of research 
conducted in developing countries. This will result in standards in health care 
and research progressively and consistently being raised. A paradigm shift of 
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this nature will be difficult to accomplish at a global level but remains a strong 
recommendation of this study. 
 
Much has been written about the disparities in health care between the 
developed north and the developing south. One way of narrowing this gap 
involves inculcating a culture of global interdependence.  This in itself is, 
however, insufficient as such a culture must evolve in tandem with institutional 
and governmental commitment to improving health care and research 
participant protection.   
 
It is imperative that the ethics review system in South Africa is strengthened 
and empowered to negotiate with sponsors from a position of strength.  
Restructuring of REC membership composition to reflect the real diversity of 
South African society generally, but particularly in respect of representation of 
research participant communities themselves, must be addressed urgently. 
 
While uncertainty has been raised regarding the effectiveness of RECs in 
protecting participants’ rights as a result of recent research related deaths, 
this must be viewed in context.  Ethics committee review, in spite of all its 
challenges and weaknesses, does protect subjects and promotes ethical 
research in the vast majority of cases.  The occasional disasters are not 
wholly the fault of RECs but rather a combination of factors including 
investigator responsibility and culpability.  This has been borne out in the 
interrogation of the deaths of Nicole Wan, Jesse Gelsinger and Ellen Roche.  
Protection of participants cannot be delegated to the REC alone.  It is a 
combined effort of all members of the research team that results in such 
participant protection. Hence the training and educational efforts must include 
REC members, members of the research team and participants. 
 
In 1969 Jonas referred to the “gratuitous” nature of the research endeavour 
that makes it imperative to grant the greatest respect, freedom and protection 
to human participants.  Now, in the 21st century, we are being reminded that 
“Conducting research with human participants is a privilege granted by willing 
volunteers” (Institute of Medicine, 2003: 44).  Al members of the research 
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team must be made acutely aware of this and protection of human 
participants must be built into every step of the research process. 
 
There are widespread challenges to ethical review in South Africa but these 
challenges are not insurmountable.  REC function in South Africa can 
certainly be enhanced.  The recommendations outlined in this dissertation as 
well as the endeavours launched as a result of the empirical work in this 
dissertation are an attempt to do just that.  The combined efforts of the various 
training programs in the country, the INHREC, the electronic communication 
system and the annual meeting of REC Chairs are positive and hopeful 
attempts at reconstruction and growth. 
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ADDENDUM: 
 
1. Interview Guide 
 
2. Questionnaire 
 
3. Table 1 : Composition of Major RECS in SA (race & gender) 
 
4. Table 2 : REC membership – vocation 
 
5. Table 3 : Review Procedures of RECs in SA, 2003 
  II 
INTERVIEW GUIDE: 
 
 
An outline of themes to be covered: The themes for the semi-structured 
interview to be held with the chairperson of each committee are as follows: 
 
1. How long have you served on the REC? 
 How long have you been chair/Vice-chair? 
 
2. What has been your major challenge as chair of your ethics 
committee? 
 
3. Are you satisfied with the constitution of your committee - 
gender/race/multidisciplinary nature/lay or community representation? 
 Depending on the response - this can be elaborated with special focus 
 on lay  representation on RECs in SA. 
 How do you deal with situations where a conflict of interest arises with 
 one of your ethics committee members ? 
 
4. Informed consent – what do you think about the length of documents? 
Are translations into ethnic languages appropriate? Is there expertise 
on the REC to evaluate ethnic translations? Do you have a system in 
place to objectively assess readability of informed consent forms? Do 
you request a summary of the informed consent form or an outline of 
the process of IC? 
 Who should take informed consent – dependent relationship of 
 investigator? 
 Is there a template available for the Patient Information Leaflet? 
 
5. Remuneration 
 - food/transport 
- time off work 
- amount 
- gifts 
  III 
6. Is there special emphasis placed on the justification of placebo 
 controlled trials? 
 What is the policy of the REC? 
 Is the DOH reasonable/too idealistic in this regard?  
 Which version of DOH is used 1996 or 2000? 
 Do you think the DOH is applicable in SA? 
 
 When equivalence trials are planned, is there expertise on the 
 committee e.g. a statistician to ensure that sample size is adequate? 
 
7. Are there specific requirements for investigators to make provision for 
treatment for participants after the trial? Should this be an integral part 
of the protocol? Do you think that such provision of post trial treatment 
would make the risk-benefit ratio more acceptable to patients? Or will 
research participants be unduly favoured especially in SA where there 
is no treatment in the public sector for HIV/AIDS, for example? 
 
8. Do you think that a 2 tier system of ethical review would be a good idea 
- scientific review by an expert panel of scientists, statisticians etc and 
ethical review of scientifically valid protocols by a multidisciplinary team 
of people including community representatives? 
 
9. Would you like to audit research after studies have been approved by 
the REC? If no, what are the obstacles to the audit process? 
 
10. What opportunities are there for training and development of REC 
members in ethical review of research? What would you like to see in 
this regard? 
 
11. Do you specify GCP training for investigators? 
 
12. Does your REC have a policy in place to handle submissions re HIV 
Vaccine Trials? 
 
  IV 
13. When dual review of protocols is required, do local committees feel 
pressurised to accept projects that have already been approved abroad 
or by developed countries? 
 
14. How do you see the NHREC functioning in SA? 
 
15. Adverse Event Reporting 
- Whose responsibility – sponsor (SAGCP) or investigator. 
- system of reporting 
 
16. Which ethical guidelines do your ethics committee abide by and 
advocate – SAGCP,  ICH-GCP,  DOH,  MRC, CIOMS ? 
  V 
QUESTIONNAIRE: 
 
 
 
A.   DEMOGRAPHIC INFORMATION: 
 
1. 
INSTITUTION:_________________________________________________ 
 
2. NAME OF COMMITTEE: _______________________________________ 
3. NAME OF CHAIRPERSON: _____________________________________ 
4. DATE OF ESTABLISHMENT: ___________________________________ 
 
B.  COMPOSITION: 
 
1.  NUMBER OF MEMBERS:  _____________________________________ 
 
2.  GENDER: 
     MALE____________________FEMALE___________________________ 
 
3. RACIAL REPRESENTATION:   
 
    BLACK__________________ WHITE_____________________________ 
 
4.  MEMBER PROFILES: 
 
  SCIENTIST:___________________________________________________ 
  CLINICIAN:___________________________________________________ 
  STATISTICIAN/EPIDEMIOLOGIST:________________________________ 
  NURSING REP________________________________________________ 
  PHARMACOLOGIST____________________________________________ 
  LAWYER_____________________________________________________ 
  ETHICIST____________________________________________________ 
  COMMUNITY REP_____________________________________________ 
  MEMBER INDEPENDENT OF INSTITUTION________________________ 
 
5.  HOW ARE MEMBERS APPOINTED?_ 
      consensus______majority vote_______direct appointment____________ 
 
6.  HOW LONG DO THEY SERVE ON THE COMMITTEE? ______________ 
 
7.  ARE THERE DISQUALIFICATION PROCEDURES?__________________ 
 
8.  WHAT IS THE RESIGNATION PROCEDURE? _____________________ 
 
9.  ARE MEMBERS REMUNERATED? _____________________________ 
 
 
 
 
  VI 
D.   OPERATING PROCEDURES: 
 
1.  MEETING FREQUENCY: ______________________________________ 
 
2.  QUORUM: _________________________________________________ 
 
3.  DO ALL MEMBERS RECEIVE PROTOCOL DOCUMENTS?___________ 
 
4.  ARE STANDARDISED APPLICATION FORMS USED?_______________ 
 
5.  IS EACH PROTOCOL DISCUSSED AT THE MEETING?______________ 
 
6.  IS AGREEMENT REACHED BY CONSENSUS OR VOTING?__________ 
 
7.  NUMBER OF PROTOCOLS REVIEWED PER MEETING: ____________ 
 
 NEW PROTOCOLS  _____________ 
 
 AMENDMENTS  _____________ 
 
8.  ANNUAL WORKLOAD – 2002: 
       protocols received =   
       number reviewed =    
       number accepted =    
       number accepted with suggestions for amendment =     
       number rejected =   
 
9. TIME DELAYS: 
    -submission = ______________  to approval = ______________________ 
 
10. CHARGE PER REVIEW OF PROTOCOL__________________________ 
 
 
D. INFRASTRUCTURE 
 
1.  ARE SPECIFIC OFFICES AVAILABLE FOR RECORD-KEEPING &  
     MEETINGS? ________________________________________________ 
 
2.  IS SUPPORT STAFF EMPLOYED FOR ADMINISTRATION?__________ 
 
E.  TRAINING & DEVELOPMENT 
 
1.  How many members have received training in research ethics?_________ 
 
2.  Is funding available to train existing and new REC members?___________ 
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Table 1. Description of Research Ethics Committees in South Africa, 2003 
 
 
 
 Committee number 1 2 3 4 5 6 7 8 9 10 11 12 
Institutional (I) or Private (P) P P P I I I I I I I I I 
Total number of members 7 8 11 29 13 11 12 27 20 16 19 11 
Percent of male members  57 50 64 59 46 82 75 63 65 75 63 55 
Percent of white members  86 50 64 76 54 82 42 85 40 75 84 10 
Percent of members trained in 
research ethics 86 50 27 100 38 18 0 100 50 79 26 18 
Number of independent members 7 1 6 3 13 1 0 2 2 3 2 0 
Duration of committee membership   
(in years; U: unlimited duration)  (U) (U) 3 (U) 5 3 3 3 2 2 (U) (U) 
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Table 2. Professional composition of Research Ethics Committees in South Africa, 2003 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note that percentages may sum to slightly more or less than 100 due to rounding. 
Committee number 1 2 3 4 5 6 7 8 9 10 11 12
Total number of members 7 8 11 29 13 11 12 27 20 16 19 11
Composition of committee [N(%)]   
Clinician or scientist 1 (14) 3 (38) 4 (36) 18 (62) 7 (54) 6 (55) 10 (83) 19 (70) 14 (70) 12 (75) 11 (58) 6 (55)
Statistician or epidemiologist 1 (14) 0 0 0 1 (8) 0 0 0 0 0 1 (5) 0
Nurse 0 1 (13) 1 (9) 2 (7) 0 1 (9) 1 (8) 1 (4) 1 (5) 1 (6) 2 (11) 0
Allied Health professional 0 1 (13) 1 (9) 3 (10) 0 1 (9) 0 0 1 (5) 0 0 1 (9)
Pharmacist 2 (29) 1 (13) 0 0 0 0 0 2 (7) 0 1 (6) 2 (11) 0
Lawyer 2 (29) 1 (13) 0 1 (3) 2 (15) 1 (9) 0 1 (4) 1 (5) 0 1 (5) 1 (9)
Ethicist 0 0 2 (18) 3 (10) 1 (8) 0 1 (8) 1 (4) 1 (5) 1 (6) 0 1 (9)
Community representative 1 (14) 0 2 (18) 1 (3) 1 (8) 1 (9) 0 2 (7) 2 (10) 0 1 (5) 1 (9)
Theologian 0 1 (13) 1 (9) 1 (3) 1 (8) 1 (9) 0 1 (4) 0 1 (6) 1 (5) 1 (9)
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Table 3. Review procedures of Research Ethics Committees in South Africa, 2003 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. F: Fortnightly; M: Monthly; Q: Quarterly 
 
2. The current exchange rate is approximately 1 South African Rand = 7.0 US Dollars 
 
3. Staffing is estimated in full-time equivalents (FTE), where a full-time worker contributes one FTE and a part-time worker contributes 
0.5 FTE
Committee number 1 2 3 4 5 6 7 8 9 10 11 12
Meeting frequency (1) F M Q M Q M M M M M M Q
Percentage of membership 
required for quorum 71 88 45 17 62 64 58 41 55 31 37 73
Average number of reviewers per 
protocol 7 2 11 2 13 2 3 3 10 1 2 11
Each protocol discussed at each 
meeting? Y Y Y Y Y Y Y Y N Y Y Y
Estimated number of protocols 
reviewed per meeting 7.5 6.5 7 15 9 17.5 15 30 13 7 15 3.5
Number of protocols reviewed 
during 2002 140 70 30 80 31 241 100 357 181 61 300 30
Estimated delay from protocol 
submission to approval (weeks) 1.5 4 7 4 6 2 2 4 9 4 4 10
Charge for protocol review (Rand) 
(2) 5500 5000 0 4845 0 2000 0 4000 4500 4000 3000 0
Dedicated office space Y Y N Y Y Y N Y Y Y Y N
Support staff (3) 1.5 1 0 3 0.5 1 1 3 1 3 1.5 0.5
 1 
 
 
 
